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EXECUTIVE SUMMARY 
During the past two decades, cancer incidence has steadily 
increased due to aging populations, lifestyle and environmental 
factors, with great personal and national economic 
consequences. Concurrently, cancer treatments have improved 
with increased treatment options as well as lengthier disease 
and disease-free survival rates. The latest innovation in cancer 
treatments are targeted biological treatments, joining the current 
arsenal of surgery, radiotherapy and chemotherapy, particularly 
significant in latter stage cancers associated with very poor 
survival. 
Despite this latest breakthrough in cancer treatment, this has in 
fact only opened the door to beginning to understand the 
complexity of cancer on a molecular and genetic basis. 
Oncology research and development (R&D) has the highest 
failure rate for new molecular entities (NME) and significantly 
higher development costs. Although tremendous scientific and 
economic barriers exist, the oncology development market has 
increased twofold over the past 5 years. 
This report aims to map current oncology R&D funding and 
management, primarily in Europe and the USA, to examine 
public-private relationships, current oncology R&D strategies 
and oncology innovation policies. Its objectives are: 
•  to map current funding and management of oncology 
R&D via questionnaire surveys and interviews of 
oncology experts; 
•  to produce a high-resolution bibliometric analysis of 
oncology drug R&D in order to better understand the 
public-private mix in research activity; 
•  to investigate the cumulative life-time funding of 
specific oncology drugs; 
•  to review current public policy affecting oncology drug 
R&D, specifically, public R&D investment policies, 
transnational investment policies, regulatory policies 
and drug reimbursement policies; and 
•  to propose future oncology policies supporting the 
R&D process. 
 
Results: Funding, Bibliometric Outputs and 
Faculty Survey 
Funding 
Public oncology R&D funding can be sourced from a variety of 
sources: national governments, regional authorities, charities, 
non-governmental organisations and supranational 
organisations. Funding can be directly tagged for oncology 
research from these organisations or indirectly flow into 
oncology research via overall budgets (i.e. hospital budgets). 
Our examination of oncology funding found 153 public research 
funding organisations (RFO) in the EU (UK 19, France 12, 
Belgium 12, Italy 11) and 21 in the USA who spent greater than 
€1 million annually. The EU RFOs collectively spent €2.79 
billion and the US RFOs €5.8 billion, although the EU did not 
include European Commission (EC) investment, which is 
significant and likely brings the EU figure closer to €3 billion. 
Individually, the US and the UK (€1.1 billion) were the largest 
oncology public R&D investors, whilst Germany (€426 million), 
France (€389 million) and Italy (€233 million) followed. 
Calculations per capita found leaders (USA, UK) unchanged, 
however, placed Sweden, the Netherlands and Norway next. 
Likewise, examination of public oncology drug R&D investment 
placed the USA (€1.67 billion) and UK (€305 million) at the top, 
regardless of absolute or per capita valuation. When direct and 
indirect funding are added together, the EU invests 0.011% of 
GDP, or €3.64 per capita, and the USA 0.018% GDP, or €5.74 
per capita. Furthermore, the EU has significantly increased 
funding by 34.7% from 2004 to 2007 whilst the USA increased 
only 9.7%. 
Examination of national cancer strategies and funding found 
only the United States and United Kingdom with strong visions 
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and policies, whilst the remaining EU countries appear to favour 
an  ad hoc approach. Philanthropic oncology remains 
impressive, estimated at over €500 million Europe and €230 
million in the USA in 2007. Private oncology investment by the 
top 17 pharmaceutical companies globally in 2004 amounted to 
€3.1 billion, 59% from European companies. In addition, public-
private partnerships (PPP) are becoming more common and 
found in 68% in the United States, 57% in the EU and 31% 
elsewhere of new oncology drug R&D projects. 
Bibliometric analysis 
Bibliometric analysis of 19 anti-cancer drug publications (1963-
2009) produced 28,752 papers for analysis. Paper outputs rose 
from 200 annually in 1980 to 2000 by 2007-2008. Examination 
of 15 main oncology research countries found the USA the 
leader (33%) followed by Japan (10.6%), Italy (7.5%) and the 
UK (7.1%). Initially, the USA and Europe dominated oncology 
research outputs, although recently other counties such as 
China and India are increasing their publication outputs. 
Neighbouring countries still favour each other (USA: Canada, 
UK: NL) despite increasing international collaboration. Further, 
countries appear to concentrate on certain drugs and produce 
less research on others. Surprisingly, most national oncology 
research portfolios were poorly correlated with their internal 
oncology burden. 
The type of oncology research performed changed with time 
from basic to clinical, although per drug this was not necessarily 
the case. Different countries produced different types of 
research (i.e. basic: India, China; clinical: Spain, Greece), with 
15% of papers describing phased clinical trials, primarily Phase 
II. 
The presence of 26 leading pharma companies, including the 
12 associated with development of the 19 selected drugs, 
occurred in 1589 papers, or 5.5% of the total. Dominating 
companies responsible for oncology paper outputs were Aventis 
(274 papers), AstraZeneca (173) and BristolMyerSquibb (155). 
Survey of oncology faculty 
Faculty were surveyed on a number of public and private 
oncology R&D issues. They felt strongly that PPP were 
important for future oncology developments, however, its ideal 
definition was not clearly defined regarding financial incentives 
and length of private support. Europeans were less agreeable 
regarding oncology R&D nationalisation than Americans and 
Canadians, whilst American faculty felt reimbursement policies 
for new oncology drugs was less important to future successes. 
All agreed, however, that the degree of national public sector 
investment was inadequate to meet future oncology demands. 
Faculty expressed concern about the inadequacy of current 
oncology R&D models and encouraged re-thinking of ideal 
models. Suggestions included greater transnational 
cooperation, support of translational research and a degree of 
institutional involvement. Specifically, regulatory bottlenecks 
must be resolved as well as ideal balance of public versus 
private funding. 
 
Policy Implications: Funding, Bibliometric 
Outputs and Faculty Survey 
Our funding analysis produced a number of interesting issues. 
First, it appears there are funding gaps between the USA and 
Europe, supplemented by further variations within Europe. 
Second, it appears public funding is more likely to support basic 
rather than applied research, whilst industry supports the latter. 
Third, European funding appears to be fragmented concurrently 
with duplication and inadequacies. Fourth, indirect and 
philanthropic funding appear to be significant and uncounted 
sources of oncology funding. Fifth, PPP investment in oncology 
is of increasing importance in addition to being complex, 
reducing economic risk, smoothing the operations process and 
will likely play an increasing role in the future. 
Our survey of oncology faculty found substantial support for 
PPP although its ideal definition remained unresolved. Both 
public and private sources of activity and funding are important 
to oncology, yet the balanced equation of their interaction and 
involvement needs further study. New models specifically for 
oncology R&D are urgently needed to reduce attrition rates, 
increase the rate and sophistication of parallel biomarker 
development and work on the vast number of combination 
regimens and indications necessary for the next generation of 
cancer drugs. 
New PPP policy development should include a number of new 
variables. 
•  Strong institutional support and dedicated public RFO 
funding. 
•  Increased freedom to operate for translational leads 
within specific projects, achieved by improved support, 
light-touch governance and decreased administrative 
bureaucracy (national legislative, private-contractual, 
public contractual). 
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•  Partnerships supporting transnational cooperation and 
collaboration focused on key cancers, including 
'orphans' not viewed as commercially attractive. 
•  Partnerships subject to high-quality peer review and 
fully disclosable upon completion to the public. 
Faculty clearly identified over-regulation and reimbursement of 
new cancer drugs as critical issues, which continues to 
overshadow public sector oncology R&D and remains a threat 
to future new breakthroughs. Of further significance was 
intellectual environment and infrastructure for oncology R&D, 
expressed as vital to institutional and national policies. Strategic 
alliances and cooperation between industry and academia are 
key to future oncology discoveries, as the complex nature of 
oncology research cannot support monopoly in knowledge and 
creation. Particularly for novel biologicals this holds true 
Fostering Oncology Innovation 
Encouraging innovation in oncology brings forth a number of 
priorities: first, the role of science, research and innovation; 
second, the role of pricing and reimbursement systems; third, 
the continuous evaluation of oncology drugs; fourth, the ideal 
environment for long-term innovation and fifth, the optimisation 
of resource allocation in health care. 
 
National and Supranational Roles in 
Innovation 
Governments play an important role in encouraging and 
fostering innovation, including direct governance for key 
research areas and indirect mechanisms including taxation. 
Governments understand this encouragement has direct 
economic consequences as well as social benefits, which 
exceed private benefits. Collaboration between public and 
private enterprises further spreads benefit and ensure greater 
likelihood of success. 
Despite this recognition, the complex nature of oncology 
requires both direct and indirect measures. Using only 
prescriptive and coercive regulations may be cumbersome, 
expensive and inefficient, whilst output- or performance-based 
regulations may have more likelihood of success. Tax 
incentives via R&D credits may be targeted to serve specific 
objectives, whilst enhanced market exclusivity periods may 
encourage intellectual creativity. Particularly in oncology 
research each player only has a portion the knowledge required 
for presenting new solutions, leading to ideally open access 
requirements. This presents the need for new model 
developments in oncology R&D to encourage innovation, 
leading to new treatments more quickly. 
In Europe, the EC has recently taken steps to encourage 
innovation by promoting translational and transnational 
research, in addition to PPP, in the hopes that cooperation will 
prove stronger than its current fragmentation. Although not all 
European countries have cancer strategies in place, particularly 
newer members, there is focused application to improve 
oncology treatments and to encourage development of new 
ones. Despite this attention, there continues to be room for 
improvement in European oncology R&D. Cancer charities are 
a significant yet neglected source of oncology funding, their 
fragmentation and duplication continues to be mirrored by many 
national oncology organisations. Furthermore, some oncology 
research may not be funded due to precisely its specialisation 
and innovation, such as very specialised basic cellular research 
found in only few countries, as it does not qualify for 
translational or transnational funding. 
In America, cancer research is less fragmented due to the 
umbrella organisation of the National Cancer Institute, which 
supports both molecular and translational research as well as 
increasingly encouraging PPP. However, it does suffer from 
state-level and indirect fragmentation (i.e. hospital research 
budgets), and its level of charitable oncology R&D funding is 
less than the EU. 
Globally, it appears translational cancer research is still in its 
infancy, only recent programmes giving focus and direction. 
Likewise, PPP have room for growth and direction both in 
Europe and the US  which should be seen as a unique 
opportunity at these cross roads. Fragmentation continues, 
particularly at charitable level, with some negative 
consequences for administration costs and research 
duplication, but perhaps benefiting highly specialised research 
areas still in experimental stages. 
 
The Uniqueness of Rare Cancers 
Rare cancers represent approximately 20% of oncology cases, 
including childhood cancers, each with variations in incidence, 
mortality and survival rates. This variability is mirrored between 
EU members with regards to treatment access, information 
availability and medical expertise. These factors present rare 
cancers as a unique case, requiring multidimensional action to 
encourage R&D, access and uptake of new treatments. Such 
actions include re-organising regulations, encouraging R&D 
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through collaboration, creating consensus guidelines on 
multidisciplinary treatment, addressing patient treatment 
access, as well as improving information access for patients 
and health care professionals. 
 
Role of the Reimbursement System 
Over the past decade, health care costs have increased, 
including drug spending although only accountable for 10%-
20% of total care costs. Management of drug spending is 
important, particularly as regressive management may cause 
access, equity and health outcome issues. Appropriate pricing 
and reimbursement can help manage health care costs whilst 
concurrently encouraging innovation in R&D and treatment. A 
number of criteria can help achieve these goals. 
First, timely treatment access is paramount, particularly for 
innovative drugs, and encouraged through 'fast track' approval 
and reimbursement procedures (e.g. FDA fast track process for 
priority drugs). Conditional reimbursement and pricing, where 
access is ensured whilst 'real-world' data collection continues, 
as well as physician flexibility in prescribing can further aid 
access and encourage innovation. 
Second, reimbursement based on values, including explicit and 
objective assessments, is important to consider. This value 
should consider both societal and individual value and include 
comparisons to current best practice. Third, reimbursement and 
pricing policies should contain some degree of flexibility, where 
levels are adjusted as new data become available. 
Fifth, collaboration should be encouraged between payers, 
providers and manufacturers to explore new pragmatic ways of 
delivering innovative value. Sixth, standard guidelines to assess 
drug benefits should include humanistic and patient-focused 
benefits such as quality of life (QoL), longer term direct cost 
offsets, indirect system costs and caregiver and patient benefits. 
 
Risk Sharing 
Traditionally, payers absorb all risks associated with purchasing 
new medical technologies. Risk sharing attempts to redistribute 
the risk balance between payer and technology supplier, 
typically involving the supplier to provide a 'guarantee' relating 
to outcome. These outcomes could include clinical parameters, 
QoL, resource usage, (d) financial and economic outcomes. 
Although new in health care, this method is likely to gain use in
the future due to total cost issues, first, for admitting new 
treatments onto national formularies and, second, to enabling 
faster uptake. In oncology in particular, this could be interesting 
due to limited patients carrying the same genetic tumour codes. 
 
Continuous Evaluation of Oncology Drugs 
Ex-ante evidence is currently required to present evidence for 
approval and reimbursement decisions, however, sole reliance 
on this method ignores evidence outside the clinical phase 
environment. Ex-post evidence is just as important, however, in 
proving value of new treatments yet is widely ignored. Collection 
and evaluation of such data is costly and perhaps should be 
shared between private and public interests, yet is imperative in 
oncology with its heterogeneous patients. 
 
Optimising Resource Allocation in Health 
Care 
Although resources are allocated mechanistically in health care, 
this does not guarantee optimal use  in fact evidence suggests 
that many health systems have room for improvement including 
oncology. Demand-side behaviours by both clinicians and 
patients, real-time information systems for payers and providers 
as well as system and policy performances all must be 
considered. Savings emerging should be re-allocated and re-
invested to improve patients’ quality of care and health services. 
 
Conclusions 
The report shows oncology R&D and treatment are on the brink 
of a new era, providing a unique opportunity now to redirect and 
refocus national, supra-national as well as regional policies and 
procedures that may impact oncology directly or indirectly. New 
models for PPP must be created, giving credence to both public 
and private ownership within complex and often unique 
diseases including cancer. Reimbursement decisions are 
important and can greatly impact future oncology innovation and 
investment and must be carefully considered prior to 
implementation (and monitored closely thereafter). Pricing 
should consider innovation and value, not just with macro-
societal views but also consider micro-individual patients. The 
overall goal is improved patient outcomes and survival, and for 
oncology this means collective operation and collaboration. 
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Table 1.1: Global cancer related deaths and burden of disease by sex (2004)
 
Source: [4]. 
1. BACKGROUND AND OBJECTIVES 
1. 1. The Burden of Cancer 
1.1.1. Risk factors, incidence and mortality 
The aging of population and lifestyle factors such as obesity, 
physical inactivity, alcohol consumption, rising number of female 
smokers and lower rates reproduction, along with genetic 
susceptibility are among the most important underlying reasons 
for the increasing cancer incidence in industrialised nations 
[1,2]. However, the burden of cancer is no longer limited to 
developed countries. On top of the growing risks of poor diet, 
tobacco, alcohol and industrial exposures, the less developed 
world is already burdened with cancers related with infectious 
agents [3] such as Helicobacter pylori, human 
immunodeficiency virus (HIV), hepatitis B (HBV), human 
papilloma virus (HPV) and others [2]. Even if the total burden of 
cancer remains highest in wealthy countries, developing 
countries are closing the gap rapidly. 
Advances in diagnostic methods, surgical techniques, 
radiotherapy, innovative vaccines and drug treatments have 
contributed to improved outcomes, particularly for patients 
suffering from the most ordinary cancers such as prostate, 
breast, colorectal and, more recently, lung. Thus, mortality rates 
have stabilised in some populations (e.g. Europe) [1]. 
Still, new cancer cases were estimated at 11.47 million 
worldwide in 2004, whilst cancer accounted for 7.42 million 
deaths that same year (Table 1.1, Figure 1.1) [4]. These figures 
could reach 27 million cases by 2030 with 16 million deaths [5], 
making cancer as cause of death the fastest increasing rate 
globally, and in some countries already the primary cause of 
adult mortality (the United Kingdom, the Netherlands) [4]. In 
most high-income countries, cancer is the second highest 
common cause of death after cardiovascular disease, with lung, 
colorectal, breast and stomach cancers together accounting for 
13% of total mortality in 2004 [4]. 
1.1.2. Prevalence and direct/indirect costs 
Cancer prevalence refers to the burden of disease in a 
population and is associated with the survival of cancer 
patients. In terms of total disease burden, malignant neoplasms 
accounted for 14.6%, 7.2% and 2.3% of disability adjusted life 
years (DALYs) ('healthy' years lost) in high-, middle- and low-
income countries, respectively, in 2004 (4) (Table 1.1, Figure 
1.1). In the EU25 and the USA, cancer ranks third behind 
mental and cardiovascular disease in relation to DALYs lost 
whilst in other industrialised countries such as Australia, Japan 
and New Zealand, cancer ranks second relative to DALYs lost, 
following mental illnesses (1). 
Despite the rising burden that cancer poses, health spending 
related to treatment of cancer patients does not reflect this 
trend. Based on 2004 total health expenditure figures from 
OECD Health Data, cancer care seems to account 
approximately for 6.6% (on average) of total direct health care 
expenditures in most developed countries [1]. Medical 
treatments for cancer account for 10%-20% of cancer
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Figure 1.1: Cancer related deaths and burden of disease grouped by income per capita (2004). 
Source: [4].
expenditure  primarily as inpatient hospital care  and 5% of 
total pharmaceutical expenditures [1]. 
Indirect costs associated with inability to work account for a 
large proportion of the total cost that cancer imposes on society. 
Relevant studies demonstrate that indirect costs range between 
65%-85% of total costs [6-8].  
1.1.3. Advancement in cancer medical treatments 
Various treatment methods exist today for cancer, including 
surgery, classical chemotherapy (i.e. agents that inhibit cancer 
growth such as alkylating agents and anti-metabolics [9,10]), 
radiotherapy and an increasing number of 'targeted' drugs 
against hormone, and growth factor receptors as well as cell-
signalling pathways.  
Cancer drugs are often introduced into clinical management in 
late-stage patients [1]. Efficacy in early-stage disease often 
translates to greater success rates when the drug is combined 
with surgery and/or radiotherapy [1]. Multiple drug regimens are 
the backbone of treatment and the newer generation of cancer 
drugs promise reductions in toxicity, improved tolerability and, in 
the case of orally delivered medicines, economic benefits and 
increased patient satisfaction by out-of-hospital and in-
community treatment delivery.  
The analysis of tumour gene/protein expression profiles, as well 
as other technologies such as circulating cancer cells, has 
driven the 'translational' science of prognostic and predictive 
biomarkers. In the latter case, such markers can help predict
whether a tumour is likely to respond to a certain treatment, the 
so-called personalised medicine. However, progress in 
genomics and proteomics has also revealed that most tumours 
are in practice genetically unique and highly complex. 
Laboratory and clinical development of these new biomarkers 
along with the next generation of cancer drugs is extraordinarily 
complex. As a result, the already costly and timely research and 
development (R&D) process in cancer drug development 
becomes even more challenging.  
 
1.2. The R&D Process 
1.2.1. General trends 
Recent advances in genomics, proteomics and computational 
power present new ways of understanding the inner workings of 
human disease at molecular level, making discovering and 
developing safe and effective drugs challenging as well as 
promising.  
Scientists in government, academic, not-for-profit research 
institutions and the pharmaceutical sector contribute to basic 
research in order to understand the disease and choose a 
target molecule. In general, it takes about 10-15 years to 
develop one new medicine from the time of discovery to when it 
is available for treating patients. Moreover, substantial research 
has been carried out on estimating the costs of drug 
development  either generally [11] or according to therapeutic 
area [12], and, although there is controversy around the use of 
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single numbers [13], it is clear that it takes a large, lengthy effort 
to get one medicine to patients. In 2005, the average cost of 
developing drugs against cancer was estimated to be 20% 
higher (€964 million) than the mean cost of developing a new 
molecular entity (NME) (€803 million) [11]. This number 
incorporates the cost of failure: For every 5000-10,000 
compounds that enter the R&D pipeline, ultimately only one 
receives approval [14].   
1.2.2. Cancer R&D 
Over 50 years ago when cancer was described for the first time 
as a genetic disease, hopes for early diagnosis and targeted 
treatments rose. However, the progress in genomic 
technologies and fundamental cancer biology has unravelled a 
complexity among cancers practically making each tumour's 
genetic fingerprint unique [15]. Therefore, it is of no surprise that 
oncology R&D has the lowest success rate (and, by implication, 
the highest cost) of any therapeutic area in the pharmaceutical 
discovery and development, making the R&D process even 
more challenging for a number of reasons. Indeed, in the case 
of cancer, when a molecule enters clinical trials, there is only a 
5% probability that it will turn out to be a commercially viable 
product [16].  
There are further R&D issues unique to oncology. First, instead 
of healthy volunteers, patient populations who have practically 
failed all other treatments participate in Phase I clinical trials. 
This imposes a major burden on the assessment of the safety 
and efficacy of the compound, as well as the identification of 
relevant biomarkers. A Phase II trial, where specific cancer 
types are being selected and dosage is determined, is often 
more enlightening. Second, contrasting most diseases, cancer 
is a set of proliferative diseases representing a variety of 
different specific conditions. Third, there are huge differences 
among cancer patients due to the unique genetic fingerprints 
that almost any tumour has, making inter-patient heterogeneity 
a major challenge. Finally, even if the drug makes it to Phase III, 
cancer patients are normally treated with multiple drugs at the 
same time, thus the standard of care has to be adapted and 
enhanced to add the new drug to it. Perhaps, it is not surprising 
that cancer drugs often fail in Phase III, which is the most costly 
part of drug development programme. 
The current knowledge of the biology of cancer targets and their 
significance in the disease process is undoubtedly deficient and 
major problems remain in how to deliver many anti-cancer 
agents that in vitro are effective. What seems to become 
increasingly likely is that there will be a shift from defining a 
cancer by site [17-19] (i.e. malignancies originating from the 
same organ system are grouped together as one single 
disease, receiving basically the same treatment) to identifying 
similar therapeutic target cancers that, regardless of whether 
they arise in the same locations or not, share alterations of the 
same genes. Thus, successful cancer drug discovery will 
require, apart from finding the best medicine for a certain target, 
also identifying the patient population whose tumours actually 
carry the relevant genetic alteration, leading to both 
individualised diagnosis and personalised therapy.  
The issue arising here is that treating cancer as a collection of 
'orphan diseases' could lead to the creation of smaller markets, 
inapt to the traditional 'best-seller' model of discovering and 
developing new cancer drugs [20]. Indeed, some 
pharmaceutical companies have been reluctant to invest in 
early basic science and pre-clinical research and development, 
given the limited revenue prospects of such a business model.  
In the end, it seems that the overabundance of these potential 
targets are major scientific hurdles to issues of drug delivery, 
target appraisal and confirmations and potential medicines 
manufacturing and effectiveness enhancement. Furthermore, 
the development of new therapeutic strategies is too much for 
industry, government or universities to do separately. 
Collaboration appears to be the key to facilitate the discovery 
and development of effective new cancer drugs and optimise 
their application.  
1.3. Trends in R&D Spending and Output by the 
Private Sector 
1.3.1 Aggregate R&D trends in pharmaceutical and 
biotechnology industries 
Whilst total pharmaceutical R&D expenditure
a has increased 
and sales
b have grown, revenue keeps on relying on a small 
number of molecules reflecting an ongoing drop in productivity 
(Figure 1.2).  
R&D costs continue to rise with development, now 
corresponding to approximately one third of all spending. 
Development times also continue to grow during all phases of 
development. Discovery and regulatory times have not marked 
any significant change during the past 5 years and are not 
expected to do so in the years to come [21]. Still, there is an 
obvious trend in some companies to invest more in early 
development in order to avoid the massive cost of late-phase 
failure. 
On the other hand, success rates are not improving as only 
20% of molecules entering Phase II will be marketed. 
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Notes: Each trend line has been indexed to 1997 values Development time data point for 2007 includes data from 2006 and 2007 only 
Source: CMR International and IMS Health 
Figure 1.2: Global R&D expenditure, development times, NME output and global pharmaceutical sales (1997-2007). 
Biotechnology-derived and self-originated substances do have, 
however, a slightly better chance of success relative to chemical 
and in-licensed entities [19]. Consequently, the number of NME 
launches dipped to a new 20 year low in 2007, despite the 
encouraging signs in 2005. In fact, during the 1997-2007 period, 
the introduction of NME dropped by 50%. Yet, biotechnology 
products have accounted for almost a quarter of all NME 
launches [19].    
The molecules currently in development are mainly looking at 
therapeutic areas with high value and significant level of unmet 
medical need [13,20]. The underlying rationale is that although 
molecules with a new action mode are associated with a 
significant success risk, at the same time they offer the greatest 
opportunity for innovative and high-value medicinal products 
[22].  
1.3.2. Cancer R&D trends 
As previously been described, R&D in the area of oncology is 
particularly challenging. However, oncology-related R&D is 
booming, and this is shown by the enormous share of oncology 
compounds in the pharmaceutical sector's clinical pipeline. In 
the USA alone, there are more than 800 new compounds in 
development for cancer in 2009, compared with 750 in 2008 
and just under 400 in 2005
c (Figure 1.3). 
This reality reflects the focus of R&D investments towards 
therapeutic areas and technologies of greatest opportunity 
(perceived as a combination of low-generic penetration and high 
price levels), associated with the highest unmet medical need. 
Hence, the opportunity associated with a potential success 
cancels out the fact that attrition rates among cancer products 
are as high as 95%.  
1.4. Aim of This Report 
The global organisation and funding of cancer research follows 
many different models. The global flow of knowledge, 
innovation, research and development has dramatically 
increased the complexity of cancer research. Since the mid-
1950s cancer drug development has become the dominant area 
of cancer research. The clinical need to find drugs to prevent 
cancer, suppress recurrences (adjuvant), downstage tumours 
for surgery (neoadjuvant), treat metastatic disease and palliate 
has driven the development of new molecular entities, be they 
chemical or biological.  
However, the vast complexity of this nexus coupled to the 
widely different paradigms that appear to operate across 
Europe, USA and the Far East do not easily lend themselves to 
strategic analysis. In particular questions arise as to:  
•  what models of funding and management have, or 
have not been successful; 
•  what is the most efficient, creative and innovative 
model for public-industry cooperation and 
collaboration; and 
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Note: Some drugs are listed in more than one category. 
Source: PhRMA ('New medicines in development for cancer'). 
Figure 1.3: Number of new cancer drugs in development by type of cancer.
•  what policies should we be developing to support drug 
development in cancer, and to whom should these be 
directed (government, NGOs, etc). 
In this context, the aim of this report is to map out the current 
funding and management structures for cancer drug R&D in 
Europe and the USA, with particular reference to the public-
private interplay, and following a review of current strategies put 
forward recommendations to improve cancer drug innovation.  
The report focuses on the USA, Germany, UK, Italy, France, the 
Netherlands, Sweden and Spain primarily, but also includes 
evidence from EU27 and Canada, where it is available. 
Although the main focus is on adults, the report includes 
paediatric oncology as drug development in this area is now a 
critical public policy issue.  
The detailed objectives of the research presented in the report 
are fivefold: 
First, to map current funding, peer review and management of 
cancer drug development. Through a mixture of questionnaire- 
and interview-based techniques, the current funding in 
oncology, peer review and management practices is mapped for 
the countries in question. This encompasses pre-clinical drug 
development, early phase clinical trials through to pivotal Phase 
III, although in the latter case this is assumed to be entirely 
within industry. The report covers both New Chemical Entities 
and Biologicals. This addresses the question as to who funds 
what and how. Within the institutional part of this mapping 
exercise the report drills down into the availability (or otherwise) 
of key platform technologies and infrastructure for the pre-
clinical and clinical aspects.  
Second, the report conducts and presents a high-resolution 
bibliometric analysis of outputs in drug development with a view 
to obtaining a better understanding of the public private mix in 
cancer research activity. Apart from early phase clinical trials 
where we know publications (outputs) do not reflect activity, the 
research presented in this report uses bibliometrics as a means 
of understanding current and past state of cancer drug 
development. The research uses major databases and 
constructs with key drug names to analyse the trends in output 
and impact by country, institution and even researcher. It 
examines how models of partnership (institution-to-institution 
and institution-industry) have changed and also at the patterns 
of funders over time. Such changes can then be reviewed in the 
context of the impact of national policies.  
Third, to investigate the cumulative life-time funding of specific 
cancer drugs. The question of how and who funds cancer drug 
development can most effectively be answered by looking at the 
cumulative lifetime from inception/discovery (NME) to clinic. 
Taking a representative sample of current cancer drugs, the 
report looks at their funding histories from inception to market.  
Fourth, to review the current public policy affecting cancer drug 
development. There is substantial literature on the generic 
process of drug development (essentially data documents) and 
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specific policy issues (e.g. Intellectual Property) but few, which 
are either disease-specific or take a horizontal approach to the 
affect of policies (i.e. how different policies interact with each 
other in a cumulative manner). This report reviews five streams 
of current public policy, which affect cancer drug development 
both in Europe and the USA, notably (a) policies affecting public 
R&D investment in cancer research, particularly at   Member 
State & Institutional (University-Hospital complex) level and 
differing polices around public-private ventures; (b) 
transnational investment polices focusing on funding by bodies 
such as the EU Commission compared to the US NCI; (c) 
regulatory policies, specifically the clinical trials directive; (d) tax 
and IPR policies and (e) the likely impact of drug reimbursement 
policies on the development of cancer drugs.  
Finally, to propose polices to support further cancer drug R&D. 
This objective has been informed by the emerging evidence in 
this report as well as by key opinion leaders (senior clinicians) in 
cancer drug discovery and development with a view to 
proposing key public policy measures to support innovation in 
European cancer drug development.  
Chapter 2 places cancer research in context by providing a 
historical background to cancer drug development; Chapter 3 
presents the public and private trends in cancer drug research 
and development; Chapter 4 presents the results of the 
investigation into the cancer research activity in both the public 
and private sectors, whereas Chapter 5 builds on the senior 
clinician survey to propose policies to support cancer drug R&D. 
Chapter 6 debates the issues surrounding public policies 
affecting cancer drug development. Finally, Chapter 7 draws the 
main conclusions and considers the policy implications. 
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2. THE HISTORY AND SCIENCE OF CANCER 
DRUG DEVELOPMENT 
This chapter provides a brief journey through the major 
historical developments in European cancer research and a 
discussion of the key areas of current cancer drug discovery  
new chemical entities and biologicals (immunotherapy). 
2.1. An European History of Cancer Research 
Europe's seminal contributions to the milestones of cancer 
research are many and can be traced back to 1889 when Dr. 
Stephen Paget, a London Surgeon, developed the ‘seed and 
soil’ hypothesis of metastasis.  
The prevailing view at that time was that cancer cells spread 
through the blood or lymph and could take up residence in any 
tissue. If this had been true, metastases would have shown a 
random distribution to other organs. Paget thought otherwise. 
‘When a plant goes to seed, its seeds are carried in all 
directions. But they can only live and grow if they fall on 
congenial soil...’ he wrote (one of the wonderful things about 
research in this era was the use of the natural world as an 
unlimited source of metaphor and analogy, sadly lost in today's 
prosaic research culture). Paget examined nearly a thousand 
cases and found that specific tumours metastasised 
consistently to particular organs.  
Although this view was challenged by James Ewing, who gave 
his name to a type of soft tissue cancer, or sarcoma, claiming 
instead that metastases settled in the first organ they reached 
as they spread through the vasculature, Paget was to be proved 
correct in 1980 by Isaiah Fidler and Ian Hart working at the MD 
Anderson Cancer Center at the University of Texas.  
Almost simultaneously with Paget in 1890, just a few years after 
the discovery of chromosomes, David P. Hansemann, a 
pathologist-in-training with Rudolph Virchow in Berlin, produced 
a theory of the pathogenesis of cancer. This included a key 
concept that the first change that occurs in cancer is an 
alteration of the hereditary material of a normal cell at the site 
where the cancerous process begins. In the process of linking 
cancer to chromosomal material, Hansemann coined the terms 
‘anaplasia’
d and ‘dedifferentiation’.
e These terms have remained 
the basis of descriptive terms concerning the microscopic 
appearances of tumours ever since.  
The great German tradition in cancer research continued with 
people such as Theodor Heinrich Boveri (1862-1915), a 
German zoologist. In his work with sea urchins, Boveri showed 
that it was necessary to have all chromosomes present in order 
for proper embryonic development to take place. His other 
discovery was the centrosome (1888), which he described as 
the special organ of cell division. He also reasoned that cancer 
begins with a single cell, in which the make-up of the 
chromosomes is scrambled, causing the cells to divide 
uncontrollably.  
It was Paul Ehrlich who was to make the link between the 
immune system and cancer, suggesting that for the latter to 
survive the former had to be suppressed. Paul Ehrlich, who won 
the 1908 Nobel Prize in physiology and medicine, also predicted 
autoimmunity calling it ‘horror autotoxicus’. He coined the 
term ‘chemotherapy’ and popularised the concept of a ‘magic 
bullet’. 
However, one should not view Europe's role in turning back the 
tide of cancer as an isolated one. Then, as now, research was a 
complex dance over distance and time. Europe's great 
contributions are intimately intermingled with those in other 
countries and continents.  
Europe has also laid the foundations of many other domains of 
cancer research. The most important discovery in the history of 
cancer epidemiology was the carcinogenic effect of tobacco. 
The pivotal studies begun by Sir Austin Bradford Hill and Sir 
Richard Doll, and later with Sir Richard Peto, were to provide 
the springboard for five decades of research on both sides of 
the Atlantic.  
In surgery there have been many seminal contributions by the 
European cancer research community. Umberto Veronesi, an 
Italian Surgeon and Oncologist, was the founder of breast-
conserving surgery, inventing the technique of quadrantectomy, 
which challenged the idea, then dominant among surgeons, that 
cancers could be treated only with aggressive surgery.  
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Europe has been at the forefront of treating bowel cancer 
through surgical advances  from 1908 when Ernst Miles first 
described the abdominoperineal resection, to the first 
description of total mesorectal excision by Bill Heald and 
colleagues in 1982. This gave rise to clinical trials in 
Scandinavian countries that were to change global clinical 
practice.  
The recent breakthrough in controlling cervical cancer through 
the use of a vaccine directed against certain types of human 
papilloma virus (HPV) rests on the work of Harald zur Hausen, 
who was first to show that the papilloma virus was the most 
significant cause of this cancer. In turn, that work owed much to 
the groundbreaking research begun in 1910 by Peyton Rous 
who first discovered tumour viruses.  
Research into the molecular and cellular biology of cancer has 
provided remarkable insights into the molecular basis of cancer, 
such as disordered cell proliferation, disturbed differentiation 
and altered cell survival, and disruption of normal tissue, 
invasion and metastasis. New discoveries in the molecular 
oncology of tumours in the last few decades have led to major 
improvements in cancer therapy. In the middle of the 20th 
century an improved molecular classification of malignant 
lymphomas paved the way for individualised therapy in cancer. 
The treatment based on these molecular classifications resulted 
in higher response rates and improved survival of patients with 
malignant lymphomas. One of the most prominent scientists 
involved in this molecular pathology research and one of the 
authors of the new Kiel classification of lymphomas was Karl 
Lennert, a German Pathologist.  
The field of breast cancer, the most frequent cancer in women, 
has seen many new developments based on the European 
research shared with other countries. Pivotal experiments 
performed in the late 1950s and early 1960s, primarily in the 
laboratories of Gerald Mueller and Elwood Jensen in Germany 
and the USA, set the stage for the development of hormonal 
therapy in hormone-responsive breast cancer. 
Acknowledgement of hormone receptors as one of the major 
biological determinants of breast cancer was actually one of the 
first discoveries that enabled the most effective strategies in the 
treatment of cancer, which is targeted therapy. Hormonal 
therapy with tamoxifen was the first individualised, targeted 
therapy in the history of cancer therapy.  
Nowadays, breast cancer can be divided into hormone-
receptor-positive and hormonereceptor-negative tumours, with 
treatment being substantially different in these two distinct 
diseases. Based on the largest meta-analysis in cancer care, 
undertaken at Oxford by Sir Richard Peto and his co-workers in 
the Early Breast Cancer Trialists' Collaborative Group, a vast 
amount of knowledge on the best possible adjuvant systemic 
therapy in hormonepositive and hormone-negative breast 
cancer was accumulated. Their work confirmed that adjuvant 
chemotherapy reduced the rate of recurrence by 33% and the 
rate of breast cancer death by 17%, saving thousands of lives of 
women with breast cancer. The same was true for hormonal 
therapy in hormone-responsive breast cancer, in which adjuvant 
hormonal therapy with tamoxifen was found to reduce the rate 
of recurrence by 41% and the rate of breast cancer death by 
34%, according to the data from the meta-analysis. Adjuvant 
systemic therapy, in addition to surgery, radiotherapy and 
screening programmes has been responsible for major declines 
in breast cancer mortality during the last two decades in the 
USA and Europe.  
In 1971 when Richard Nixon proclaimed war on cancer ‘a quick 
and decisive victory was predicted’.
f However, despite the 
expenditure of billions of pounds and some real improvements 
in survival, especially in paediatric oncology, the morbidity and 
mortality associated with cancer remains high. Although the 
majority of cancer treatments are due to the surgical scalpel and 
radiotherapy it is advances in chemotherapy that hold the key to 
controlling and ultimately defeating cancer [1].  
2.2. New Paradigms in Chemotherapy 
The problem with conventional cytotoxic chemotherapy is rather 
obvious  the therapeutic window is narrow and only partially 
effective. This leads to poor efficacy and tolerability, as well as 
the development of serious adverse reactions. Combination 
chemotherapy has been the intellectual development to address 
the former issue but at the expense of tolerability and toxicity. 
Chemotherapy that targets all abnormal cells whilst sparing 
normal tissues has seemed a distant prospect, but now the 
ability to probe the most intimate details of the cell through the 
application of genomic and proteomic technologies has the 
potential to fulfil this dream. At the heart of this is the vision that 
new chemotherapy can be developed to selectively target 
cancer [2]. The new paradigm couples technology, such as 
robotic high-throughput screening, combinatorial chemistry, 
structural biology and molecular modelling with new insights into 
the pathophysiology of cancer and therefore new therapeutic 
strategies, for example the role of new blood vessel formation 
for metastatic disease and development of anti-vascular and 
angiogenic agents [3]. There have been encouraging signs that 
this approach may work. A signal transduction inhibitor 
(Imatinib) that selectively targets the abnormal BCR-abl fusion 
protein (Philadelphia chromosome product) that drives Chronic
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Myeloid Leukaemia, has demonstrated remarkable efficacy, 
with little toxicity. The more that we learn about cancer biology 
the more approaches present themselves  growth factor 
receptors, immune system modulation, cellular matrix, targeting 
of proliferation, migration and survival (apoptosis).  
Natural product drugs that continue to play the dominant role in 
armoury of therapeutic options are also complimenting designer 
chemotherapy. Some of today's most clinically successful 
chemotherapies are derived from nature  paclitaxel, vincristine, 
vinorelbine and analogs of camptothecin [4]. In fact, in the last 
50 years only the rational structural design of 5-fluorouracil by 
Heidelberger has bucked the serendipity trend [5]. However, 
since the early 1990s this has changed dramatically with agents 
designed against rational targets  cetuximab, bevacizumab, to 
name but two. The hope is that efficacy can be enhanced by 
combining these cytotoxics with the newer targeted agents. 
Furthermore, it has become apparent that individual responses 
 efficacy and toxicity  are in part determined by genetically 
determined factors. This has led to the emerging disciplines of  
pharmacogenomics and pharmacogenetics that, using 
emerging technologies such as single-nucleotide polymorphism 
typing, aim to tailor chemotherapy [6]. However, this is still a 
very nascent field that has yet to be fully validated.  
The past 10 years has seen a paradigm shift in cancer drug 
development away from direct acting anti-cancer agents, be 
they antibodies, novel signal transduction inhibitors or 
conventional cytotoxics, which have been at the heart of 
chemotherapeutic strategies for more than 40 years. 
Conventional wisdom underpinned by solid evidence from 
randomised controlled trials dictates that direct tumour 
cytotoxicity is an effective strategy. However, in spite of success 
in curing a variety of cancers from paediatric to adult with 
modest gains in the adjuvant/neoadjuvant setting for a subset of 
patients as well as much needed palliation in other settings, the 
fact remains that new strategies, or combinations of strategies, 
are needed to deal with advanced, metastatic disease.  
2.3. Attacking Cancer 
Cancer cells, despite their escape from normal intra- and extra-
cellular controls, are still highly dependent on interactions 
between their cell surface receptors and other cells (cell-to-cell 
adhesion), growth factors, cytokines, hormones and elements of 
the extracellular matrix. Furthermore, they must continue to 
evade immune detection and, beyond a certain size, need to 
stimulate new blood vessel growth  angiogenesis. Targeting 
the world around the cancer cell is role of indirect acting anti-
cancer agents.  
Remarkably, targeting the tumour blood vessels as a 
therapeutic option was first suggested some 20 years ago by 
Juliana Denekamp and colleagues at the Gray Laboratory 
writing in the British Journal of Cancer. Aided by quantum leaps 
in technological development, particularly in real-time imaging of 
vascular flow and function through such techniques as dynamic 
contrast-enhanced  magnetic resonance imaging (DCE-MRI), 
positron emission tomography (PET) and laser doppler 
flowmetry, targeting angiogenesis has been a leading research 
area. Two broad fronts have been engaged. One approach 
targets the intracellular protein tubulin and has the dual 
attraction of acting as a mitotic poison for tumour cells and an 
antivascular agent. Various novel candidates are in 
development, and early phase clinical development has been 
completed for combretastatin A4 phosphate [7]. 
The other front has been to exploit the differential expression of 
endothelial surface proteins. Various approaches are being 
trailed, including immunotoxins and targeted gene therapy. 
Multiple mode-of-action agents
g are also being examined. One 
of the most promising agents to demonstrate exceptional 
antivascular properties is a low-molecular weight compound 
termed DMXAA, derived from the non-steriodal anti-
inflammatory flavone acetic acid [8]. This is currently the focus 
of a number of studies. More advanced and well-validated 
approaches have been through the targeting of blood vessel 
growth factor receptors utilising recombinant humanised 
monoclonal antibodies or small molecule inhibitors.
h  
The dual finding that many solid cancers not only have 
deregulated signalling pathways but also trigger new blood 
vessel formation by the cancers suggests a need for 
combination direct/indirect strategy. One such new molecular 
entity that takes this approach is a pyrrolo-pyrimidine derivative 
(AEE788), and dual inhibitor of both these pathways, which has 
reported activity in pre-clinical models, particularly head and 
neck squamous cell carcinoma, a tumour notoriously resistant 
to treatment.
i Although exciting science, it remains to be seen 
whether these '2-in-1' agents are better than combining two 
different classes of agents, for example antibody against VEGF 
and tyrosine kinase inhibitor for EGFR or vice-versa. 
Interestingly, it is not just novel compounds with dual 
mechanisms-of-action (indirect & direct acting) that are 
attracting interest. Thalidomide appears to exert its anti-cancer 
activity through numerous actions via growth factors tumour 
blood vessels and cytokine modulation. 
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Broadly speaking, immuno modulation
j has not proved itself yet 
to be the success that William Coley's seminal work in the 19th 
century suggested it could be. Coley, a New York   Surgeon 
demonstrated clinical remission in advanced cancer patients 
treated with an mixture of inactivated S. pyogens and Serratia 
marcesens, work that was not reported until after his death by 
the careful scholarship of his daughter Helen Nauts [9]. 
Modulation of innate and adaptive immunity has been a 
complex and difficult task. One approach has been to target 
cytokines
k. A number of these molecules with a variety of 
immuno-modulating properties are currently being assessed in 
clinical trials with some (e.g. IL-2, IFN-α/γ, TNF-α) at late stage 
development [10]. Many cytokines have also been shown to be 
important survival factors for various tumours, for example IL-6 
for breast and prostate cancers. IL-6 has also been shown to 
enhance pancreatic cancer survival, cell migration and 
proliferation in the presence of HER2 inhibition. Such insights 
are vital for guiding potential combination therapies, in this case 
for instance this work suggests that without IL-6 inhibition any 
HER2 targeted therapy, for example trastuzumab (Herceptin) 
would be at the very best ineffective. A dual indirect/direct 
acting strategy is also being employed by the generation of 
antibodies fused to cytokines [11]. Recombinant cytokines are 
also being combined with other indirect acting immunological 
therapies including cancer vaccines [12]. 
Numerous approaches have been utilised in developing cancer 
vaccines from tumour antigens to naked DNA or RNA [13]. 
Despite early disappointment that vaccines failed to 
demonstrate clinical efficacy, promising immunostimulation has 
been achieved, and new approaches such as DNA vaccines, 
particularly if used in combination therapies, have the most 
realistic prospect of success. Likewise, promising early results 
with dendritic cell vaccines (DC's are essential for the induction 
of adaptive immunity) have not been replicated in larger trials. 
Part of the problem may lie in DCs' interactions with growth 
factors [14]. Either such inhibitory networks need to be 
circumvented or inhibited by targeting the relevant growth 
factor.  
Anti-cancer agents targeting the tumour environment are 
essential for a number of reasons, namely the ability of cell-cell 
and of cell-matrix interactions to:  
•  enable immune evasion; 
•  act as proliferation and survival signals; 
•  enhance migration (metastasis);  
•  enable tumours to acquire multi-drug resistance 
(MDR). 
Part of the problem with targeting the tumour environment has 
been the difficulty in identifying key, rate-limiting factors, and 
therefore potential targets that support cancer cell proliferation 
and survival. Even when such factors are identified, there 
remains the difficulty of tumour selectivity in any therapy 
designed against a component of the normal extracellular matrix 
 the tissue architecture in which normal cells function. 
However, there are encouraging signs of progress in identifying 
novel targets in the extracellular matrix that surrounds cancer 
cells and in further determination of their pathophysiological 
role. Spangaletti and colleagues have recently demonstrated 
the importance of a basement membrane organising protein, 
Sparc, secreted from stromal cells, for the immune protection 
and development of new blood vessel formation for breast 
cancer cells [15].  
The observation that the extracellular matrix surrounding tumour 
cells can protect against inhibition with new chemical entities 
targeting signalling pathways suggests, again, a need for dual 
direct/indirect anti-cancer therapies. The multi-factorial nature of 
drug resistance will also require combination therapies that can 
target a variety of environmental factors from extracellular 
matrix proteins to key growth factors and cytokines [16].  
Development of novel screening methodologies, such as target-
related affinity profiling (TRAP), have also led to further 
developments towards first-in-man trials, in this case the 
identification of novel small molecule lead compounds against 
targets implicated in promoting tumour proliferation and 
survival.
l Another major area of research has been in preventing 
cancer cell migration/invasion through the use of matrix 
metalloproteinase inhibitors such as marimastat, and the Bayer 
and Bristol-Mayers-Squibb compounds BAY12- 9566 and 
BMS275291. The universally negative results to these 
compounds to date indicate a deficiency in our knowledge about 
the actual pathophysiological of migration/invasion. More 
research is needed to understand the complex interplay 
between tissue architecture, secreted growth factors, non-
cancerous and cancerous cells if rationale combination 
strategies are to be formulated.  
Will these strategies be a solution? By themselves it is unlikely, 
but in combination (e.g. targeting various in-direct domains  
angiogenesis, growth factors, etc. or with direct acting agents) 
there is real potential. Substantial difficulties remain  
resistance secondary to plasticity in the various signalling 
pathways, the potential for significant side-effects, insufficiently 
'potent' anti-cancer activity and the difficulty of designing agents 
with sufficient selectivity, as well as the perennial problem of 
delivery.  
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In his concluding remarks to the 12th Annual Pezcoller 
Symposium, Ed Harlow commented that it would be important 
to utilise complex read outs to spread information on how 
different actions interact in a cell as well as the combined 
expertise of different laboratories; this was just to address 
single-cancer cell signalling pathways [17]. In fact, integrating 
anti-cancer strategies is an order of magnitude greater in 
complexity for dissecting biological crosstalk and key 
interactions compared to the level of single cancer cell and its 
signalling pathways. There remains much to understand 
mechanistically about tumour-environment interactions, but the 
goal must be to try out these combinations in imaginative and 
perhaps even in empirical manners. There is now good 
evidence that tumour responses are a group phenomenon 
rather than the summed responses of individual cells to injury. 
Thus the classic description of the bystander effect in radiation 
oncology may be relevant to chemotherapeutic strategies where 
indirect and direct acting anti-cancer agents are combined to 
substantially enlarge the direct injury to the tumour cells.  
How is this likely to be best achieved? Clearly, the parallel 
investigation of cancer biology and selection of new 
indirect/direct-acting combination strategies requires integrated 
clinical studies that maximise pharmacological, cellular 
biological and molecular pathological information capture. The 
ability to take time and explore unusual or counter-intuitive 
avenues will be essential. Strong academic centres supported 
by high-quality organisational structures funding specific 
projects underpinned by long-term programmatic funding are 
the ideal environment to investigate these complex areas [18]. 
This strength has already led to substantial biotech spin-offs 
and provides a rich environment within which public-private 
partnerships can work to tackle these therapeutic challenges.  
2.4. Biologicals for Cancer Therapy 
The last decade has seen a surge of research and development 
focused on biologicals, which must be considered now as being 
one of the hottest areas for anti-cancer drug discovery.  
Last year was the celebration of the 100th anniversary of the 
'birth' of immunology, following the Nobel Prize Award to Paul 
Ehrlich and Elie Metchnikoff. Ehrlich was the first to 
demonstrate humoral adaptive immunity (the antibody arm of 
the immune system) whilst Metchnikoff's discoveries of the 
critical host-defence of phagocytosis, notably the engulfment of 
cellular debris and pathogens, made him the father of cellular 
innate immunity. As in all matters of science, progress since 
these heady days have not been smooth. A chemical 
explanation for Ehrlich's discoveries was sought, but quickly 
came to a dead end. It took Frank Burnett's and David 
Talmage's theory of clonal selection to bring matters back on 
track, but it would not be until 1939 that Susumu Tonegawa 
would solve antibody diversity, using the then newly acquired 
tools of molecular biology, and so set in motion developments, 
which were to lead to today's great array of therapeutic 
antibodies. On the other hand, it took nearly a 100 years to fully 
understand what Metchnikoff started that non-specific cellular 
and specific humoural system are complimentary and of equal 
importance [19].  
Immunotherapy to treat cancer also had the good fortune to find 
one William Coley, then at the hospital destined to become the 
Memorial Sloan-Kettering, who first used bacterial toxins to 
induce responses in sarcoma [20]. Whilst extraordinary 
progress has been made in the development of cancer biologics 
as well as their application in other diseases (e.g. in monoclonal 
antibodies   both therapeutic and diagnostic; therapeutic 
interferon's and interleukins and human growth factors for 
supportive care), disappointments and set-backs still fog this 
therapeutic domain. Despite, or perhaps because of these 
issues, immunotherapy generates huge excitement.  
The recent TGN1412 (anti-CD28 monoclonal) clinical trial for 
certain types of blood cancers gave an unwelcome insight into 
how much and yet how little we really understand about the 
human immune system. With so much work carried out on 
animal models it is now becoming clear that the only realistic 
model is man. As Adrian Hayday and colleagues point out we 
do not even have a good physiological definition of a healthy 
human immune system [21]. From an evolutionary standpoint, it 
is perhaps no surprise that as a species we seem to be so very 
immunologically different. The hominin lineage (the evolutionary 
line from which Homo Sapiens descended) has penetrated 
every ecological land niche on this planet and immunological 
plasticity has been mandatory. Indeed, from the 30 or so extant 
animal phyla examined by comparative immunology, it is now 
clear that there has been a huge acquisition of immuno-
complexity, leading to totally unforeseeable alternatives in 
immune receptor diversification and systems interaction. In light 
of this knowledge, developing complex immunotherapeutics is 
inevitably an exercise in stochastic experimentation rather than 
rationale development.  
In an excellent article, Antony Melcher, Peter Selby and 
colleagues set out the state of knowledge in how the human 
immune system does (or not) respond to cancer [22]. Whilst 
studies of tumour-infiltrating lymphocytes (TILs) provide a 
strong case for immunosurveillance of established cancer, 
precious little is known about the ability of the immune system
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to detect and clear pre-clinical tumours. Animal model(s) have 
suggested a role for NK, NK T cells, alpha/beta T cells as well 
as gamma/delta T cells. New concepts  such as 
immunoediting composed of three phases of elimination, 
equilibrium, escape  if supported by further in vivo studies 
would greatly aid many avenues of immunotherapy 
development.  
In the same vein, work over the last 5 years has placed the 
relationship between the emerging tumour and stromal tissue 
centre stage. This complex and dynamic process injects a new 
paradigm into the overall theory of immunoediting by seeing 
immune-cancer interactions across the spectrum from 
quiescence to low-level inflammation and to full blown acute 
reactions. Specific studies on how tumour cells interact and 
exploit complement open up new theoretical avenues for 
therapy.  
Part of the translation problem lies in the fact that some of the 
'basic' knowledge about the human immune system is lacking. 
The question that has exercised researchers is how to address 
this. whilst 'big science' is always controversial, the jury appears 
to be coalescing around the idea that a human immunological 
genome project is needed to establish essential genetic road 
maps [23]. The obvious problem is that this would still be a long 
way off from understanding the 4-D immuno-oncology system 
(the interaction between the immune system and the initiation 
and development of cancer), but in order for the systems 
biologists to really understand such a problem perhaps the time 
has arrived to launch such an initiative. Such a project, properly 
integrated with some of the key global programmes in cancer 
immunotherapy R&D, might well fill in key lacunae in our basic 
understanding.  
Broadly, the efforts to treat cancer with immunotherapy have 
included the use of cytokines (e.g. IL-2 to treat malignant 
melanoma), adjuvants
m (e.g. BCG to reduce recurrence of 
bladder cancer), the far less successful attempts utilising 
vaccines and other approaches. The crowning achievement has 
been the use of humanised monoclonal antibodies (MAb) that 
continue to be developed into new therapeutic niches, for 
example by the harnessing idiotypic networks to elicit tumour-
antigen specific immune responses. Moreover, MAb make 
commercial sense with studies, showing a higher success rate 
than small molecules (14% compared to 10% between 1990-
2007). In an attempt to leverage the success of trastuzumab 
and bevacizumab pharma continues to re-stock its 
immunotherapy pipeline with biotech specialising in humanised 
antibodies (MAb). Unfortunately, however, many cancers
develop resistance to MAb, or are refractory from the outset, 
which has spurred a raft of work into immunotoxins. These 
immunoconjugates, notably processes where an antibody is 
bound to a novel 'warhead', are now being developed to use a 
wide range of 'warheads', including chemotherapeutic agents, 
radioisotopes, enzymes or toxins [24]. Some immunotoxins, for 
example IL-13 and EGFR targeted agents, are now in Phase III 
clinical trials (both against glioblastomas
n), but the majority 
remain at an early stage of development.  
One of the major issues is, whereas haematological 
malignancies appear to be responsive, solid tumours are not, 
probably due to a combination of immune system  impairment 
secondary to previous therapy and the lack of accessibility of 
the immunotoxin. One fascinating approach to tackle solid 
tumours is by targeting cancer stem cells (CSC) with MAb. This 
exciting area suggests that the major cause of conventional 
treatment failure is an inability to kill off the CSC, which then 
give rise to a highly aggressive and resistant population [25]. 
Three approaches are now in pre-clinical development  OMP-
21M8 against multiple solid tumours, RAV17/RAV18 against 
prostate and colon and ARH460-16-2 against leukaemia, 
breast, colon and prostate. All these biologicals utilise novel and 
complex mechanisms of action to target cancer stem cells. 
Beyond the enhancement of MAb immunotherapy using toxin 
conjugates, one of the key areas for development is their 
combination with chemoradiotherapy. In the case of 
radiotherapy, the evidence that it can promote sufficient 'danger' 
signals to enhance immunotherapy, particularly, lymphocyte 
trafficking, is thin. However, there is 20 years old data, which 
suggest that such an effect may be possible [26]. The need now 
is to follow this up with specific studies. The ability of 
chemotherapy to augment immunotherapy is highly attractive. 
There are numerous ways in which this could, from a 
mechanistic standpoint, be achieved but the myelosuppressive 
(reduction in bone marrow activity) nature of many regimens 
coupled with many tumour kill mechanisms often generating 
either weak danger signals for immunotherapy and/or tolerating 
effects is a serious challenge. Two notable recent failures, both 
in lung cancer, provide salutary lessons. The first was the failure 
of a MAb bevacizumab & EGFR inhibitor erlotinib combination 
to arrest non-small cell lung cancer (NSCLC), and second, the 
poor showing of a heat killed suspension of mycobacterium 
vaccae (SRL172) again in a Phase III against NSCLC. There 
were tantalising indications of activity in both cases, particularly 
an enhancement of response rate and median progression free 
survival in the first combination. However, the effect may well 
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have been diluted out by NSLC heterogeneity as well as an 
enhancement of survival from additional therapies after each 
progression.  
Two clear lessons come out of these experiences. The first is 
the need to be much more selective about patient selection 
criteria and tumour type, although this does then beg the 
question as to the commercial viability if indications become 
increasingly narrow, and the second is the need to rebuild and 
maintain the immune system if immunotherapy is to be an 
effective add-on to conventional chemotherapy [27]. 
Furthermore, defining immunogenic regimens and schedules 
will be key to taking this approach forward; for example 
temozolomide is known to be a powerful inhibitor of the immune 
system and gemcitabine depletes B-cells and so would be a 
poor choice for combination therapy with a biological.  
There are four important issues to consider in designing an 
effective cancer vaccine: how to prevent immune evasion, how 
to avoid autoimmune pathology, how to stimulate an effective 
anti-tumour response, and finally, how to identify potent tumour 
rejection antigens [28]. Sadly, few have made it through to the 
clinic and when one takes the most cursory look at the range of 
approaches it is clear that this field is full of complexity. One of 
the main approaches has been to engage cell-mediated 
immunity through either using isolated antigen presenting cells 
or attempting to stimulate them in vivo. Thwarted by the relative 
recent finding of active immunosuppression within the tumour 
microenvironment, a whole range of new strategies have 
emerged to circumvent this. Such complexity and inherent 
development risk has meant that fewer than one fifth of 
oncology biologic therapeutics in pipeline are vaccines. The 
upside is the creativity of approaches in both early and late 
stage development. The majority of late stage clinical trial 
promise is focused on either whole-cell-based autologous or 
allogeneic tumour cells (off the shelf) approaches, but the great 
range, outcome uncertainty and increasing costs make this a 
high-risk area. Delivery has also been a key technical 
challenge. As Freda Stevenson and colleagues discuss in the 
context of DNA vaccines, this has been a challenging area, but 
novel approaches such as electroporation, namely using electric 
charge to 'force' the uptake of DNA, may solve the delivery 
issue [29]. In summary, cancer vaccine development has had a 
many false starts but creative approaches and new 
technologies certainly increase the chance that a winner(s) will 
be found in the next 5 years.  
Our next exploration perhaps gives some idea of the vast range 
and complexity of cancer immunotherapy. It is arguably one of 
the most challenging approaches to cancer immunotherapy and 
yet is utterly absorbing science. Tumour-targeted oncolytic 
viruses (virotherapy with replication-selective viruses) have a 
range of important features that make them a viable 
immunotherapeutic option, in particular the potential for 
selective replication in tumours to increase the therapeutic 
index, the lack of cross-resistance with conventional 
chemoradiation (viruses kill by a numerous other mechanisms) 
and the ability to circumvent either tumour or iatrogenic-induced 
immunosuppression [30]. The technical challenges to achieve 
tumour-selective virus replication are focused around four areas 
 limiting the uptake of viruses into tumour cells whilst ablating 
the uptake into normal cell populations, deletion of gene 
functions that are critical for replication in normal cells, limiting 
expression of the E1A gene product to tumour tissues, or using 
a virus, for example reovirus that is inherently tumour selective. 
A whole slew of approaches using adenoviruses, herpesvirus, 
vaccinia virus, reovirus, etc. are in pre-clinical development. 
Importantly, for such a diverse and complex area, a well-
characterised and quantitated virus dl1520 ONYX- 015 has 
provided important proof-of-concept data in an early clinical trial 
setting. Whilst much has been achieved in this area, for 
example demonstrating the feasibility of virus delivery through 
the blood stream to tumours, major barriers such as the lack of 
model systems and potency issues remain.  
Finally, there are a whole range of novel approaches to 
immunotherapy, which are not easily categorised. 
Immunostimulation as a way of directly killing tumour cells 
and/or indirectly improving chemoradiation effects is being 
explored. Rationally designed approaches utilising MAb have 
been proposed despite the recent toxicities seen with the use of 
the 'super-agonist' anti-CD28 MAb (TGN1412) serving as a 
sobering lesson in the need for careful and cautious research 
and development. However, for cancer, drug development 
biologicals remain a rich and increasingly diverse source for 
new approaches.  
2.5. Concluding Remarks 
It has been barely 50 years since the cancer clinician had but a 
handful of chemotherapeutic agents with which to tackle the 
huge range and diversity of cancers. There has been an 
extraordinary explosion in both our understanding of cancer as 
a disease and in the evolution of new molecular entities. 
Research and development of anti-cancer agents has become a 
highly complex, globalised endeavour, and whereas once the 
private and public sector ploughed separate paths the needs of 
cancer science and the proliferation of the anti-cancer pipeline 
have slowly but inextricably pulled these 'two cultures' together. 
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This Chapter has provided some sense of the complex science 
that underpins cancer drug development. Clearly, this will 
increase with the molecular stratification of cancers, and novel 
prognostic/predictive biomarkers. Policies that understand and 
evolve complex systemic approaches to research organisation 
and management will be essential to deal with the broad church 
of cancer drug development. The classical linear pathways of 
R&D are redundant and a new paradigm is required, one that 
harnesses the strengths and opportunities of both private and 
public sector.  
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3. PUBLIC AND PRIVATE FUNDING FOR 
CANCER DRUG RESEARCH AND 
DEVELOPMENT 
3.1. Background and Objectives 
In policy terms, critical issues around sustainability, productivity 
and patient impact of cancer drug development have never 
been and will not simply be a product of industry. With such an 
extensive portfolio of present and future cancer medicines, the 
funding contribution of the public sector is absolutely vital. 
However, public policy decisions around investment in cancer 
research need to be anchored in evidence, and one of the 
necessary key understandings is the source and flow of capital 
and revenue to support the themes or domains of research.  
A significant number of publications to date on the funding of 
cancer drug development and indeed other disease-specific 
domains have focused on the funding by industry [1,2]. 
Although there is controversy around the use of single numbers 
[3], there is currently a much clearer picture of the expenditure 
by industry on the full development costs of cancer drug 
development for policy making. Yet, annualised figures for 
contribution from the private sector to cancer drug development 
specifically are also missing.  
A major issue lies in the fact that there are almost no reliable 
estimates of what the public sector (philanthropic and federal / 
governmental spending) contributes to cancer drug 
development. Broad-brush policy research has addressed some 
aspects of public sector investment, for example the US 
Institutive of Medicine (IOM) review of public sector cancer 
funding from the late 1990s [4], the mapping of drug 
development expenditure for public sector at national level in 
the United Kingdom [5] and an updated map of European / USA 
public sector spend on general cancer research [6], which 
provide useful denominators. However, data on how these 
funds do (or do not) interconnect with private sector (industry) 
funding or, indeed, from whom this funding flows and how, are 
not available (Figure 3.1).  
The public sector is both source and sink for a huge range of 
research activities in cancer drug development. Furthermore, it 
is the public sector, which mostly trains and hosts today's and 
tomorrow's drug development research faculty, both clinical and 
non-clinical. Broadly speaking, there are two major sources of 
public sector funding for cancer drug development, first, 
philanthropic (which can again be sub-divided into endowed 
charities, e.g. the Wellcome Trust, and annual fundraisers, such 
as Cancer Research UK) and, second, federal (through either 
federal funding organisations or ministries, e.g. BMBF in 
Germany, or as general infrastructure funding to host 
institutions   hospitals/universities sector). In the latter case, 
increasingly, major cancer centres and other host institutions 
are generating their own sources of revenue and capital for 
cancer research. 
Understanding public and private spending on cancer drug 
development either to support direct research costs or through 
general infrastructural funding is essential so as to build a 
coherent picture of the long-term health and stability of cancer 
research and to understand the future of cancer drug 
development. 
The objectives of this chapter are to: 
1.  understand which major public sector research funding 
organisations are supporting cancer drug development 
and how this is aggregated by country and region; 
2.  compare public sector investment by country and 
region, compare and highlight which 
region(s)/countries have committed public sector 
support for cancer drug development and which have 
not. How does this heterogeneity translate to national 
and regional strategies in this area, for example is the 
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Source: The authors. 
Figure 3.1: The public-private interface in cancer drug research and development. 
3.  European Innovative Medicines Initiative building on 
strong foundations? 
4.  explore whether and how cancer research funding 
flows directly to projects or indirectly through general 
infrastructure funds; 
5.  quantify the relative contributions of individual 
countries and understand how this compares with their 
overall cancer research spends; 
6.  understand the breakdown of public sector funding by 
the highest common scientific outline level, for 
example cancer treatment development relative to 
spending in other areas, for example fundamental 
cancer biology; 
7.  outline the relative contributions of charities and NGOs 
versus governments; 
8.  distinguish between the contributions to cancer R&D 
by political grouping in Europe, that is EU member 
states, accession countries and European 
Commission; 
9.  estimate the annual direct spend by major 
pharmaceutical companies, stripping away associated 
costs up- and downstream, in order to provide a more 
complete picture of available funding sources; 
10.  explore the public-private interface (Figure 3.1) and 
how funding flows to cancer drug development along 
this critical boundary; 
11.  discuss how the sources and sinks of funding compare 
between countries, and whether there are policy 
learning points from those deemed 'successful'; 
12.  determine what trends emerge in terms of overall 
'financial commitment' to cancer drug development 
research, by using high-resolution studies of cancer 
centres, and the research portfolios of the United 
Kingdom, USA and Canada. 
3.2. Methods 
In seeking to extract data from both public sector and industry 
organisations as to their funding of cancer research and cancer 
drug development, a survey of public and private sector 
spending on cancer drug research and development was 
conducted with a view to obtaining hard data on monies 
expended on research. Furthermore, in order to provide 
background information as well as to compare the present 
results to those of previous studies, a literature review was also 
carried out.  
3.2.1. Surveying public sector spending on cancer 
drug research and development 
The inclusion criteria for this part of the survey related to (a) the 
choice of country, (b) defining and contacting individual 
Research Funding Organisations (RFOs) for cancer (c) 
classifying the categories of spending for the identified 
organisations into recognisable groups to enable comparisons 
and (d) distinguishing between direct and indirect cancer 
funding.  
With regards to country selection, all EU27 Member States 
together with European Free Trade Association (EFTA) 
countries, Israel and Turkey were included as part of the 
'Europe' region to reflect the breadth of public sector 
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collaborations between countries. Such a broad number would 
also allow a sub-analysis of different R&D systems. The USA 
was also included in the analysis.  
With regards to RFO for cancer, they were defined as those 
public sector bodies with spending over one million Euros per 
annum, as below that level there were estimated to be more 
than 1500 smaller charities in EU15 alone. These organisations 
were classified according to whether they were a ‘federal’ 
(governmental) funder or philanthropic. Federal funders could 
be either ministries or arms-length government funding bodies, 
whereas philanthropic organisations would be either annual 
fundraisers or endowed charities. The identification of the 
organisations was based on broad studies of the public funders 
of cancer research across Europe [7], the USA [4] and, more 
recently, Canada.  
Definitions for categories of spending, for example cancer 
control, biology, treatment were derived from the International 
Cancer Research Portfolio (ICRP) definitions. The ICRP 
enables direct access to cancer research information. Cancer 
research funders from several countries have joined in a 
partnership to classify their research portfolios in a common 
manner. Using the Common Scientific Outline (CSO) as a 
unified classification system, the ICRP allows users to search 
and view cancer research in a variety of ways, including by type 
of cancer, by area of research and by funding organisation.  
A distinction was also made between direct and indirect cancer 
research funding. Direct cancer research funding was defined 
as funding originating from RFO to specific host institutions in 
the form of grants. It does not include educational grants, non-
research staff salaries, physical plant improvements, spending 
on advocacy and service delivery. Indirect cancer research 
funding is funding derived from general taxation allocated to 
support host institution infrastructure and is usually given as a 
block general grant by government authorities.  
A standard procedure was followed for surveying the RFO for 
self-reported spending on cancer drug development involving 
five distinct steps, as follows:  
First, letters were sent to the Directors/CEO's of each RFO 
requesting funding data for 2007/08. The letters provided a full 
explanation of the project. As most RFOs are obliged to provide 
public figures for spending and had been cultivated, there were 
no outright rejections.  
Second, RFO websites were interrogated to ascertain whether 
self-reported figures matched published figures.  
Third, when received, the requested financial information was 
reviewed and crosschecked. Guidelines were established to 
help with this quantification and were followed through the entire 
data collection and data entry phases. For instance, if a funding 
organisation reported spending levels between two amounts, 
the higher amount was always used. Any RFO reporting spend 
in currencies other than Euro had the reported amount of spend 
converted using the web site www.xe.com, all currencies were 
converted within two days of receipt of the information.  
Fourth, the United States spending on cancer drug development 
was based on RFOs identified previously [8]. Many RFOs in the 
USA, such as the Department of Defense and the National 
Cancer Institute, report their cancer research expenditure in 
annual reports and a breakdown of spend by specific 
intervention, that is cancer drug development. Furthermore, the 
RAND Corporation's RaDiUS (Research and Development in 
the United States) database was also interrogated [9]. The 
database identifies by agency all intramural and extramural 
projects or tasks in which the search criteria appear in the title 
or abstract.  
The following terms were used during the relevant search of the 
database: (a) cancer drug development and (b) new active 
substance, new molecular entity (including biologicals and new 
chemical entities as cross check MESH terms). These were 
believed to have the widest possible chance of collecting all 
relevant spending, without including projects out of the scope of 
interest of this survey. The abstracts of the projects were 
reviewed to extract projects that were not focused on cancer 
drug development (such as when cancer was only listed as 
criteria for exclusion in the study).  
Fifth, certain cancer RFOs in the USA, United Kingdom and 
Canada belong to the ICRP, a very high resolution coding of 
spending against domains of cancer research. This database 
was interrogated for project spending levels/activity by the main 
funders of these countries.  
3.2.2. Private sector contribution 
Finally, in order to provide a more complete picture and given 
the fact that the private sector, that is pharmaceutical and 
biotechnology firms, are major investors on cancer research
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and particularly on cancer drugs, we also gave estimates for the 
annual direct spend by major pharmaceutical companies [7].  
3.3. Findings 
The challenging and complex task of developing new ground-
breaking medicinal therapies for cancer relies on a collective 
and multifaceted effort of both public and private investment into 
cancer R&D.  
Funding for cancer research comes from a complex network of 
private and public organisations and from a broad church of 
commercial enterprises to philanthropic causes.  
Understanding 'source to sink' for cancer research funding is 
essential for the development of institutional and national 
policymaking. In cancer drug development, there are three 
broad domains for this funding:  
1.  The basic research that underpins the discovery of 
new targets and molecular entities against these 
targets, as well as the fundamental biological 
processes that drive cancer 
2.  The clinical development phase, including biomarker 
and associated translational research. 
3.  The postmarketing phase as new drugs are further 
developed in new regimens, in combination with 
radiotherapy or against new indications. 
3.3.1. Public (non-commercial) funding 
The majority of cancer R&D globally is carried out within the 
USA and the EU. Research can be funded publicly by the 
national governments or regional authorities (e.g. 'Communidad 
Autonoma de Madrid), by various charities and NGOs, or by 
supranational organisations such as the European Commission 
within the EU. Funding deriving from cancer-specific 
organisations is considered as direct funding and can be either 
governmental, flowing through either federal funding 
organisations or ministries (e.g. BMBF in Germany, INSERM in 
France and the Netherlands Genomics Initiative), or 
philanthropic including charities such as the 'Wellcome Trust' 
(UK), the 'Ligue Nationale contre le cancer' (France) and annual 
fundraisers such as 'Cancer Research UK' and the Dutch 
Cancer Society. On the other hand, funding flowing through 
from general taxation usually as general infrastructure funding 
to host institutions  hospital and/or university sector is 
considered to be indirect. In the latter case, increasingly, major
cancer centres and other host institutions are generating their 
own sources of revenue and capital for cancer research.  
In this section, the presentation of the leading cancer research 
organisations identified and included in the review will be 
followed by a series of metrics aiming to capture the 
performance of individual countries from different perspectives. 
The metrics used are (a) absolute direct public expenditure 
(investment) on cancer research and drug development, (b) 
proportion of total public investment on cancer research that 
goes into drug development, (c) a comparison between the 
absolute direct and indirect investment on cancer R&D in 
Europe and in the United States, (d) per capita direct 
expenditure (investment) in cancer research and development 
and (e) cancer R&D spend as a percentage of GDP.  
(I) Research funding organisations 
The inclusion criteria for this part of the survey with regards to: 
1.  Country selection included the USA and as part of 
the 'Europe' region all EU27 member states together 
with European Free Trade Association (EFTA) 
countries, Israel and Turkey to reflect the breadth of 
public sector collaborations between countries. It is 
noted that from now on  and unless stated otherwise 
 the term 'Europe' will refer to EU27 member states, 
the EFTA countries (i.e. Iceland, Norway and 
Switzerland), the EU candidate countries (i.e. Turkey) 
and the associate states (i.e. Israel). The EU 
Commission  and any funding deriving from it  will 
not be included in that term.  
2.  Research Funding Organisations (RFO) for cancer 
included all those public sector bodies with spending 
over one million Euros per annum and were classified 
according to whether they were a ‘federal’ 
(governmental) funder, such as ministries or arms-
length government funding bodies, or philanthropic, 
such as annual fundraisers or endowed charities;  
3.  Definitions for categories of spending, for example 
cancer control, biology, treatment were derived from 
the International Cancer Research Portfolio definitions 
classifying the categories of spending for the identified 
organisations into recognisable groups to enable 
comparisons and 
4.  Distinguishing between direct and indirect cancer 
funding, included as direct cancer research funding
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Source: The authors. 
Figure 3.2: Number of public sector funding organisations by country.
the funding originating from RFO to specific host 
institutions in the form of grants. It does not include 
educational grants, non-research staff salaries, 
physical plant improvements, spending on advocacy 
and service delivery. As indirect cancer research 
funding was included the funding that derived from 
general taxation and is allocated to support host 
institution infrastructure and is usually given as a block 
general grant by government authorities. 
In total, 153 non-commercial RFO that satisfied the above 
criteria were identified across European countries and 21 in the 
United States and were included in the analysis (Figure 3.2). 
Apart from these 153 RFOs numerous, other smaller charities 
exist but were not included in the survey as their annual 
spending was less than one million Euros. For instance, it has 
been estimated that more than 1500 such charities are 
operating in EU15 alone. Their large number and their relative 
small direct contribution to cancer research made their inclusion 
inefficient, if not impossible. Although, this omission may lead to 
a slight underestimation of the overall level of public funding on 
cancer research, the goals of the analysis (i.e. to built a 
coherent picture of the long-term health and stability of cancer 
research and to understand the future of cancer drug 
development) are still achieved.  
It must also be acknowledged that part of the federal funding is 
indirect, in the sense spending on hospitals/universities, and 
even though it is used for cancer research it is not explicitly 
earmarked. As a result, the survey mainly addresses direct 
cancer research investment and there may be underestimations 
on the level of indirect contributions.  
Finally, funding flowing in from the European Commission is 
likely to be underrepresented, as the annual average during 
Framework Programme 6 was used, and it is expected that the 
Framework Programme 7 average will be higher.  
 
(II) Summary of policies and organisations 
supporting cancer drug research and development in 
Europe and North America 
The European Union 
The EC has a number of programmes to help encourage cancer 
drug R&D. The primary overall research support programme is 
the Framework Programme (FP), which provides funds and 
support to all areas of research activity in Europe [10]. Cancer 
research is one of those activities, channeled into the 
'Combating Cancer' initiative. Previous reports have criticised 
EU cancer research with its fragmentation and diversity, as well 
as different support mechanisms and funding bodies. Recent 
action has been proposed from the EC with 'Action Against 
Cancer', with financial support from the FP, as well as further 
support from the European Research Areas (ERA) whose 
objectives include forming partnerships between EU, national 
and regional research programmes, activities and policies [11]. 
As a result, the previous FP6 (2002-2006) invested some €480 
million to 108 transnational cancer research projects, whilst the 
current FP7 (2007-2013) has to date invested €265 million to 65 
projects and 700 research groups (one-third to large 
transnational projects), with more monies allocated in the future 
(Table 3.1).  
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Table 3.1: Synopsis of policies and programmes encouraging cancer drug development globally
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Box 3.1: Examples of Transnational Cancer Research Projects in the EU under FP7 [17] 
GENINCA: to examine cancer genome instability, in the hopes of leading to novel targeted cellular cancer treatments 
(11 partners in eight countries; €3 million 2008-2011). 
ERA-NET: to increase cooperation and coordination of research, including cancer research, activities throughout the 
EU by networking national and regional level activities and mutual opening of national and regional programmes (€2 
million 2009). 
INFLA-CARE: to develop innovative anti-inflammatory strategies and novel agents for cancer prevention and treatment 
by studying inflammation-driven cancer (20 partners in nine countries; €12 million 2009-2014). 
ADAMANT: to generate superior anti-cancer agents relying on antibody-based delivery of cytotoxics, radionuclides or 
immunostimulatory cytokines to vascular tumour antigens or tumour cell membranes (€3 million; eight partners in six 
countries). 
 
The FP6 promoted research activities with long-term impact, 
which strengthened Europe's general scientific and 
technological basis. In particular, funds were invested where 
European cooperation was seen to have significant benefit, 
striving for EU level research with many areas and levels of 
integration. This integration and broader longitudinal view were 
new compared to previous FPs. The FP7 continues along this 
same principle, with even greater interest in EU level 
cooperation and coordination of research activities.  
Due to this transnational focus, many of the previous FP6 and 
current FP7 funded projects encompass many countries and 
research institutes (Box 3.1). Previous FP5 (1998-2002) 
research focused on molecular mechanisms underlying cancer,
P
o
l
i
c
y
 ecancer 2010, 4:164 
 
 36  www.ecancermedicalscience.com 
 
Box 3.2. Examples of FP6 Transnational Cancer Research Projects in the EU, under Framework Programme 6 
(FP6). 
aa, [12,13] 
EUROCAN+PLUS: to coordinate European national cancer research activities after initial consultation found significant 
fragmentation, poor leadership and poor sustainability as major barriers to innovative cancer research. Research 
duplication, wasting time and money, limited intellectual concentration, poor communication and tensions between 
funders and researchers were seen as additional obstacles. The project recommended to creation of an independent 
European Cancer Initiative (ECI) assuming responsibility for: 
•  stimulating innovative cancer research and facilitate processes; 
•  common voice for cancer research; 
•  interface between public and private cancer stakeholders; 
•  develop solutions to eliminate collaboration and coordination barriers; 
•  regulatory and legal issues. 
This ECI should have a platform for translational research encompassing: 
•  coordination between basic, clinical and epidemiological approaches; 
•  formal cooperation agreements between cancer centres and research laboratories throughout EU; 
•  networking between EU funding bodies. 
Creation of the ECI has yet to be developed (Aug 2009). 
ATTACK: to improve engineered T-cell function and perform pre-clinical trials, with the potential application of gene 
therapy treatment (17 partners in eight countries; €11.9 million 2005-2010).  
CANCER IMMUNOTHERAPY: to develop a therapeutic cancer vaccine with defined tumour antigens, refining 
vaccinations and combining vaccines with other cancer treatments (22 partners in eight countries; €12.2 million 2006-
2010). 
TRANSBIG: to develop individualised breast cancer treatment, to facilitate translational breast cancer research and to 
organise a clinical trial examining tumour genetic signature for use in targeted treatments (40 partners in 22 countries, 
€7 million 2004-2011). 
 
whilst FP6 and FP7 focus on translational research, to bring 
basic knowledge into practice more quickly (Boxes 3.1,  3.2). 
The FP6 funded EUROCAN+ PLUS project (€5 million budget) 
aimed to improve EU research coordination, bringing together 
the Karolinska Institute, Institute Gustave Roussy, Instituto 
Europeo di Oncologia, ministries and foundations. Further 
support for research coordination is brought by the ERA 
Networking project (ERA-Net), focusing on coordinating national 
and regional research organisations.  
Another major EC programme, which encourages cancer drug 
research and development, is the Innovative Medicines Initiative 
(IMI), a public-private partnership focused on speeding up the 
process of drug discovery and treatment [14]. This initiative is a 
collaboration between the EC and the European Federation of 
Pharmaceutical Industries and Associations (EFPIA), with the 
EC supporting research and development for Academic as well 
as Small to Medium sized enterprises, whilst Large Biopharma 
fund themselves, with equal support from each partner. The IMI
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Box 3.3: Examples of National Cancer Research Projects Supported by NCI (USA) [22]. 
•  Molecular Targets Development Program identifies and evaluates potential molecular targets for 
drug development. 
•  Chemical Biology Consortium accelerates discovery and development of first-in-class targeted 
therapies, choosing high-risk targets of low interest to pharma industry 
•  Rapid Access to Intervention Development (1998) creates bridges between academic discovery 
and clinical trials, as well as supporting investigations into orphan diseases. To date, RAID has 
supported 133 projects, resulting in 21 small molecule and 25 biological investigation new drug 
approvals. 
•  Phase 0 clinical trial development, where low doses of investigational drugs are given to few 
patients in order to determine whether further investigation is worthwhile. 
•  Advanced Technology Partnerships Initiative (ATPI) new research facility to encourage 
collaborations between public, private and academic stakeholders. 
•  Office of Biorepositories and Biospecimen Research to ensure high-quality human specimens 
available for research and the creation of a non-profit national biobank. 
•  Action as broker between various public and private investors in clinical trials (Life Sciences 
Consortium) to ensure speedy contract negotiations (which can cost companies greater than $1 
million in delays and take between 180-300 days). The LSC has created a Master Agreement 
template in 2008 (freely available online) to minimise contract delays due to language, now 
supported by the Department of Justice 
 
has a new focus, the Joint Technology Initiative, to support 
public-private research cooperation for faster development of 
new medicines by addressing key bottlenecks in the drug 
development process (Table 3.1) [15,16]. The IMI is managed 
by an autonomous body in Brussels, with half the governing 
board composed of EC members and half by industry, with 
industry setting the first round of priorities. 
A new initiative, European Action Against Rare Cancers, has 
recently been announced by the EC, as part of their 'Action 
Against Cancer' initiative [18]. This focus will be on rare 
cancers, both in prevention and treatment, with goals to be 
determined in the Fall of 2009. All but the major five cancers 
(breast, colorectal, prostate, lung and bladder cancers) are 
classified as rare disease [19].  
Another organisation in Europe is the European Organisation 
for Research and Treatment in Cancer, whose aim is to 
stimulate translational and clinical research in Europe. This 
organisation is funded via various cancer charities in Europe, 
the FP, industry, and the NCI, primarily for clinical trials.  
 
The USA 
The National Cancer Institute (NCI) in the United States is the 
main source of cancer research funds in America. The NCI is 
part of the National Institute of Health and the US Department of 
Health and Human Resources, established in 1937 as part of 
the National Cancer Institute Act, and receives its funds from 
the US Congress [20]. The 2008 budget included a 1% increase 
from 2007, and 43% was allocated to 5380 Research Project 
Grants and 15% to intramural research (Table 3.1) [21]. The 
NCI has a specific drug development platform, which supports a 
variety of drug development initiatives, from speedier entry into 
the marketplace to robotic high-throughput screening allowing 
fast biochemical, genetic and pharmaceutical testing 
(Box 3.3).  
The NCI also supports international research via its 
International Portfolio, supporting cancer research activity in 
both developed, transitional and developing countries [22]. The 
activities range from acting as liaison between entities, 
supporting training and education, organising global clinical 
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Box 3.4: Examples of activities supported by the NCI International Portfolio [22] 
•  German trial of radioimmunotherapy for NHL, the radioisotope bismuth-213 was provided by the 
NCI through a Material Transfer Agreement 
•  National Cancer Institute of Canada (NCIC) participates in the NCI Clinical Trials Cooperative 
Group Program. Currently, more than 90% of investigational drugs shipped internationally by the 
NCI Cancer Therapy Evaluation Program are sent to Canada  some of these are included in 
Phase II trials, the only country to do so outside the United States. 
•  International clinical trial, led by the NCIC Clinical Trials Group, on letrozole (Femara-Novartis) to 
reduce the risk of breast cancer recurrence. Patients registered in the trial come from: Canada, the 
United Staes, United Kingdom, Belgium, Ireland, Italy, Poland, Portugal and Switzerland. 
•  Collection of more than 50,000 plant specimens from Africa, Madagascar, Central and South 
America, Southeast Asia for the NCI Developmental Therapeutics Program. 
•  Support to International Center for Studies of Traditional Chinese Medicine, partnering the 
University of Texas with Fudan University in Shanghai. 
•  Support for the AIDS Malignancy Consortium to pursue clinical trials in resource poor 
 
trials and collecting information about experimental drugs and 
protocols with global collaborators (Box 3.4).  
Further support for cancer drug research in the United States is 
given by the Foundation for the National Institutes of Health, 
established by the US Congress to support the National Institute 
of Health via public-private partnership. It is a non-profit 
organisation raising private funds to support NIH's public 
actions, including drug research and development.  
The United Kingdom  
The main cancer research agency in the United Kingdom is the 
National Cancer Research Institute (NCRI), whose new focus in 
medicine development is translational research (Box 3.5). The 
NCRI works with industry, developing relationships and 
collaboration with private enterprise. A number of companies 
are involved in various NCRI boards, and the NCRI portfolio 
now includes 34 clinical trails with 17 different companies with 
likely increases in the future.  
The Medical Research Council (MRC) in the United Kingdom is 
an additional source of cancer drug development funded by the 
Department for Innovation, Universities and Skills [23]. The 
MRC works with the National Institute for Health Research, as 
well as having close ties with industry, recently increasing 
expert industry board members. It has recently joined with 
Cancer Research UK, the Wellcome Trust and University of 
College London to form the UK CMR International, bringing 
academics, clinicians and industry together to build a worldclass 
cancer research institute (building complete 2014) [24]. Their 
Drug Discovery Group (DDG) includes cancer research as a 
main focus and includes therapeutic antibodies (Therapeutic 
Antibody Group) and kinase programme (Protein 
Phosphorylation Unit) research. They also collaborate 
internationally with other EU and global cancer research 
agencies.  
Canada 
In Canada, the two main cancer research bodies are the 
Canadian Foundation for Innovation and Canadian Institute of 
Health Research [27]. Together, they fund more than 50% of 
  cancer research, the remainder funded by 33 different 
agencies, including provincial, federal, voluntary and multi-
funded organisations, which together invested $390 million 
(CDN) in 2006. The Canadian Foundation for Innovation is an 
independent organisation created by the Government of 
Canada to fund research infrastructure in order to assist 
universities, hospitals and non-profit research agencies in 
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Box 3.5: Examples of UK Cancer Research Activities supported by the NCRI [25,26],
 a. 
Oncology Information exchange (ONIX): launched in July 2009, which allows the public, scientists and physicians to 
search and access global online research data in order to encourage the flow of cancer research information between 
vested bodies (£2.5 million, 2003-2010). 
National Cancer Research Network (NCRN): supports cancer clinical trials in the National Health Service (NHS) to 
improve coordination, integration, quality, inclusiveness and speed of cancer research. Currently, 11.2% of cancer 
patients are now entered into clinical trials, now supported by 33 Cancer Research Networks that are integrated with 
Cancer Services Network (£150 million, 2001-2011). 
Experimental Cancer Medicine Centres (ECMC): aims to expand the experimental cancer medicine portfolio and to 
attract industry-sponsored experimental cancer medicine. It is funded by the Department of Health and led by Cancer 
Research UK. It consists of 17 centres, and 2 in development, throughout the United Kingdom, with each centre 
receiving £2.5 million annually (£35 million, 2007-2012) 
Confederation of Cancer Biobanks (onCore UK): systematic collection of cancer biosamples organised by the 
Department of Health, Cancer Research UK and Medical Research Council (£5 million, 2008). 
performing excellent quality research, including cancer research 
[28]. One such project is the Canada-California Strategic 
Innovation Partnership Initiative, a public-private partnership, 
targeting cancer stem cell research.  
The Canadian Institute of Health Research is composed of 13 
institutes, the Institute for Cancer Research (ICR) being relevant 
[29]. They support the Canadian Clinical Trials Group, which 
carries out oncology clinical trials across Canada via 90 
member institutions (Phase IIII). In addition, they began the 
Strategic Training Initiative in Health Research (STIHR), which 
supports research training as well as cross-collaboration with 
other disciplines.  
Germany 
The main German cancer research organisation is the German 
Cancer Research Centre (Deutsches Krebsforschungszentrum, 
DKFZ), which is the largest biomedical research institute in 
Germany, and focus on cancer research as well as patient 
information services [30]. The centre is funded primarily by the 
government, both federal and state, and donations.  
France 
France has two main cancer research organisations, the 
National Institute for Cancer (Institut National du Cancer, INCA) 
and the Association for Cancer Research (Association pour la 
Rescherche sur le Cancer, L'ARC) [31]. INCA has two main 
goals to develop cancer expertise and to develop scientific 
oncology programmes, in order to address public health, quality 
of care, information dissemination and conduct scientific 
research [32]. Financing comes from public-private 
partnerships, government and public sources. L'ARC has 
supported more than 7500 research projects over the past 6 
years, primarily on cellular and clinical research.  
Other 
Other organisations in Europe include the Danish Cancer 
Society, Swedish Cancer Society, Finnish Cancer Organisation, 
Spanish Cancer Association, Italian Medical Oncology 
Association, Norwegian Cancer Society, Swiss Institute for 
Cancer Research, Dutch Cancer Institute (NKI), and a number 
of others.  
Also, very important to consider are cancer charities, which 
contribute significant private funds and vision to cancer 
research. As these monies can be significant, and in many 
instances greater than national cancer research funding, their 
role in providing advances in cancer treatment cannot be 
ignored. In some instances, funds are allocated outside of the 
home country's charity, whilst others are allocated only to 
national research.  
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Overall 
The diversity of organisations associated with cancer research 
is large, often with significant overlap or duplicity in purpose. 
Most organisations are specific only to a certain country (i.e. 
Danish Cancer Society) or region within a country, whilst others 
are true only to specific disease (i.e. Children's Oncology Group 
Soft Tissue Sarcoma Committee) even as far as a specific 
disease in a region of the country (i.e. Quebec Breast Cancer 
Foundation). It is estimated there are more than 120 cancer 
organisations in Europe, Canada and the United States that 
participate partially or solely in cancer research. 
Although this diverse representation of research, as well as 
national or regional, aspects are understandable, the result may 
be duplication and fragmentation. Administrative costs are 
duplicated, available funds for similar purposes are split and the 
cancer research 'voice' may be weakened. The Framework 
Programme in Europe seeks to rectify this somewhat, however, 
has been criticised for adding yet another layer of cancer 
research bureaucracy [33,34]. Recently, it has been discussed 
that EU level leadership on cancer research needs to be 
improved and strengthened as well as improve partnership with 
industry in order to foster innovation [35].  
Furthermore, differences in national laws can provide a further 
barrier to performing transnational research [36]. For example, 
tissue sample banking in one country may be 'opted in' whilst 
another 'opted out'. Data protection and anonymity is another 
hurdle, particularly where long-term follow-up is necessary. 
Even the designation of medical specialties is universal, there 
are a number of countries without the medical oncology 
specialty (falling under internal medicine domain). The sparse 
combination of research and medical speciality (MD, PhD) is 
also a barrier to cancer research. Although in the United States 
this combination exists, in Europe this combination is rare.  
The EU introduced a Clinical Trials Directive in 2004, designed 
to harmonise clinical trials in Europe; however, it has been 
criticised for increasing the bureaucracy and creating another 
barrier for clinical trials to occur in Europe. In the United 
Kingdom, it has been held responsible for decreasing clinical 
trials activity [37], whilst in Europe overall it is a factor in longer 
trial regulatory procedures [38]. Particularly for childhood 
cancers, it has been seen as responsible for difficulties in 
recruitment, increased insurance costs and difficulties between 
countries in interpretation and direction of trials [39]. It will be 
reviewed in 2010. 
(III) Variation in spending by nation 
(a) Direct cancer research funding 
The 153 European public funding organisations spent altogether 
€2.79 billion on oncology research during 2006-2007. Moreover, 
the 21 US public funding organisations spent €5.8 billion during 
the same period (Figure 3.3).  
It is, therefore, obvious that the USA dominates in terms of 
absolute direct expenditure, investing in cancer research more 
than double the combined investment of European countries. 
Still, it must be noted that the European figure is likely to be an 
underestimate as it does not include EU funding by bodies such 
as the European Commission estimated to have invested on 
average €90 million per annum during FP6.  
The results further suggest that there is a wide variation in direct 
funding among different nations. In Europe, the highest single 
source of public funding was the United Kingdom with €1.1 
billion expenditure. Germany, France and Italy also invested 
significant amounts, which when put together, amounted the 
same as the United Kingdom. From the countries included in 
the survey only Malta reported no direct investment in cancer 
research, whilst Bulgaria failed to report on any expenditure.  
Another interesting finding is that drug development accounts 
for a relatively large part of direct public investment (Table 3.2). 
However, this excludes late stage clinical development and, 
furthermore, much of this funding is focused on pre-clinical 
development. 
(b) Indirect cancer research funding 
From previous funding surveys [7] it was clear that, particularly 
in Europe, significant levels of support for cancer research flow 
from general taxation into R&D support for hospitals/ 
universities. Through the interrogation of major EU countries 
and reverse engineering using bibliometrics, the level of this 
'indirect' funding supporting cancer drug development in the 
public sector both in Europe and the USA was estimated for 
2007 (Figure 3.4). 
(c) Per capita direct spending for cancer research 
Reviewing total public sector direct funding per capita
o 
demonstrated substantial direct funding by the USA (€19/capita) 
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Table 3.2: Drug R&D as percentage of total direct spending 
 
Source: The authors. 
 
Source: The authors. 
Figure 3.3: Direct cancer drug R&D (Spending on log scale).
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Figure 3.4: Estimated indirect cancer R&D funding. 
Source: The authors. 
Figure 3.5: Cancer R&D direct spending (€) per capita. 
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Table 3.3: Top-10 public spenders on cancer R&D per capita versus absolute spending 
 
Source: The authors.
and the United Kingdom (€18/capita) (Figure 3.5). Scandinavian 
countries and the Netherlands are also strong supporters of 
cancer research with Sweden, the Netherlands and Norway 
investing €12.1, €8.8 and €7.2 per capita, respectively. In 
absolute terms, apart from leading US and UK funding, 
substantial European funding derives from remaining large 
Western European countries (Germany, France, Italy and 
Spain) (Table 3.3). 
Regarding drug development, the United States and the United 
Kingdom remain leaders, both investing more than €5 per capita 
for drug development. Additionally, eight more European 
countries spend at least one Euro per capita on drug 
development (Table 3.4). In absolute terms, large Western 
European countries dominate in drug development funding as 
they did in the case of overall cancer research. 
The USA and United Kingdom have a long history of public 
sector support of cancer drug development (Table 3.5). In the 
USA, this has been in place since the early days of the National 
Cancer Institute (NCI) and has formed a major backbone of its 
strategy through a variety of funding streams both direct project 
related and infrastructural. In the UK cancer drug development 
in the public sector has enjoyed a major philanthropic backer 
and, more recently, increased governmental support through 
the creation of the Experimental Cancer Medicine Centres 
initiative (ECMC)
p. However, apart from the USA and the United 
Kingdom who appear to have a national strategy on cancer drug 
development, overall the levels of funding per capita do not 
appear to equate with any coherent national strategy on cancer 
drug development, rather these levels reflect an ad hoc 
approach by governmental and philanthropic funders. 
When averages are examined, it becomes apparent that Europe 
fails to match the public funding levels of the United States in 
cancer research and development. Indeed, the average per 
capita spend on total cancer research across the entire Europe 
was €3.45 whilst the per capita spent in the United States was 
€19.34. However, this gap is reduced to threefold if the United 
States spending is compared with the spending of the EU15 
countries only (average per capita spend €5.64).  
Compared to 2004 funding levels [1] Europe spend per capita 
on average in 2007 34.7% more whilst the United States 9.7% 
more revealing an obvious trend for Europe to close the existing 
gap with the US (Figure 3.6). 
(d) Direct spending for cancer research as a 
percentage of GDP 
A similar pattern is evident when one reviews cancer research 
spend relative to GDP (Figure 3.7). The average cancer 
research spend for 'Europe' was 0.0143% of GDP, which is a 
decrease of 19.2% from 2004 figures (average spend was
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Table 3.4: Top-10 public spenders on cancer drug R&D per capita versus absolute spend 
 
Source: The authors. 
Table 3.5: Main funding sources of Europe's top funding countries (public sector) 
 
Source: The authors from National Sources.
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Source: ECRM (2004 data) and the Authors (2007 data). 
Figure 3.6: Direct cancer R&D spending per capita, 2004 versus 2007 (€). 
 
Source: The authors. 
Figure 3.7: Cancer drug R&D and cancer R&D direct spending, % of GDP. 
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Source: The authors. 
Figure 3.8: Route of cancer drug R&D funding. 
 
Source: The authors. 
Figure 3.9: Cancer drug R&D spend per capita (€).
0.0177%). The average cancer research spend in the USA was 
0.061% of GDP in 2007, representing an approximate 10% 
increase more than 2004. The European spend is driven by the 
United Kingdom (0.072 of GDP on cancer research), followed 
by Sweden (0.048% of GDP).  
In the case of drug development, again the United Kingdom and 
the United States are investing a larger part of their GDP than 
the rest of the countries in the survey. 
(e) Cumulative spending for cancer drug R&D 
Total public sector support from all research funding 
organisations and through hospitals/universities (indirect) 
identified by this survey for cancer drug development in Europe 
and the USA was estimated to be €2.8 Billion in 2007/2008 
(Figure 3.8). 
Adding indirect spend for Europe as a whole dramatically closes 
the 'gap' with the US public sector funding of cancer drug 
development (Figures 3.9, 3.10). In effect, when both direct and 
indirect funding is taken into account, Europe spends 0,011% of 
GDP into cancer drug development compared to 0018% by the 
USA and €3.64 per capita compared to €5.74 by the USA. 
(f) Spending by CSO in Europe 
In order to compare and contrast research portfolios of public 
(i.e. NGOs and governmental) research organisations using a 
certified vocabulary, the Common Scientific Outline (CSO) [40] 
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Source: The authors. 
Figure 3.10: Cancer drug R&D spend, % of GDP. 
 
Source: The authors. 
Figure 3.11: European cancer R&D spend by CSO category.
was used quantify cancer research expenditure. The CSO is a 
classification system, originally validated by the International 
Cancer Research Portfolio (ICRP) [41] and now in use by the 
USA, United Kingdom and Canada [27] that is used to classify 
spending around seven broad areas of scientific interest in 
cancer research.  
One hundred and two research funding organisations were 
interrogated across Europe, of which 47 returned usable data of 
self-reported percentage breakdown of their annual spending on 
cancer research by the highest common scientific outline level. 
Briefly, €750.6 million was spent on cancer research by both 
charities and governmental research agencies, from which 
€557.1 million was placed in CSO categories (Figure 3.11).  
This dataset found a strong and growing commitment by 
European funders to supporting cancer drug development. In 
nearly all projects there was a complex mixture of funding 
sources supporting various components of the research project, 
whether laboratory based or clinical. Whilst distinct funding 
streams do exist from research funding organisations, once 
these resources hit the front line then research groups and 
P
o
l
i
c
y
 ecancer 2010, 4:164 
 
 48  www.ecancermedicalscience.com 
 
 
Source: The authors. 
Figure 3.12: Number of active cancer drug development projects by funder, grouped by country (log scale). 
 
Source: The authors. 
Figure 3.13: Scatter plot showing percentage of spend according to domain of research (by CSO category) for a sample of European Cancer 
Centres (n= 20).
centres utilise both private and public financing in a mixed 
economy to deliver on the group's or centres goals.  
A high-resolution analysis of all projects falling under cancer 
drug development (including associated biomarker studies) has 
also been derived from the ICRP database. Figure 3.11 shows 
the distribution of active drug development projects (2007/08) 
by research funder in the USA, United Kingdom and Canada.
q 
In total, these public sector major RFOs in three countries are 
currently supporting 5105 cancer drug development projects 
(591 projects by 14 Canadian RFOs; 455 projects by 9 UK 
RFO's and 4059 projects by 5 USA RFO's) (Figure 3.12). 
Using the ICRP database, a high-resolution study of the major 
European Cancer centres involved in drug development has 
also been conducted to assess Institutional level spend on 
cancer drug development relative to other domains of cancer 
research.  
Fundamental biology and research into treatment, of which 
cancer drug development accounts for around 82% of the total 
spend, dominate the research funding allocations by this 
sample of major European Cancer Research Centers (Figure 
3.13). Research into cancer drug development is a significant 
aspect of all those centres' portfolio and across research 
domains we have estimated from this high-level coding that
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Source: The authors. 
Figure 3.13: Scatter plot showing percentage of spend according to domain of research (by CSO category) for a sample of European Cancer 
Centres (n= 20).
circa 36% of all cancer research activity in major European 
Cancer Centers is focused on cancer drug development. 
(g) Spending by charities versus governments 
There are a very large number of charities supporting cancer 
research worldwide. Some charitable organisations focus on 
specific types of cancer and give priority in funding research 
related to this specific cancer. Examples of charities falling into 
that category included in this survey are 'Associazione Italiana 
contro le Leucemie, Linfomi e Mieloma' and 'Associazione 
Italiana per la Lotta al Neuroblastoma' in Italy, which focus on 
Leukemia, Lymphoma, Myeloma and Neuroblastoma, 
'Breakthrough Breast Cancer', 'Breast Cancer Campaign' and 
'Leukemia Research Fund' in the United Kingdom and 'Prostate 
Cancer foundation', 'The Leukemia and Lymphoma Society' and 
'The Komen Breast Cancer Foundation' in the USA.  
These charities are usually smaller and do not fund in absolute 
terms as much as the ones that focus on cancer broadly. For 
instance, the American Cancer Society, The American Institute 
for Cancer Research, Cancer Research UK, the Belgian 
Federation Against Cancer, the Danish Cancer Society, the 
'Association pour la Reserche contre le Cancer' and the 'Ligue 
Nationale contre le Cancer' in France, the Irish Cancer Society, 
'Associazione Italiana per la Ricera sul Cancro (AIRC) in Italy, 
the Dutch Cancer Society and the BMBF in Germany are 
organisations that fund significant amounts in overall cancer 
research.  
In addition, some charities do not focus specifically on cancer 
as they finance a broad variety of medical research. However, 
some invest significant amounts on cancer research such as the 
Wellcome Trust42 that represents the largest charity in the 
United Kingdom and the 'Fundación la Caixa' in Spain.  
In the USA, governmental sources of funding for cancer 
development dominate mostly through the National Cancer 
Institute (NCI) and NIH Research Project Grant Program (RO1) 
grants from the National Institutes of Health (NIH). On the other 
hand, Europe is actively supported by the philanthropic sector.  
In this respect, some countries have well-developed 
philanthropic and governmental funders for public sector drug 
development both in terms of number of funding organisations 
and in absolute investment, for example the United Kingdom, 
the Netherlands, France and Germany. However, most 
countries are heavily reliant on the private sector to support 
both individual projects and some basic infrastructure within the 
hospitals/universities sector.  
In particular, whilst philanthropic funders support a wide range 
of cancer drug development projects, there appears to be a 
relative deficit of funding from governmental sources in Europe 
(Figure 3.14). In fact, more than 50% of non-commercial funding 
in Europe derives from the philanthropic sector. 
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Source: The authors. 
Figure 3.14: Drug R&D funding by charities and government (2007). 
 
Source: The authors. 
Figure 3.15: Percent of direct spend by political group in Europe (2007). 
It should also be mentioned that in Europe, for six countries (i.e. 
Bulgaria, Estonia, Latvia, Lithuania, Romania and Slovenia), 
there were no philanthropic funding organisations for oncology 
research. In contrast, in Cyprus, there was no government R&D 
funding organisation for cancer. 
(h) Spending by political EU membership status 
Current European Union member states (EU27) contributed 
more than €2693 million to non-commercial cancer research. 
The accession countries contributed only for the 0.75% of the 
total expenditure in Europe. The European Commission (EC), 
according to the per annum average during FP6, contributed 
€90 million to cancer research, although this number may be 
underestimating the actual support as cancer research is being 
funded by other, indirect streams from the EC (Figure 3.15). 
3.3.2. Private sector cancer funding organisations 
[I] Types of private funding for cancer research 
Private/commercial funding for cancer research derives from the 
industry (Pharmaceutical and Biomedical/Biopharmaceutical 
Industry). Information on industry-related funding is difficult to 
determine partly because of proprietary concerns. Moreover, it 
is said that marketing and administration costs are often 
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Note: *The figure does not include all industry (e.g. SME and biotechnology). 
Source: [7]. 
Figure 3.16: Private cancer drug development spend: major pharmaceutical companies (2004/ Phase III)*
included into the reported R&D expenditure [8]. The private 
funding focuses primarily on drug development [43].  
[II] Commercial expenditure on cancer research 
Various publications have estimated commercial expenditure on 
cancer R&D using a variety of sources. In general, there are 
three different ways to calculate worldwide private R&D 
spending:  
1.  Based on development cost of a new chemical entity 
(NCE). 
2.  Based on total R&D expenditure weighted by share of 
oncology drugs. 
3.  Total oncology and immunomodulant R&D expenditure 
(e.g. according to CMR International). 
Because the variety of accounting methods used as well as the 
inclusion of 'marketing' expenditure as part of these estimates. it 
has been notoriously difficult to estimate the true level of 
disease-specific expenditure.  
One novel way to estimate direct cancer-related expenditure 
using bibliometrics is by assigning cost per unit of research 
based on outputs, that is the proportion of each company's 
published papers that are in cancer research (Figure 3.16). 
Stated R&D expenditure from annual reports is considered to be 
the total R&D cost for each major pharmaceutical company. 
However, one issue with this method is that it is likely to 
underestimate the true activity of a company in certain areas 
from which publications do not adequately reflect output, for 
example early phase clinical trials. We can correct for this 
relative underestimation to give a broad picture of direct spend 
on cancer drug R&D.  
Total expenditure by 17 major pharmaceutical companies was 
almost €3095 million (2004 figures, reported in 2008). By 
separating the US-based from the Europe-based companies, 
we can get an idea of what proportion of private spending flows 
from each area (Figure 3.17). In fact, 59% of the total private 
cancer R&D funding derived from Europe-based companies. 
3.3.3. Public-private partnerships in cancer drug 
development 
Public-private partnership is strong in both Europe and the USA, 
particularly in the former this is growing. Philanthropic and 
federal funders must recognise and reward these joint 
enterprises, particularly in light of the growing complexity and 
number of the cancer drug pipeline and associated predictive 
markers.  
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Source: The authors. 
Figure 3.17: Private cancer R&D funding by company origin.
 
Source: The authors. 
Figure 3.18: Cancer drug development projects with joint private-public funding (%) (2007-2008). 
The figure below (Figure 3.18) gives a 'snapshot' of recent 
annual spending from which we can assess the relative amount 
of public-private collaboration. Although this only looks at one 
metric (i.e. outputs), it nevertheless provides an indicator of the 
current health of private-public collaboration in cancer drug 
development. These measure real collaborations, that is joint 
intellectual input, but do not take into account projects for which 
industry have provided basic infrastructure funding to research 
units, unrestricted educational grants or in-kind support (e.g. 
free-drug supply). All these activities could legitimately be put 
into the public-private 'partnership' category. Furthermore, an 
analysis of the projects detailed in Figure 3.12 has also been 
used to estimate the degree to which industry and the public 
sector already cooperate on cancer drug development. 
Looking at trends, whilst the USA and the Rest of the World 
have been relatively static since the mid 1990s, Europe has 
seen substantial growth in its private-public joint research 
projects on cancer drugs. We have also found some evidence 
(from interviews with key opinion leaders) to support the fact 
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that the practice of unrestricted grant support appears a more 
widespread practice in Europe than the USA.  
3.4. Discussion 
The burden of cancer has broad consequences that go beyond 
individuals and their families to the health care systems and 
economies of individual countries. Therefore, as human lives 
are increasingly burdened by cancer, the fight against the 
disease relies on both a strong privately and publicly funded 
research base.  
Understanding public and private spending on cancer drug 
research and development, either to support direct research 
costs or through general infrastructural funding, is essential to 
build a coherent picture of the long-term health and stability of 
cancer research and to understand the future of cancer drug 
development. Any public policy decisions regarding the setting 
of priorities and investment in cancer research need to be 
anchored in evidence, and one of the necessary key 
understandings is the source and flow of funds to support 
research presented in the previous section. Moreover, 
comparable and reliable data on ongoing research activity are 
essential in order to promote and coordinate strategic planning 
of cancer research both at national and international levels.  
This section discusses the motives behind public cancer 
research funding and identifies the emerging trends in terms of 
overall 'financial commitment' to cancer drug development 
research. In parallel, it explores how the sources and sinks of 
funding compare between countries and whether there are 
policy learning points from those deemed as successful. 
Moreover, the role of the private sector, its partnership with the 
public sector, and the national/supranational interface are 
underlined. Finally, it discusses whether a clear picture is 
emerging in forming policy options by highlighting the lack of 
data, the gaps and the limitations in our understanding of 
cancer research funding.  
3.4.1. Public sector funding 
[I] Motivation for publicly funded research 
In general, there are two main kinds of motivation for publicly 
funded research: 
The first is the economic motivation that derives from the market 
failures that accompany the production of new knowledge. 
Specifically, the difficulty in establishing property rights within 
the process of producing scientific and technological 
advancements makes the engagement to such research 
unattractive to profit-seeking investments [44,45]. Simply put the 
probability of spillover effects along with the high risk of failure 
and the timely process of creating knowledge are often 
responsible that basic research is often a poor target for private 
investors.   
On the other hand, micro-level empirical evidence [46-50] has 
shown that the public rate of return on investment in research to 
produce such knowledge tends to be many multiples of the 
rates for private investors due to positive spillovers to 
consumers and competitors. Macro-level evidence [51,52] 
suggests that the growth rate of the economy's productivity is 
associated with the creation and adoption of innovative 
technology.  
Consequently, private investment in types of scientific R&D, 
such as medical and biomedical research, is not expected to 
reach the optimal societal level and therefore, public 
contribution is necessary. One form of intervention is the 
establishment of firm intellectual property rights in the form of 
patents, copyrights and market exclusivity periods. Tax 
subsidies of private research are also common, but such 
instruments may often be ineffective as it is hard to target basic-
discovery research for which there is underinvestment unless 
such incentives are targeted accordingly. As a result, applied 
development research that could anyway attract enough private 
funds also winds up being subsidised.  
The above discussion leads to the conclusion that the most 
reliable tool to assure socially beneficial levels of R&D is direct 
funding. Long-term funding programmes could also contribute to 
the stability of research levels regardless of business cycles in 
industry or the economy. In addition, provision of research 
infrastructure and high-quality training for the next generation of 
scientists could lead to further beneficial effects [53].  
The other type of motivation for public funding of research 
stems from political and social reasons. Historically, it has been 
more likely that political concerns such as national esteem and 
defence agenda have been the key incentives of public funding 
for scientific research rather than economic ones. Furthermore, 
social needs have been another catalysing driver of public 
investment in R&D. Diseases such as cancer affect millions of 
people every year, place a significant burden on society and, in 
consequence, the public demand for the alleviation of such 
disease-related burden puts a lot of pressure on governments.  
A good example is the NIH in the United States that has been 
the key player in the fundamental progress of bioscience, 
representing the public motivations through its system of 25 
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Box 3.6 The Vannevar Bush vision of national science policy 
•  In 1941, Vannevar Bush, former Dean of Massachusetts Institute of Technology School of Engineering and 
president of the Carnegie Foundation, was assigned the management of the Office of Scientific Research and 
Development by President Roosevelt. Bush successfully coordinated the application of academic knowledge 
to support the war effort leading  among other  to the mass production of penicillin, the manufacturing of a 
feasible synthetic rubber and the atomic bomb. 
•  In an attempt to assure the harnessing of such results in the post-war era, Vannevar Bush described in his 
influential Carnegie Foundation report 'Science: The Endless Frontier' the establishment of a permanent 
federal science policy. 
•  According to his vision, basic scientific research including medicine, physical science and life sciences would 
be carried out by both state and academic scientists and would be supported by federal funds. 
•  Bush rejected 'economic' motivation and adopted the humanistic argument that excessive political or 
commercial direction of scientific research would inhibit the scientists' curiosity motives, which he believed to 
be the most effective. Thus, he proposed that scientists would be in charge of the fund allocation through the 
establishment a peer review system. 
•  To date, the purest application of his ideal is considered the National Science Foundation, founded in 1950. 
However, the NHI is itself an example of an  at least partial  application of his vision. 
Source: [53,54]. 
 
institutes organised around 'body systems' (such as the 
National Lung Institute), and illnesses (such as the National 
Cancer Institute). The proportions of the NIH budget devoted to 
each health condition reflect that condition's relative threat to 
the US nation. Still, in harmony with Vannevar Bush's vision 
(Box 3.1), an extensive peer review system is employed to 
allocate each institute's resources to researchers and research 
projects (Box 3.6). Bush's vision of course is just one of the 
many different ways the US government can and does fund 
scientific research, as shown in Figure 3.19.  
[II] National and supra-national spending 
The USA has a well-established national cancer strategy, 
making the USA the largest single source of funds invested in 
cancer research globally (Box 3.7). The direct public sector 
spending in 2007 was €5.8 billion, whilst indirect public 
spending was estimated at €477 million. In addition, US-based 
pharmaceutical companies invested €1.3 billion in cancer R&D. 
All these figures together result in €7.06 billion of cancer 
research funding in 2007.  
 
In Europe, the public sector invested directly €2.79 billion in 
cancer research in 2007. Adding to that the €90 million of 
European Commission Funding, the €1.8 billion spent on cancer 
R&D by Europe-based pharmaceutical firms and taking into 
account the indirect funding of €1.6 billion that flows through 
hospitals/universities, it is clear that a strategic plan to 
coordinate the allocation of these significant funds is 
indispensable. The above figures result in a grand total of €6.28 
billion for cancer research funding in 2007, which is comparable 
(although slightly inferior) to the sum invested in the USA.  
The findings of this survey brought to the surface three major 
facts: 
First, there are prevailing gaps in funding between Europe and 
USA as well as among European countries and especially 
between EU Member States themselves. In Europe, most of the 
funds are raised and invested within EU15 Member States. 
Particularly, the United Kingdom, Germany, France and Italy 
dominate cancer research investment in absolute terms. Yet, in 
terms of spend per capita or spend as a percentage of GDP, 
apart from the United Kingdom that supports cancer R&D with
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Source: Adapted from [51]. 
Figure 3.19: Interaction between basic versus applied science and between market versus government.
outstanding amounts of funds (Box 3.8), the other major funders 
were Sweden and the Netherlands.  
The disparities in national spending are even more apparent in 
the case of the new Member States that joined the EU during 
the 2004 and 2007 enlargements. These countries limit their 
activities primarily to prevention and awareness programmes 
(e.g. tobacco control). The need for further political commitment 
on cancer research as well as the development of a specific 
cancer policy framework is highlighted in order for the whole 
enlarged Europe to meet  even with some delay  the target of 
increasing science and technology research spending to 3% of 
the EU's GDP set at the Lisbon European Council of March 
2000 [56].  
On the other hand, countries such as the USA, the United 
Kingdom and Sweden spend a significant proportion of their 
GDP in cancer research (i.e. 0.061%, 0.072% and 0.048% of 
GDP, respectively), which demonstrates that cancer ranks 
highly among their sociopolitical priorities. Despite the 
discrepancies among European nations, Europe on average 
increased in 2007 the per capita investment in cancer research 
by 34.7% since 2004, compared to a just 9.7% increase by the 
USA, illustrating a desire for Europe to close the existing gap 
with the USA.  
Second, the weight that nations place on cancer drug 
development and, therefore, into more applied clinical research, 
varies significantly. The evidence suggests that public funding 
primarily focuses on basic rather than applied research, as the 
latter is more likely to attract private funds.  
The third issue has to do with cancer research funding at the 
EU level. The average annual spend was estimated at €90 
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Box 3.7 Public Funding Sources for Cancer Research in the United States 
In 1971, the National Cancer Act launched the War on Cancer, a disease that apart from causing suffering and deaths 
among the Americans also has significant economic costs. The War on Cancer greatly amplified the priority of cancer 
research in the federal budget, and the Act set up a model of public-private collaboration built around a national net of 
research laboratories and cancer centres.  
The advances in cancer research that followed led to improved screening methods and better treatments, which along 
with the greater understanding of risk factors such as smoking, resulted in bringing to an end the increasing rate of 
cancer mortality in 1991.  
Today, the USA leads cancer research and drug development and is the largest single funding source in the world. 
Indeed, in 2007 €5.8 billion were directly invested in cancer research just by the non-commercial sector, reflecting the 
USA's well-established national cancer strategy.  
Most of the funding for cancer research derives from federal sources: 
•  The National Cancer Institute (NCI), established in 1937, is the first categorical institute of the National 
Institutes of Health and also its biggest one. Although the NCI is not the only NIH funder of cancer research, it 
is the largest one and almost all funds dedicated to cancer R&D derive from it. Its annual strategic research 
and academic research are openly published but NCI also supports drug development research. The NCI's 
role in R&D includes: (1) the integration of discovery activities through inter-disciplinary partnerships; (2) the 
speeding up of innovations and provision of technology that will facilitate accomplishments of translational 
research and (3) the measuring of the application of knowledge deriving from these innovations in cancer care, 
for instance in clinics or public health programmes. 
•  Other National Institutes of Health also support cancer research. The National Lung and Blood Institute, for 
example contribute through its agendas for lung and blood diseases respectively. The National Institute's of 
Environmental Health Sciences research on biological responses to environmental agents also includes 
cancer. As cancer concerns all organs and systems and every age group, each NHI institute and the majority 
of centres contribute to some cancer-related research. 
•  Other Department of Health and Human Services Agencies (DHHS) such as the Centers for Disease 
Control and Prevention (CDC), the Agency for Healthcare Research and Quality (AHCPR) and the Health 
Care Financing Administration (HCFA) spend significant amounts on cancer-related research. 
•  Other Federal Agencies also fund cancer R&D projects. For example, the Department of Defense (DOD) has 
become a major source of funds in recent years for research on breast, ovarian and prostate cancer. 
Moreover, the Department's of Veterans Affairs (VA) research initiatives focus on cancer, among other on 
chronic diseases and conditions that affect veterans. Agencies such as the Environmental Protection Agency 
(EPA), the Department of Energy (DOE), NASA, the National Science Foundation (NSF) and Department of 
Agriculture (USDA) also fund some cancer research, but their contribution is relatively small. 
Public funding also streams from non-profit organisations such as independent endowments and funds, corporate 
giving foundations and community-based donors. Funding deriving from such organisations is tracked by the 
Foundation Center.  
•  The  Howard Hughes Medical Institute is a strong supporter of the biomedical research and especially 
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cancer-related research. 
•  Voluntary Health organisations such as the American Cancer Society (ACS), the American Institute for 
Cancer Research (AICR), the Cancer Research Foundation of America and the National Foundation for 
Cancer Research support the fight against cancer by collecting donations from the general public and by 
funding apart from basic cancer research, treatment services and prevention programs. Similarly, charities that
focus on specific types of cancer such as the Leukemia Society of America (LSA), the Association for the Cure 
of the Cancer of the Prostate (CaP CURE) and the Komen Breast Cancer Foundation, contribute a great deal 
in cancer research projects. 
Finally, several State Governments directly support financially cancer centres or have established cancer research 
programs. 
Source: Sources of Research Funding in the US/concerning Trends and Outcomes for National Institutes of Health 
Funding of Cancer Research 
 
 
million during FP6. It is probably the case that this amount has 
been insufficient to cover the research needs of cancer
r [57]. 
However, FP7 (2007/2013) has already been launched and with 
a cancer research budget set at €5,984 million [58], it is 
expected to improve both the existing cancer research effort 
and its clinical applications.  
During the FP6 and the first two calls of FP7, around €750 
million was allocated to cancer research. On 26 June 2009, an 
EC Communication underlined that most research in the field of 
cancer is carried out at Member State level, and hence, is 
'fragmented' [59]. In this direction, the Communication proposed 
an 'European Partnership for Action against Cancer', which 
apart from public health measures (e.g. screening) and good 
treatment practices recommends additional coordination and 
collaboration in cancer research. With the objective to achieve 
coordination of one third of cancer research from all funding 
sources by 2013, the Commission proposed the creation of a 
large stakeholder forum to undertake the work of the 
Partnership that will include all kinds of organisations, in the 3rd 
quarter of 2009. The stakeholder working groups will be based 
on the following areas of action: prevention, healthcare, 
research and information, and their work will be coordinated by 
a 'steering' group.  
As part of the governmental funding is indirect (i.e. flows 
through hospitals/universities) although used for cancer 
research, it is not clearly earmarked. In consequence, this 
survey primarily addresses direct cancer research investment 
and, therefore, there may be underestimates of the level of 
indirect contributions. Moreover, there are likely further 
underestimates of the contribution of several smaller charities 
with annual spending of less than one million euros. For 
instance, it has been estimated that more than 1500 such 
charities are operating in EU15 alone. Furthermore, the 
contribution of European umbrella bodies (e.g. the Federation of 
European Cancer Societies, FECS), relevant patient groups and 
policy initiatives for cancer research such as EUSTIR and 
EURoCAN+Plus
s that have some involvement in cancer 
research, has also been underestimated.  
[III] Role of indirect and philanthropic funding 
In the USA, the NCI alone spent €3.58 billion on cancer 
research in 2007, an amount accounting for 62% of the total 
direct public sector spent in the USA. This is reflecting the fact 
that for the USA cancer research is a long-established priority, 
supported mainly by a centralist financing model. On the other 
hand, in Europe, cancer research represents a different priority 
for different countries, whilst its funding is widespread across 
numerous diverse funding sources.  
Specifically, in Europe, significant funding supports indirectly 
cancer research flowing through academia and health care 
systems (e.g. only 3.2% of cancer drug development research 
comes from indirect sources in the USA, compared to 44.7% for 
Europe). Hence, taking additional indirect investment into 
account, Europe as a whole considerably closes the gap with 
US public sector funding of cancer drug development (i.e. 
0.011% of European GDP goes into cancer drug development 
compared to 0.018% of the USA GDP). 
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Box 3.8 Cancer research funding in the United Kingdom 
Cancer is major health condition in the United Kingdom and as the population ages and lives longer; it is becoming 
increasingly a greater burden to the National Health System (NHS). 
In 2007, the United Kingdom's non-commercial sector invested €1.1 million in cancer research, an amount that 
corresponds to more than one third of Europe's overall investment. This is consistent with the fact that cancer has long 
been a national priority for the United Kingdom.  
In the United Kingdom, cancer research is supported by several different government agencies, most of which fund 
medical research in general, rather than having a cancer-specific focus. The most important funders among these 
include the Medical Research Council (MRC)
1, the Department of Health (DoH), the Biotechnology and Biological 
Sciences Research Council (BBSRC), The Economic and Social Research Council (ESRC), the Northern Ireland HPSS 
R&D and the Wales Office of R&D. 
Furthermore, what distinguishes the United Kingdom from most other countries is the fact that it has an exceptionally 
large charity sector. We have indeed estimated that about 250 different charities support cancer research in the United 
Kingdom:  
•  Cancer Research UK
2, the result of merging the Imperial Cancer Research Fund and the Cancer Research 
Campaign, is the largest non-government cancer research organisation worldwide. Cancer Research UK 
collaborates with other charities, public research organisations and the pharmaceutical industry to better 
understand the disease, to improve prevention, diagnosis and treatment of cancer and to keep cancer a top 
priority of the national health agenda. During 2007-2008, Cancer Research UK raised £477 million and spent 
on cancer research a record of £333 million. 
•  Other important NGO's that invest at least £1 million on cancer research in the United Kingdom include: the 
Association for International Cancer Research, the Breakthrough Breast Cancer, the Leukemia Research 
Fund, the Ludwig Institute for Cancer Research, the Macmillan Cancer Support, the Marie Curie Cancer Care, 
Tenovus, Roy Castle Lung Cancer Foundation, Children with Leukemia and Yorkshire Cancer Research .  
As a response to the need for coordination of cancer research and collaboration among the numerous governmental,
non-governmental and private sector funders, the National Cancer Research Institute (NCRI)
3 was founded in 2001. 
NCRI brings together the 20 largest of the charity and government funders, along with industry represented by the 
Association of the British Pharmaceutical Industry (ABPI). NCRI's role consists in maintaining a strategic overview of 
cancer research in the United Kingdom and in encouraging greater consistency among the major funders. In order to do 
so, NCRI maintains a Cancer Research Database, develops research schemes, assists the organisation of clinical trials 
on experimental cancer drugs and develops research facilities and resources (e.g. data management using IT). 
                                                            
1 See: www.mrc.gov.uk 
2 See: www.cancerresearchuk.org 
3 See: www.ncri.org.uk 
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Furthermore, a great deal of cancer research relies on 
charitable organisations' support in Europe. Indeed, direct non-
commercial spend is almost equally shared between 
governmental (€298.7 million) and philanthropic (€301 million) 
organisations. In contrast, in the USA only 13.76% of non-
commercial cancer research comes directly from charitable 
funders.  
For some EU countries (e.g. Sweden and Hungary) the fact that 
this balance does not exist and charitable funding is dominating 
reveals the different philanthropy patterns that exist among 
countries  60. Charitable fundraising relies on altruism, often 
associated with uncertainty, but is quite significant in some 
cases and is an additional source to governmental and industry 
funding [61]. Ideally, there could be a closer collaboration and 
coordination between governmental and charitable funders. 
Although a politically challenging goal [62], steps towards 
establishing this funding model have already been established 
both in the USA and in Europe with the founding of 'umbrella' 
organisations such as the C-Change
t (USA), the NCRI (UK) and 
INCa (France).
u  
As the strategies of the charitable organisations were beyond 
the scope of this review, the possibility that several fundraising 
organisations supporting cancer care delivery may not have 
been taken into account exists. Moreover, EU Commission 
funding was not included in the calculations of cancer research 
spending for Europe as a whole neither in absolute terms, nor 
per capita, nor as a percentage of GDP. Therefore, it is likely 
that the gap between Europe and USA is overestimated.  
[IV] CSO coding system: National strategic planning 
with international context 
In order to ensure progress in cancer research, international 
cooperation is essential. Recognising that, in September 2000, 
several international cancer funding organisations decided to 
use a common scientific outline, known as the Common 
Scientific Outline (CSO), to code their research portfolios. The 
Initial Cancer Research (ICR) Partners, formerly known as the 
CSO Partners, were US and UK organisations such as the US 
NCI and Cancer Research UK. In 2007, the Canadian Cancer 
Research Alliance (CCRA), which represents key government 
and non-governmental cancer funding organisations,  joined the 
ICR Partners.
v 
The CSO makes it possible to compare and contrast the 
research portfolios of multiple organisations and provides the 
information needed to improve coordination among research 
organisations. To facilitate information sharing between ICR 
Partners, the International Cancer Research Portfolio (ICRP), 
an information database on ongoing cancer research funded by 
the ICR Partners was created. The ICRP public website can 
provide contacts for multidisciplinary research and partnerships 
between researchers conducting similar work, in addition to 
inform internal and joint policies of cancer funding organisations 
and government/policy officials and to set directions for future 
research efforts.  
3.4.2. Private sector funding 
Private (i.e. commercial) sector cancer research funders, which 
are represented by the pharmaceutical and the biotechnology 
industries, are estimated to invest around €6 billion annually 
worldwide [63], an amount that accounts for one quarter of total 
global research expenditure and that is mainly invested in the 
USA and Europe [64].  
Pharmaceutical companies seem to account for the great 
majority of total private expenditure. Indeed, the research 
budget of the pharmaceutical firms has increased steeply 
(approximately by 13% annually) since 1970 [65]. Furthermore, 
it has been estimated in previous studies, using 2004 data, that 
7% to 12% of the total industry R&D expenditure is dedicated to 
cancer research [7,50]. Taking into account that oncology drug 
sales account for 5% of total drug sales and that 15% of total 
cancer drug sales are reinvested in R&D compared to 10% of 
global drug sales, the increasing interest of pharmaceutical 
manufacturers to invest in oncology is further reflected [19].  
Despite the increase of R&D expenditures across the industry, 
the amount of New Drug Applications (NDAs) has stayed flat 
during the 30 last years, reflecting an almost 10-fold drop in 
R&D productivity [51,53]. The recent overall drop in the number 
of New Chemical Entities (NCEs) approved by the US Food and 
Drug Administration (FDA) each year is a key challenge for the 
pharmaceutical industry [7]. Given also that many patents are 
about to expire, the problem becomes bigger, as many firms do 
not have adequate effective new medicines to balance this loss 
[56].  
Traditionally, large pharmaceutical manufacturers used to 
conduct in-house discovery research, designed their own 
clinical trials, manufactured their own drugs and were in charge 
for their sales and distribution channels [66]. In response to the 
challenges discussed above, the industry has recently 
experienced a major transformation. A growing number of new 
drugs derive from in-licensing rather than in-house research. 
For instance in 2002, 40% of the big pharmaceutical companies' 
pipelines originated from in-licensed resources, in contrast to
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Box 3.9 Cancer research through Public-Private Collaboration in the USA 
•  Big biopharmaceutical companies are the principal source of R&D funding for innovative drugs, both for 
projects in their own laboratories as well as for research licensed from other sectors. 
•  Smaller companies also drive innovation, conducting basic research, drug discovery, pre-clinical experiments 
and, in some cases, clinical trials.  
•  The  National Institutes of Health (NIH) provides leadership and funding support to universities, medical 
schools, research centres and other non-profit institutions and stimulates basic research and early stage 
development of technologies that enable further targeted drug discovery and development.  
•  The National Cancer Institute (NCI) often seeks Cooperative Research and Development Agreements 
(CRADAs) with pharmaceutical or biotechnology companies. The goals of the CRADAs commonly include the 
rapid publication of research results and timely commercialisation of products, diagnostics and treatments 
resulting from the research. The CRADA Collaborators usually have the option to negotiate the terms of an 
exclusive or nonexclusive commercialisation license to subject inventions arising under the CRADAs.  
Sources: See [14] in Chapter 1. 
Cooperative Research and Development Agreements (CRADAs): http://www.usbr.gov/res earch/techtransfer/together/
crada/whatcrada.html 
 
merely 16% in 1980 [67]. This highlights the changing dynamics 
in R&D and, probably, also underscores the need for a different 
R&D model that makes better use of technological advances 
from a wider pool of knowledge.  
The fact that increasingly big pharmaceutical companies invest 
in other start-up biomedical/biotechnology companies is also an 
interesting trend (e.g. the Novartis Venture Fund was launched 
in 1996 and Lilly Ventures in 2001) [68]. The finding that key 
venture investment prospects keep emerging when the 
vertically integrated pharmaceutical industry is considered from 
the perspective of the potential of developing large horizontal 
players, can explain this trend [57].  
Comparing Europe's private sector to USA, it seems that when 
the geographical origin of industry's publications is taken into 
account, the cancer research activity between the two areas is 
balanced. Indeed, Europe accounted for 45.9% of total 
pharmaceutical cancer research spend in 2004, despite the 
established opinion that Europe is weaker in attracting industry 
research funds [51].  
Finally, it must be noted that the significant contribution of the 
private sector may be underestimated in this review due to the 
lack of direct industry data on cancer research spend and our 
approximation through bibliometric exercises. In addition, data 
were limited to major pharmaceutical companies, and despite
 
the fact that they account for the overwhelming majority of 
private funding, the contribution of small and medium firms as 
well as biotechnology companies was not taken into account. 
3.4.3. PPPs in cancer drug development 
Modern drug discovery has become the product of 
collaboration. Many sectors contribute, particularly in building 
the basic science foundations, as both public and private 
organisations play unique but increasingly interdependent roles 
in translating basic research into medicine (Box 3.9).  
[I] Industry and academia collaboration against 
cancer 
Increasingly research policy has been directed to supporting the 
transfer of technology from knowledge generating organisations 
in the public sector (e.g. universities) to firms through the 
establishment of cooperative links. Rather than feeling 
challenged, the industry welcomes academic contribution in 
identifying and validating early drug targets, as this can lead to 
reduction of corporate risk and to a smoother drug development 
operational process. The potential of closer collaboration among 
universities, biotechnology and pharmaceutical companies, 
could lead to universities conducting basic research, 
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biotechnology firms developing technology and chemistry, whilst 
pharmaceutical firms would be in charge of developing clinical 
trials. Hence, it is not surprising that discovery centres have 
been established close to major academic research hubs. For 
instance, Novartis and Merck funded in 2002 drug discovery 
centres in Boston, USA, not far from the Harvard and MIT 
Universities [69,70].  
[II] Integration of public and private investment 
As a result of the high sociopolitical priority given to health by 
countries such as the USA, the United Kingdom and Sweden, 
total research and development budgets are increasing whilst 
emphasising cost-effective innovations. At the same time, the 
industry is more and more utilising research funded directly from 
public sources and cooperating with public research institutions 
[71].  
Over half of the significant cancer research activity conducted 
both in the USA and in Europe is the product of partnerships 
with the public sector, a trend that has been increasing [53]. In 
fact, recently, the majority of cancer research funding policies 
have accentuated the public-private partnership path. However, 
as EU funds are often being joined with industry, there are 
concerns that 'if all increases in EU cancer research funding go 
this way Europe's intrinsic creativity would be distorted by 
encouraging subsidy-seeking behaviour and essential areas of 
public health relevant to cancer, but not amenable to a business 
approach would remain orphans' [53].  
3.5. Concluding Remarks 
Cancer drug research and development is a multi-faceted 
activity that seeks to relieve the burden of more than 15 million 
people estimated to face the disease by 2020. It comprises not 
only the discovery and development of new drugs but also in 
the enhancement of current therapies, the improvement patient 
quality of life and the prevention of the disease.  
As research activity and high-quality health care delivery are 
linked, intensive research and drug development is likely to 
have a positive effect on the overall care, and therefore, the 
quality of life of cancer patients. Triggering cancer research 
funding and creating the necessary infrastructure to conduct 
research can also make a country more attractive to research 
and contribute to the prevention and likely reversal of 'brain 
drain'.  
This survey identified 174 major public funding sources across 
Europe and USA, which were estimated to have invested €8.6 
billion in cancer research in 2007. Adding in the private sector 
contributions, that are estimated to be in the region of €6 billion, 
it becomes clear that significant amounts are spent on cancer 
research. Still, the private sector's contribution is both an 
approximation and an underestimate as important components 
could not be included due to lack of data.  
Whilst the contribution of the non-profit philanthropic sector is 
growing, some EU Member States still fail to provide adequate 
governmental funding. This is of some concern in the case of 
countries that can afford higher levels of cancer research 
funding and that have the required research workforce.  
Public-private partnerships are also strong and growing in both 
Europe and the USA, and public funders should recognise and 
support these joint efforts, given the increasing complexity and 
quantity of the oncology drug pipeline.   
However, difficult policy decisions need to be made on what 
research will be funded given the need to prioritise and optimise 
resources. 
Despite the likelihood of any omissions and over- or 
underestimations, this section has mapped the diverse funding 
sources of cancer R&D and underlined that bureaucracy is often 
a major threat to this complex, multi-faceted, but important 
effort. In the face of the steps that have been taken recently in 
promoting cancer research, more countries need to recognise 
cancer prevention as a high national priority and to engage in 
international collaboration and coordination strategies.  
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4. RESEARCH ACTIVITY IN DRUG 
DEVELOPMENT: A BIBLIOMETRIC 
ANALYSIS 
4.1. Background and Objectives 
Traditionally,  policy analysis of cancer drug discovery and 
development have relied on qualitative interview-based 
methodologies and quantitative data gathered from sales. The 
use of bibliometrics is a novel way to gather objective 
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intelligence on research domains and the funding of these 
domains [1].  
Research into the causes, prevention, diagnosis and treatment 
of cancer is a US$ 17 billion global enterprise, encompassing 
basic research on genetics and cell science, epidemiology, 
diagnostic tools and procedures, as well as the three main 
treatment paths of surgery, chemotherapy and radiotherapy. 
Each year, about 40,000 papers relevant to cancer research are 
published in scientific journals, providing a rich source of 
intelligence on who, what and where particular domains and 
types of research in cancer are being conducted [2]. 
Publications of research findings can be used as a proxy 
indicator, enabling examination of geographical distribution of 
cancer research activity, its characteristics (which 
manifestations of cancer? which approaches to tackling the 
disease? patient- or laboratory-based?), and whether these 
correlate with the burden of disease. Transnational comparisons 
may reveal that particular countries are under-researching 
cancer or certain aspects of the disease.  
The funding of research is not always top-down, as driven by 
clear policy from government in response to a perceived need, 
but may also be bottom-up, especially where research projects 
are proposed by investigators and then selected for funding 
after a peer-review process. The motivation here may be 
intellectual, or it can be the personal experience of individual 
researchers whose family members or friends may have 
succumbed to a particular manifestation of the disease. Current 
methodologies to estimate research expenditure do not, as a 
rule take into account the complexity of funding sources and so 
given figures are often nothing more than guess-estimates. The 
use of bibliometrics provides an objective method for describing 
the funders of cancer research. That cancer research covers 
such a huge range of scientific endeavour, from the social to 
natural sciences, makes the task of developing realistic 
measures of the state and funding of global cancer research 
complex [3]. In this chapter, we provide the first application of 
bibliometrics to the study of cancer drug development.  
The broad objectives of this chapter are as follows: 
1.  To study the trends in global cancer drug discovery 
and development, including a focus on 19 specific anti-
cancer drugs chosen as a surrogate subset to cover 
specific time periods, types of anti-cancer drugs (new 
chemical entities and biologcals) and sources. 
2.  To understand the relationship(s) between research 
activity and site-specific Disability Adjusted Life Years 
(DALYs) are specific areas being under (or over) 
represented? 
3.  To review the trends in drug development research in 
terms of their research level, geography (who, where) 
and funding mix. 
With regards to the first objective, apart from early phase clinical 
trials where we know publications (outputs) do not reflect 
activity, bibliometrics provides an objective window on the 
current and past state of cancer drug development. With access 
to the major databases we are able, using algorithms developed 
with key drug names, to analyse the trends in output and impact 
by country, institution and even researcher. We can look at how 
models of partnership (institution-to-institution and institution-
industry) have changed and also at the patterns of funders over 
time. Such changes can then be reviewed in the context of the 
impact of national policies. This objective will focus on those 
cancer drugs with an MA and depending on complexity may 
also sample a cross-section of those NME's that failed to make 
it to market.  
With regards to the second and third objectives, the question of 
how and who funds cancer drug development can most 
effectively be answered by looking at the cumulative lifetime 
from incept (NME) to clinic. We know that this R&D lifetime is a 
complex interplay between many different countries, funders 
and people. Taking a representative sample of current cancer 
drugs, we will look at their funding histories from inception to 
market. 
4.2. Methods 
4.2.1. Focus of study 
This study focused on a set of anti-cancer drugs composed of 
19 new molecular entities, together with trigraph codes used in 
this chapter to designate them in the tables and figures (Table 
4.1). These drugs were chosen, using statistical methods, as a 
representative group for drug development as a whole to cover 
new chemical entities (including endocrine therapies) and 
biologicals as well as to cover three distinct periods of cancer 
drug research.  
The main information gathered was: 
1.  the numbers of papers from 1963 to 2009 for each of 
the 19 drugs published in the Web of Science (WoS); 
2.  their research levels (on a scale from clinical to basic); 
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Table 4.1: Major 19 selected cancer drugs used for data collection 
 
Source: The authors.
3.  their geographical origins (USA, Europe, Rest of the 
World); 
4.  the cancer site(s), for example breast, lung, for which 
the drug was being investigated; 
5.  the funding sources for the papers. 
Data were also obtained on the total numbers of cancer 
research papers from 1984-2008 and on the numbers of such 
papers concerned with named drugs from a list of 150 (including 
pre-clinical designations) (Table 4.2). 
4.2.2. Selection of papers 
Articles, notes until 1996 and reviews were identified from the 
WoS from 1963 to mid-2009, using search statements looking 
for the selected drugs (Table 4.1) appearing in the paper title. 
Bibliographic details (authors, title, document type, language, 
source, addresses) of all such papers were downloaded to an 
MS Excel spreadsheet.  
Subsequently, titles were filtered to allow all papers involving 
each of the 19 drugs to be marked with a ‘1’ in a separate 
column of the spreadsheet. The numbers of papers ranged from 
10,299 for cisplatin (CIS) to 83 for lapitinib (LAP); early years 
(from 1963) contained only papers concerning vinblastine (VBL) 
and vincristine (VCR), whereas papers on sunitinib (SUN) 
appeared only from 2003. For drugs with longer histories, the 
papers were divided into five quintiles based on publication 
years, but the quintile sizes varied covering different numbers of 
years
w.  
Next, papers were examined for funding acknowledgements. 
The intention was to select reasonable size samples permitting 
a valid analysis for each drug and to uniformly cover the time 
frame in which papers appeared. Due to large variations in 
paper numbers per drug, more than two orders of magnitude, it 
was decided to make the sample sizes proportional to the cube 
roots of the paper numbers, then to make a selection of an 
equal number of randomly chosen papers per year if available 
(although in early years, very often all the papers were needed 
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Table 4.2: List of all drugs listed as being approved for cancer treatment (2009) 
 
Source: The authors. 
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Table 4.3: Estimated total disease burden (DALYs) and cancer burden (DALYs, %) in 15 countries (2004) 
 
Source: The authors
for the sample). The sample sizes varied from 360 for CIS to 72 
for LAP, and the number of papers per year varied from 21 for 
bevacuzimab (BEV) to 4 for exemestane (EXE) and VBL.  
4.2.3. Comparison with outputs of all cancer research 
and all drugs 
The WoS was searched separately to determine the numbers of 
cancer research papers each year from 1994-2008 (15 years) 
by means of a filter, labelled ONCOL, consisting of two parts: a 
list of specialist cancer journals (e.g. British Journal of Cancer, 
Cancer, Leukemia) and a list of cancer title words (e.g., 
adenoma
x, BRCA1, carcino
*, daunorubicin, EBV), and papers 
were selected if they were in one of the specialist journals, or 
contained one of the list of title words, or both. The filter was 
developed by Dr. Lynne Davies of Cancer Research UK, and 
recently updated to include new drugs used only for cancer as 
well as genes pre-disposing to cancer. Its specificity (precision) 
and sensitivity (recall) were both close to 0.95. A subset of 
these papers was also identified having as a title word one of a 
list of 150 drugs used for cancer treatment (Table 4.2)  some 
are also used for other indications. There were 46,796 papers 
and analysed by year, by country (leading 15 countries whose 
papers were in the original set, Table 4.3) and also by cancer 
manifestation (site), leading 16 listed by WHO in its burden of 
disease statistics (Table 4.4). 
Cancer represents over 16% of the estimated overall disease 
burden measured in DALYs in the 12 developed industrialised 
countries (Table 4.3) (excluding China, India and South Korea), 
but accounts for 5% of the world disease burden (Table 4.4). 
Lung cancer has the highest cancer burden in both DALYs and 
deaths, followed at some distance by stomach, liver, colorectal 
and breast cancer, although the latter receives much more 
publicity than the others [4]. 
The 15 leading countries vary in degree of overall cancer 
burden (Table 4.3). The proportion of world mean values for 
each country is cross-matrixed (Table 4.3, DALY %) with the 
proportion of each cancer site (Table 4.4, % DALYs) (Table 
4.5). Particularly high values are tinted pink and grey whilst or 
particularly low values are tinted bright or light green. Some 
cancer types are relatively uncommon in high-income countries, 
such as cervical, leukaemia, liver, mouth/head and neck, 
oesophageal and stomach cancer (except in the Far East); 
others are more common such as bladder, colorectal, 
melanoma (especially in Australia), pancreatic, prostate and 
uterine cancer. Breast and lung cancer are a major burden 
everywhere, lung cancer especially in North America and 
Greece, although breast cancer is low in Korea and China. 
4.2.4. Research levels 
For each year, the ratio of papers outputs of the major 19 
selected drugs was compared with total oncology research and 
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Table 4.4: Main 16 cancer sites, disease burdens (DALYs) and mortality rates (2004) 
 
Source: See [4] in Chapter 1.
Table 4.5: Ratios of relative disease burden (DALYs) for 16 cancer sites to global average in 15 countries 
 
Notes: Values over 2.0 coloured pink; values over 1.41 in light grey; values below 0.71 in light green; values below 0.5 in bright green.
total cancer drug-related papers. The latter tally was broken 
down by country and by cancer site to provide information on 
how cancer drug research overall is conducted. This was 
determined in two ways: by analysis of the actual titles of the 
papers, and by an analysis of the titles of all the papers 
published in the same journal for the relevant period. The 
procedure has been described earlier [2], based on the 
presence of more than 100 ‘clinical’ and more than 100 ‘basic’ 
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words in the titles of papers. Examples include clinical words 
(abdominal, breast, child, depression, elderly) and basic words 
(apoptosis, binding, channel, DNA, embryos, folding, gene). 
Groups of papers were allocated a mean research level on a 
scale from 1 = clinical observation to 4 = basic research, both 
on the basis of their titles (RL p) and their journals (RL j). 
Comparison of these two mean values showed whether the 
papers were published in more clinical or more basic journals. 
The determination of values of RL p and RL j for the different 
quintiles for each drug also allowed time variations to be seen. 
(For the ensemble of papers, the tendency was for them to 
become more clinical, but this was not so for all drugs.) 
An additional indicator of research type was information on 
whether the paper was a report of a clinical trial, and if so, 
whether Phase I, Phase II or Phase III. This was obtained from 
the paper titles. Although most used Roman numerals, a few 
used Arabic numerals instead to indicate the phase number; 
also some papers described Phase I/II or II/III trials and thus 
allocated to both groups. 
4.2.5. Geographical analysis 
A special macro allowed for an analysis of the addresses on the 
papers and for each country's contribution to be determined on 
a fractional count basis
y. For some of the analysis, countries 
were divided into three groups: the USA, Europe (consisting of 
the EU27 Member States, plus Iceland, Norway, Switzerland) 
(EUR30), and the Rest of the World (RoW) dominated mainly by 
Japan, but also included Canada, South Korea, China, Australia 
and India. The contribution of the latter group normally 
increased over the five quintiles, but not always. For each of the 
19 selected drugs, the geographical percentage distribution of 
papers in the five quintiles was determined, although for drugs 
with rather few papers these values often moved erratically. 
In addition, the contribution of each of the 15 selected countries 
was determined for the whole set of papers and also for the 
individual drugs. International collaboration between the 
selected countries was calculated and presented as each 
country's preference (or lack of it) for each other country, based 
on that country's percentage presence in the set of papers. 
4.2.6. Cancer manifestations and disease burden 
The papers for the 19 selected cancer drugs was filtered to 
identify those papers concerned with one (or more) of the main 
16 cancer sites (Table 4.4). For each cancer site, a set of title 
words and journal name strings was developed by Professor 
Sullivan, and applied to the file by means of another special 
macro written by Philip Roe. This listed in a single column the 
manifestation(s) investigated in each paper; about half the 
papers did not mention any of them. Each of these sub-filters 
was also prepared in the format used in the WoS and used to 
determine how many of all the drug-related cancer papers were 
directed to each cancer site, year by year. This allowed time 
trends to be seen after normalisation for the overall numbers of 
cancer research papers. 
Comparisons were also made between the amount of research 
effort on all cancer drugs, on the 19 selected cancer drugs, and 
on the worldwide burden of disease of the 16 cancer sites. 
Some cancer sites appeared under-researched in relation to 
their burden; however, this may mean that other treatments 
were used (surgery and radiotherapy) including adjuvant. 
4.2.7. Funding of cancer drug research 
Funding of papers for each 19 drugs was also determined for a 
sample of papers. The methodology for this process has been 
established for many years and found that the number of such 
financial acknowledgements plays a major role in determining 
whether the papers will be published in high impact journals, in 
turn receiving many citations [5,6]. 
Acknowledgements were recorded as three codes: first, a 
trigraph denoting the individual funding body (e.g. MRC = UK 
Medical Research Council; CUK = Cancer Research UK); 
second, a digraph denoting the category (government, private-
non-profit, industry, international and sub-categories of each of 
these) and third, the ISO digraph denoting the country (EU for 
the European Union, XN for international bodies). Previous 
funding analyses to date have been for papers from individual 
countries with distinctions made between country funding from 
government or charities and that from abroad. In this study, the 
focus was on individual drugs and their development over time 
so this distinction was dropped, and the analysis focussed 
simply on whether the funding sources were governmental, 
private-non-profit, commercial or international  or none. The 
latter is not uncommon in medical research, particularly for 
clinical work; in Europe such papers would normally be funded 
indirectly by the state either through the higher education or the 
hospital system. We also investigated the extent to which 
pharmaceutical and biotech companies other than that 
associated with the initial marketing of a drug were involved in 
supporting both early and later research. 
In addition to recording all funding for a sample of the papers, 
addresses of all papers were searched for the presence of the 
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Table 4.6: Pharmaceutical companies involved in 19 cancer drugs: trigraph identifying codes, search strings and drug codes 
 
company responsible for first marketing of each of the 19 drugs 
using company names, trigraph codes and search strings 
(Table 4.6). Twenty-six pharmaceutical manufacturers were 
identified in this way, 12 of which were responsible for 
developing the 19 drugs under investigation. A sub-set of 
papers from the year of marketing approval and previous years 
for each drug was separately analysed to test the hypothesis 
that the company developing the drug would be the only one 
supporting such research intra-murally during that time. 
4.3. Results 
4.3.1. Volume of cancer drug paper outputs 
The number of papers for the 19 selected drugs increased 
rapidly over time, both because of the general rise in drug-
related research and because new drugs have been 
successively added to the portfolio (Figure 4.1). The proportion 
of the 19 drugs in total cancer research and has remained 
relatively stable with a slight upward trend (Figure 4.2). 
Papers on the 19 selected drugs increased from an average of 
2.7% of all oncology in 1994-1998 to 3.6% in 2004-2008, 
whereas overall drug papers have only increased from 6.9% to 
7.8% over the same period. The numbers of papers per 19 
drugs are presented on a logarithmic scale (some double 
counting occurred: the sum of individual totals is 30,635, 5.4% 
more than the total number of papers in the file) (Figure 4.3). 
The overall distribution of papers for the 15 nations, per integer 
and fractional count bases, found integer counts exceeding 
fractional counts due to international collaboration  particularly 
high for Australia and Sweden, but rather low for Japan, Korea, 
Greece and India (Figure 4.4). Language of the papers is 
predominantly English, with major European languages 
decreasing over time (Table 4.7). 
4.3.2. National involvement in cancer drug research 
[I] International collaboration 
It is possible to determine how much the different countries 
value research participation in relation to their international 
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Figure 4.1: Total WoS output for 19 cancer drug research papers (3-year running means) (1970-2007). 
 
Figure 4.2: Proportion of total drug (blue) and 19 drugs (red) cancer research papers of total cancer research papers. 
 
Figure 4.3: WoS cancer drug papers for 19 cancer drugs (1963-2009). 
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Table 4.7: Publication languages in cancer drug research papers (1963-2009) 
 
 
Figure 4.4: Distribution of papers in 15 countries (integer, fractional counts).
collaboration in total, best calculated on a fractional count basis 
(Table 4.8). This is not symmetrical on a fractional count basis, 
although it would be if calculated on an integer count basis. 
For example, Canada contributed 104 papers to the US integer 
count of 10,430, whereas the US contributed 163 papers to the 
Canadian integer count of 1090, with 309 papers with both 
Canadian and US authors. Since Canada's fractional count 
contribution to the total paper set was 2.77%, or 4.13% if the US 
presence accounting for 32.9% was neglected, thus contributing 
0.0413 x the foreign contribution to US papers (10430  9452 = 
978), or 40 papers. Its actual contribution was almost 2.6 times 
this estimate, showing that Canadian scientists are very much 
preferred international partners for US researchers, statistically 
highly significant. The situation for Japan is the reverse, with 
only 86 contributions to US output compared with an 
expectation, on the basis of its percentage presence in the 
world less the USA, of 154 papers. On the other hand, Chinese 
scientists are somewhat over-selected (by x 1.2) by US 
researchers, showing that its policy of openness has achieved 
results. 
The matrix of values of observed to expected contributions 
shows that international collaboration is still firmly based on 
geographical proximity, linguistic and cultural ties, though intra-
European collaboration is of major significance (Table 4.9). 
Thus Canada and the USA favour each other, although the USA 
also has good links with Japanese and Indian scientists. Three 
far Eastern countries (China, Japan and Korea) all give above-
average preference to each other, and Korea (but not others) to 
India. Within Europe, the Netherlands and the United Kingdom 
appear to play important roles in collaboration, and there are 
strong reciprocal links between the United Kingdom and 
Australia. Perhaps surprisingly, India prefers Germany to the 
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Table 4.8: Matrix of total cancer research papers per country to the 19 selected cancer drug papers per country (fractional counts) 
 
 
Table 4.9: Matrix of ratios of observed to expected cancer drug research papers per country 
United Kingdom among European countries (this has been 
observed in other fields), but its preferred partner is Australia. 
[II] Countries involvement in research for 19 selected 
drugs 
Table 4.10 shows that there is a big variation in the relative 
emphasis the different countries place on research in each of 
the 19 drugs. This pattern is seen more readily if the values of 
observed expected paper counts are calculated. For example, 
the expected UK output of papers on alemtuzumab (ALE) is 447 
x the UK overall fractional percentage presence (7.06%) = 31.6, 
whereas the actual output was 143, showing a relative 
concentration of 143/31.6 = x 4.53. Naturally, there are also 
drugs where the relative concentration of the United Kingdom is 
less than unity. Table 4.11 shows the values, with the cells 
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Table 4.10: Cancer drug paper ouputs in 15 countries for 19 selected drugs (fractional counts) 
Table 4.11: Relative research concentration of the 15 countries for 19 selected drugs (1963-2009) 
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Table 4.12: Global cancer drug research in 15 countries for all drugs (ALL) and 19 selected cancer drugs (19D) (%, integer counts) (1994-2008)
 
Table 4.13: Research paper outputs: 19 cancer drugs per top 16 cancer sites (1963-2009) 
tinted to reveal the ones where the values depart from unity, up- 
or downwards. 
Almost all the 19 drugs have countries with a particular interest 
in them, highlighted in bright green, or for some in pale green, 
and conversely most of the countries have done more work than 
average on some selected drugs. We note that two of the three 
drugs developed by AstraZeneca (anastrozole and tamoxifen) 
and the one developed by SmithKline Beecham (lapatinib) all 
have a strong UK presence; the one developed by Aventis 
(docetaxel) has a strong French presence and the one 
developed by Schering AG (temozolomide) has a strong 
German presence. 
Data were also obtained on outputs of the 15 leading countries 
for all cancer drugs in the WoS in 1994-2008, presented as 
integer counts. Table 4.12 shows the comparison between their 
percentage presence in this dataset with the corresponding 
figures for the 19 selected anti-cancer drugs in the same years. 
The differences in percentage presence are mostly very small, 
but the UK's presence is higher here (since 4 of the 19 drugs 
were developed by UK companies) and China's is lower. 
4.3.3. Site-specific research in cancer drug research 
Most of the 19 drugs have been tested for their utility in treating 
many different cancer manifestations, only four of them have 
been tested on eight or fewer manifestations. Nevertheless, it 
does appear that the drugs have been tested more in some 
cancers than others, shown by the relative application 
compared with norm values of each drug and manifestation 
(Table 4.13). 
Data were obtained on research outputs of all cancer drugs 
against particular cancer manifestations (1984-2008), compared 
to research outputs for the 19 selected drugs (Table 4.14) and 
also to the relative burden for the 16 cancer manifestations in 
15 leading countries collectively (Figure 4.5). (The relative 
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Table 4.14: Cancer drug research outputs in 16 cancer sites for all drugs (ALL) and 19 selected drugs (19 D) (1984-2008) 
 
 
Figure 4.5: Cancer drug paper outputs (1994-2008) versus cancer burden of disease (% DALYs) (2004)  (weighted by the countries' presence in 
cancer drug research). 
burden has been weighted to take account of the relative 
numbers of papers on cancer drugs, so that the USA has the 
highest weighting and India the lowest. This allows comparisons 
between perceived overall burden and the cancer drug research 
portfolio.) 
Research work on the 19 selected drugs clearly concentrates 
on gynaecological cancers (uterine, cervical, ovarian) and to a 
lesser extent on breast cancer; on the other hand, there is less 
work on leukaemia and lymphoma drugs. The comparison with 
the disease burden suggests that although for many sites the 
amount of research is about right, it is much too low for some 
relatively neglected cancers, such as lung, colorectal, 
oesophageal and pancreatic cancer. Only leukaemia seems to 
be somewhat over-researched, at least in comparison with its 
disease burden. 
[I] National interest in cancer drug research related to 
site-specific cancer burden 
Further analysis was carried out, again on a fractional count 
basis, to see if countries with bigger relative disease burden 
from particular cancer sites took this into account with their work 
on the selected 19 cancer drugs (Tables 4.15, 4.16). 
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Table 4.15: Numbers of cancer papers (fractional counts) for the 15 leading countries for 19 selected drugs in 16 cancer sites 
 
Table 4.16: Ratios of observed to expected cancer drug research paper outputs for 15 countries for 16 cancer sites 
Again, the observed number of papers can be compared with 
the expected number on the basis of each country's overall 
output and the numbers of papers concerned with each cancer 
manifestation (Table 4.17). Ideally, the tinting of the cells in 
Table 4.17 should be just the opposite of that in Table 4.5, with 
countries with high cancer burden of a particular cancer site 
carrying out similar amounts of research. The correlation for 
individual countries should, in theory, be higher than for all 
types of cancer research, as the size of the national markets for 
drugs to combat these cancer manifestations are well known to 
pharmaceutical companies. In fact, the correlation is very poor 
for most of the 15 countries, except for China (r2 = 0.76), 
suggesting there is a national cancer drug research strategy in 
place. Australia is fair (r2 = 0.51), mainly because the relatively 
greatest output is in melanoma research (x 2.8) of which 
Australia has high incidences (x 5.0) (Figures 4.6 and 4.7) 
4.3.4. Clinical versus basic cancer research types 
For the analysis of research levels, the papers involving each of 
the 19 selected drugs were divided into five (and in four cases, 
only four) quintiles. Overall, the papers have become slightly 
more clinical over time, on both as a journal and an individual 
paper basis (Figure 4.8). 
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Table 4.17: Phased clinical trials paper outputs in 19 cancer drugs (1963-2009) 
 
Figure 4.6: Country-specific correlation coefficient of cancer drug paper outputs versus burden for 16 cancer sites.
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Figure 4.7: China: cancer drug research output versus burden from 16 cancer sites. 
 
Figure 4.8: Mean research level (RL) of all cancer drug papers in five quintiles. 
However, the situation with individual drugs varies greatly. First, 
there are big differences in the mean research levels of their 
papers (Figure 4.9): the vinblastine papers are the most basic 
and those on capecitabine and bevacizumab are the most 
clinical, with the difference being quite large. Second, the 
individual papers are mostly more clinical than the journals in 
which they are published. Third, for a few drugs the papers 
become more basic with time (anastrazole and tamoxifen based 
on paper titles, and cisplatin and vincristine on both scales). 
Fourth, for some drugs the second quintile is much more clinical 
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Figure 4.9: Mean research level (RL): journal source (RLj) versus title source (RLp) in 19 cancer drug papers (1963-2009).
than the first, but then the subsequent quintiles become more 
basic (Figure 4.10). There is a much bigger variation between 
the countries in terms of the mean research level of their papers 
(Figure 4.11). 
India and China publish the most basic papers, probably 
because their clinical journals are not processed for the WoS, 
and Greece the most clinical ones. Indian and Chinese papers 
are, on average, more clinical than the others in the same 
journals, but for most other countries the reverse is true  
particularly for those doing clinical work. 
[I] Anti-cancer drug research activity according to 
clinical development phase 
Some of the papers referred specifically to the work being part 
of a clinical trial, either Phase I, II or III (occasionally 
combinations). The percentage of each drug's papers that 
formed part of a clinical trial ranged from below 3% (tamoxifen) 
to almost 40% (capecitabine) (Table 4.17). 
Table 4.18 shows that Phase II trials dominated, with nearly two 
thirds of the total. This was also true for all the individual drugs 
except three, although the numbers of papers were not large for 
these (bortezomib, lapatinib and sunitinib). Perhaps surprisingly, 
Phase II trials usually came first, as early as or even earlier than  
Phase I trials, as shown in the example time pattern of papers 
for carboplatin (Figure 4.12). For this drug, the number of 
papers peaked around 1996, decreased, then rose again to a 
second, smaller peak in 2006. Clinical trial papers also showed 
two peaks, but this second peak (2006) was higher than the 
first. 
Different countries showed different clinical trial outputs, 
negatively correlated with the mean research level of their 
papers (Figure 4.13). Greece produced relatively the most trials 
and India the least. Sweden produced fewer than expected 
based on the research level of its papers whilst Korea rather 
more, largely attributable to their choice of drugs on which they 
concentrated their efforts (Table 4.11)   Sweden on 
alemtuzumab and tamoxifen (fewer than 3% of trials papers) 
and Korea on capecitabine and irinotecan (30%) and gefitinib 
(15%). 
4.3.5. Trends in global and regional cancer drug 
development 
There was a gradual shift over time from the USA and the 
EUR30 countries to the RoW (Figure 4.14), with the latter group 
overtaking the USA and seems likely to overtake EUR30 
shortly. Its recent rise is mainly due to increasing Chinese 
publication outputs, showing rapid increases lately after a 
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Figure 4.10: Average research level (RL) per time quintile for 6 cancer drugs. 
 
Figure 4.11: Mean research level (RL) from 15 countries in 19 cancer drug research papers per paper title (paper) and per journal source 
(journal). 
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Table 4.17: Phased clinical trials paper outputs in 19 cancer drugs (1963-2009) 
 
Table 4.18: Global percentage of 10 RoW countries in 19 cancer drug papers (fractional counts) (1980-2009) 
 
 
Figure 4.12: Phased carboplatin clinical trials longitudinal paper outputs (3-year running means). 
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Figure 4.13: Percentage cancer drug clinical trials output per mean research level in 15 countries.
 
Figure 4.14: Geographical distribution of cancer drug papers in three world regions (USA, EUR 30, RoW) (quintiles, fractional counts) (1963-
2009).
temporary halt from 2001-2004 (Figure 4.15). This major 
expansion in scientific output parallels that seen in other areas 
of science but not yet on the scale seen in the physical sciences 
[7]. 
The pattern shown in Figure 4.14, with decreasing presence 
since the 1990s of both the USA and the EUR30 countries and 
an increasing presence of the RoW, does not prevail for all the 
drugs. First, there is a big variation in the US presence from 
almost 60% to barely 20% (Figure 4.16, Table 4.10), similarly in 
EUR30 countries and RoW. Second, for two drugs the US 
presence has increased over time (alemtuzumab from 10% to 
44%; exemestane from 6% to 22%), and for six drugs the 
EUR30 presence has increased (bortezomib, lapatinib, 
sunitinib, trastuzumab, vinblastine and vincristine). The RoW 
presence has almost always grown, indicating a steady shift 
away from the USA and Europe. 
Which countries in the RoW have made the largest 
contribution? Table 4.18 shows the percentage presence in six 
quinquennia for 10 RoW countries  the six listed in Table 4.3, 
plus the next four (Turkey = TR, Israel = IL, Taiwan = TW and 
Brazil = BR) and all others. 
Although Korea, China, Turkey, Taiwan and Brazil have 
increased their outputs both absolutely and relatively, others 
have declined relatively from an earlier peak. This is greatest for 
Israel, whose output has even declined in absolute terms from 
1995-1999. 
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Figure 4.15: Chinese cancer drug papers, 3-year running means (fractional counts) (1996-2008). 
 
Figure 4.16: Distribution of 19 cancer drug papers by geographical region: USA, EUR30 and RoW (fractional counts).
4.3.6. Funding of cancer drug research 
The analysis of the addresses for the presence of names of 
pharmaceutical companies (Table 4.6) yielded their paper 
outputs (Table 4.19). The 12 companies developing one or 
more of the 19 selected drugs were involved in a total of 1295 
papers; in addition, the other 14 leading companies were 
involved in 337 papers. In total, 1589 papers had a 
pharmaceutical company address (5.5%); in addition, there 
were papers whose addresses included smaller pharmaceutical 
and biotech companies not listed in Table 4.6. Each paper was 
examined for each of the 19 individual drugs to see what part 
had been played by the drugs' developers both before and after 
marketing approval (Table 4.20). 
Overall, the number of papers involving companies other than 
the primary developer exceeds those involving the drug 
development company, but as expected, the latter dominates in 
the years leading up to marketing approval. This pattern holds 
true for all drugs except irinotecan, tamoxifen, trastuzumab and 
the two longestablished Eli Lilly drugs vinblastine and 
vincristine. These drugs all have more papers involving other 
companies than the development company as do several others 
such as anastrozole and cisplatin. 
[I] Funding of cancer drug research by sector 
The main analysis was in terms of the four main sectors: 
government, private-non-profit, industry and international. For 
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Table 4.19: Intramural papers in 19 cancer drugs per phama company (1963-2009) 
 
Table 4.20: Pre- and post-marketing approval paper output in 19 cancer drugs by their developing pharmaceutical company versus other 
companies 
 
the 19 selected cancer drugs, the breakdown of financial 
funding was analysed (Table 4.21). The sample sizes varied by 
about 6:1, but the complete set of papers for the different drugs 
varied by more than 100:1. The tinted cells in the five right-hand 
columns show there is a substantial variation in the amount of 
support from the different sectors for the 19 drugs. Bortezomib 
and vinblastine receive most from government (see also the 
blue bars in Figure 4.17) and exemestane and anastrozole the 
least; there is relatively less variation in the support from 
private-non-profit sources although temozolomide benefits
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Table 4.21: Funding sources in 19 selected cancer drug papers (1963-2009) 
 
 
Figure 4.17: Funding sources in 19 cancer drug papers (1963-2009). 
most; exemestane, followed by capecitabine and anastrozole, 
have the most support from industry (red bars in Figure 4.17). 
There is very little international support for any of the drugs. 
Papers with no funding acknowledgements must be in practice 
funded, normally they would be supported by university or 
hospital funds, which in Europe would come from national or 
regional governments. 
Variation in longitudinal support for drugs with sufficient papers 
was completed, six drugs had 130 or more papers with funding 
data and chosen for a funding analysis in five quintiles (Figure 
4.18). There appears to be a modest reduction in the amount of 
support over time, both of government and industrial funding 
between the first and second quintiles, though the latter 
increases again subsequently to about 27%. Private-non-profit 
funding is fairly constant averaging 39% for these six drugs. 
Variation in sectoral support for papers from different countries 
was examined on an integer count basis for the 15 leading 
countries (Table 4.22,  Figure 4.19). Sample sizes were not 
modified to take account of the much smaller numbers of 
papers from lesser-producing countries, for example the sample 
of Chinese papers is only 20, and that of Indian papers only 11, 
whereas there are 761 US papers. 
The number of internationally funded papers is too small for the 
analysis to be meaningful, but there are several interesting 
trends. The far eastern countries (China, Japan, Korea) rely 
mainly on government sources with very little private-non-profit 
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Table 4.22: Funding sources for cancer drug papers in 15 countries: Ratio of percent of national papers to world mean (1963-2009) 
 
 
*Six drugs = carboplatin, cisplatin, docetaxel, irinotecan, tamoxifen and vincristine. 
Figure 4.18: Funding sources for 6 out of 19 cancer drugs
* in different time quintiles. 
 
Figure 4.19: Funding sources for cancer drug papers in 15 leading countries (1963-2009). 
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Table. 4.23: Funding sources for cancer drug research papers in 16 cancer manifestations (1963-2009) 
Table 4.24: Governmental organisations supporting cancer drug research (1963-2009) 
 
 
sources, whilst both China and Korea have little industry 
support from industry. Of the European countries, Greece and 
Sweden have little government support; however, Sweden 
together with the United Kingdom enjoys high private-non-profit 
funding. Germany, France and the United Kingdom have the 
largest proportion of support from industry, noticeably more than 
the USA. Canada and the USA receive more government 
support than any of the European countries. 
Finally, we examined the sectoral support for drugs intended for 
use in the 16 cancer sites (Table 4.23). Data for cervical and 
oesophageal cancer were omitted due to insufficient papers (7 
and 5, respectively). The differences are relatively minor 
between the different sites, particularly when accounting for 
small paper sample size (13 of the 16 cancer sites were less 
than 100 papers). Leukaemia, followed by lymphoma, gets most 
support from government; the situation with respect to private-
non-profit funders is similar. Industry relatively favours research 
on the application of drugs to breast and colorectal cancer. 
[II] Leading funders of cancer drug research 
The 1953 papers whose funding had been recorded 
acknowledged a total of 2833 funding sources. These were 
tallied in order to list the leading sources of support for cancer 
drug research, under the three sectoral categories (Tables 4.24 
and 4.25). The individual institutes of the US National Institutes 
of Health have been grouped together, as some authors
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Table 4.25: Non-profit organisations supporting cancer drug research (1963-2009)
acknowledge the institute, and some just the NIH. Similarly, 
acknowledgements to subsidiary companies have been 
grouped under the main parent company, even if it was not the 
owner at the time of the research, with the sole exception of 
Genentech, Inc., Table 4.24 shows the dominant position of the 
US National Institutes of Health/National Cancer Institute in 
funding cancer drug research, with support to over one third of 
the US papers. 
4.4. Conclusions and Policy Issues 
This chapter examined research papers on 19 selected cancer 
drugs (articles, notes and reviews) from the WoS for 1963 to 
mid-2009. The papers were identified via the drug names in 
their titles, including trade and code forms. A total of 28,752 
papers were included in the analysis, after removal of ones that 
had been identified in error and almost all were in English. 
Papers on the 19 selected drugs rose from 200 annually (1980) 
to 900 (1995) to more than 2000 annually by 2007-2008. The 
latter figure represents about 4% of all cancer research output 
and half of the research paper output of all 150 cancer drugs. 
The number of papers on the individual drugs varied from 83 for 
lapatinib, first marketed in 2007, to 10,299 for cisplatin from 
1978. The leading countries contributing to the research were 
the USA (33% of fractional count total), Japan (10.6%), Italy 
(7.5%) and the United Kingdom (7.1%). 
International collaboration has increased but is still firmly based 
on geographical, historical and linguistic links between nations. 
Thus, the USA and Canada each preferentially select co-
authors in the other country, as well as between EU Member 
States, especially the Netherlands and the United Kingdom. A 
matrix of the ratios of observed to expected papers from leading 
15 countries for 19 selected drugs showed most drugs having 
one or two countries with concentrated output yet conversely 
with less work on other drugs. The 19 drugs were compared 
against 16 leading cancer manifestations, finding some cancer 
sites favoured over others (e.g. tamoxifen for breast and uterine 
cancer, cetuximab for colorectal cancer). However, the research 
portfolios for these 19 drugs in 15 countries correlated very 
poorly with their national cancer burdens of the 16 cancer 
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manifestations, except for China and to a lesser extent 
Australia. 
Over time, the research levels of the papers (on a scale from 
clinical = 1 to basic = 4) became slightly more clinical, but not 
for all the 19 selected drugs (exceptions were cisplatin, 
vincristine, anastrazole, tamoxifen). Work on vinblastine and 
bortezomib was the most basic, whilst bevacizumab and 
capecitabine the most clinical. Papers from India and China 
were the most basic likely, as their national clinical journals are 
not covered in the WoS, and those from Spain and Greece the 
most clinical. About 15% of the papers described phased 
clinical trials, mostly Phase II. Greece produced most of such 
trials (34%) and India the least (2%), and negatively correlated 
with the research level of the countries' papers. 
Over the period of analysis, the geographical balance shifted 
from the USA and Europe to the RoW, particularly China, which 
accounted for almost 5% of global output by 2008. The US 
presence varied between 57% for lapatinib to 20% for 
exemestane and increased over time for alemtuzumab and 
exemestane. 
In the papers' addresses, the presence of 26 leading pharma 
companies including the 12 associated with development of the 
19 selected drugs, occurred for 1589 papers (5.5%). Leaders 
were Aventis (274 papers), AstraZeneca (173) and 
BristolMyersSquibb (155). In the years up to and including when 
initial marketing approval was given, the company developing 
the drug dominated the output for 14 of the 19 drugs, as 
expected. 
4.4.1. Policy conclusions 
Modern cancer drug discovery and development 'starts' in the 
early 1970s, follows a slow trajectory, and then activity 
increases substantially between 1990 to 2000. From 2000 
onwards, the trajectory of outputs increases dramatically, whilst 
the overall output of cancer drug development papers globally 
remains constant at just under 10%. This is entirely the result of 
a concomitant major increase in world cancer research activity. 
We found that the rate of drug development activity has 
substantially increased, with more publications per time period 
for newer agents than older ones. However, from cumulative 
data, we show the development of cancer drugs does not stop, 
even for those with more than 20 years of marketing 
authorisation (e.g. Cisplatin 1978, Tamxoifen 1986). The main 
geographic locations are the USA, Japan and Europe (primarily 
Italy, the United Kingdom, Germany, France) with over 98% of 
publications in the English language. 
Trend analysis shows collaborations at the national level have 
remained very stable since the 1990s. International 
collaboration is still firmly based on geography, linguistic and 
cultural ties, although intra-European collaboration has grown 
since early 2000. Thus Canada and the USA favour each other, 
although the USA also has good links with Japanese and Indian 
scientists. The three far Eastern countries (China, Japan and 
Korea) all give above-average preference to each other, and 
Korea (but not the others) to India. Within Europe, the 
Netherlands and the United Kingdom appear to play important 
roles in collaboration, and there are strong links between the 
United Kingdom and Australia. Perhaps surprisingly, India 
prefers Germany to the United Kingdom among European 
countries (this has been observed in other fields as well), but its 
relatively preferred partner is Australia. Whilst cultural 
transmission of science between geographically or linguistically 
close countries is to be expected from previous research, a 
question mark has always remained about whether 
outreach/international policies set at the national (or supra-
national) level have any affect on the direction of collaborations 
and cooperation. Our data on intra-European and USA-China 
collaboration support the premise that topdown 'iron triangles' 
can promote cooperation [8]. In the former case, the temporal 
concordance between the evolution of the European Research 
Area and the increase in intra-European cooperation in cancer 
drug development is strongly suggestive [9]; however, the lag 
time in seeing the benefits of such policies, at least in this area, 
is around a decade. 
Apart from the Japanese focus on EGFR inhibitors, we found no 
specific trends or associations between geographic regions and 
development life cycle of specifc NMEs. It appears one or two 
countries appear take a 'lead' in research around a specific 
cancer drug. Up to mid-1990s, there was a strong association 
between location of pharmaceutical companies and research 
activity; however, this association has loosened with increasing 
numbers of NME being developed in a distributed manner. We 
also found, in absolute terms and contrary to 'negitive views' of 
Europe's weakness compared to the USA [10], Europe and the 
USA were equal 'intellectual' partners in cancer drug research 
outputs. 
In policy terms, discussion of a balanced portfolio has tended to 
focus either on relative investments (and activity) in specific 
cancer research domains (e.g. prevention, fundamental biology) 
or in the balance between effort allocations to different disease 
areas by pharma companies [11]. Relatively little has been 
asked about the balance in site-specific later stage cancer drug 
development. Using this bibliometric approach we have found 
an objective way to quantify the relative focus and lacunae in 
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cancer drug development. The comparison of disease burden 
suggests that although for many sites the amount of research is 
as expected, it is too much low for some cancers such as lung, 
colorectal, oesophageal and pancreatic. Only leukaemia seems 
to be somewhat over-produced compared to its disease burden 
 perhaps as a result of using leukaemia as a 'model system' 
for testing many NMEs. 
At the country level, we found little correlation between the 
burden of site-specific cancer and associated site-specific 
cancer drug development, confirming bottom-up market forces 
are the predominate drivers in most countries. Interesting 
exceptions are China, and less so Australia, with clear, long-
term correlations between disease burden and site-specific drug 
development. China in particular has long pursued a central 
cancer drug development policy in line with its other S&T 
strategies [12]; however, overall, there is no evidence that either 
approach leads globally to better or worse outcomes in terms of 
site-specific development. The key policy message is that for 
some cancers a site-specific focus may be required. 
A widely held assumption is that cancer drug discovery and 
development progresses through set phases of pre-clinical, 
mostly basic laboratory, research to eventually clinical research. 
Whilst this view may hold true for the absolute extremes of 
development, our results show cancer drug development 
progression mixes both basic and clinical research over time. 
There is no simple hand off from one type to the other at any 
point. Individual countries also produce either predominantly 
basic or clinical cancer drug development research. Thus, 
cancer drug development policies should cover the full 
spectrum research, both clinical and basic. 
Cancer drug development between the 1970s and 1990s had 
some linearity, yet the emergence of 'translational' research has 
driven increasingly complex, multi-party collaborations and 
parallel research at the class as well as individual drug level 
[13]. Most clinical development occurs at the Phase II stage; 
however, the 'clinical development' phase continues throughout 
a drug's lifespan from pre-MA onwards. Indeed, our data clearly 
show that individual cancer drug development never stops 
either clinically or pre-clinically. Unsurprisingly, Phase III (large-
scale clinical trials) only make up a very small proportion of 
overall research activity, which has important policy 
implications. Cancer drugs are continually 'in development' 
against new indications in addition to being refined with new 
schedules, regimens, etc. The old paradigm of cancer drug 
development ending with its marketing authorisation is no 
longer valid in any way, supported by continued publication 
production post-marketing. 
Our data support current perception that cancer drug discovery 
and development is entering a global phase. Outputs from the 
RoW (in particular China) are set to overtake those from Europe 
and the USA, giving some indication of the competitive nature of 
this area of drug development and huge opportunities for major 
breakthroughs. It will be essential to develop new policies 
containing collaboration and cooperation to bridge geographic 
and sociocultural gaps between investigators in different 
countries and regions. This is no easy task as numerous 
hurdles block sustainable cooperation [14]. At individual drug 
level, all three regions contribute in different capacities to overall 
output but with large variations (e.g. USA 20%-60%) and 
increasing RoW share as the only clear trend. 
The current policy paradigm around cancer drug discovery and 
development views research activity progression from an 
exclusively private (industry)-based activity to eventually a 
mixed economy with both private and public investment in the 
post-marketing phase [15]. Our findings indicate a much more 
complex picture with important policy implications. Drug-by-drug 
basis, large variations in government, philanthropic and industry 
sectors support were found to contribute to overall drug 
development. Rationales for this variability accounting for 
primarily one funding source or another are often based on a 
drug's life history (e.g. temozolomide primarily produced by 
academic). What is clear is that all three sectors are equally 
important in contributing to drug development. Furthermore, 
even the earliest development period have funding contri- 
butions eventually brought into public domain. This is an 
important point, as industry contribution is underestimated due 
to unpublished research activities. Our data clearly shows that 
public-private partnerships, even in early stages, is of major 
importance to the overall development life cycle. Federal and 
philanthropic funders making up public sector support are a 
mixture of endowed and collecting charities, as well as 
ministries and arms-length funding bodies. In the pre- 
marketing phase, development is primarily by one company, but 
post-marketing most of the publications cite multiple private 
funders, which indicate a multi-sourced flow of private capital 
into further development. Our data indicate public-private 
partnerships are now the normative model from early pre-
clinical to clinical development and beyond into 
Phase IV. 
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5. PROMOTING AND SUPPORTING CANCER 
DRUG R&D  RESULTS OF A SENIOR 
SCIENTISTS SURVEY 
5.1. Background and Objectives 
The purpose of social and public policy in cancer drug 
development is to understand, evaluate, interpret and define 
policies that form priority areas for the future. The existing 
literature is replete with studies examining consumer, patient 
and industry perspectives on drug development policy, but a 
key often neglected stakeholder group are those clinicians and 
scientists carrying out front-line research into the next 
generation of anti-cancer treatments [1-3]. Background sources 
on public policy development in cancer and drug development 
per se, such as the Institute of Medicine (IOM) Forum and the 
Tufts Centre for the Study of Drug Development, intellectually 
underpin the objectives framework for this study of key opinion 
leader views on anti-cancer public policy. 
The objective of this research was to elicit and semi-quantify the 
views of key clinical leaders in cancer drug development from 
Europe and the USA to: 
•  critically examine whether policies affect funding 
models and, if so, how; 
•  define the scope of public sector involvement in the 
process of discovery and research in cancer 
medicines; 
•  critically evaluate key environmental policies for 
successful cancer drug development; 
•  understand which policies are likely to have the 
greatest pay-back in providing the correct environment 
for R&D; 
•  identify the strengths and weaknesses of public-private 
partnership (PPP) models; 
•  critically examine these models in terms of the balance 
between policies affecting public and private sector; 
•  state the key policy areas for 'success' in anti-cancer 
drug development; and 
•  compare the relative importance of different policy 
areas across different domains. 
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5.2. Methodological Approach 
In order to elicit the views of senior clinicians and scientists on 
policy issues around cancer drug development, we proceeded 
in three steps: first, we identified the relevant faculty; second, 
we developed a tool that would be used for this purpose and 
third, after validating it, we administered that tool to the 
identified faculty. 
5.2.1. Semi-structured interviews 
From October 2008 until March 2009, we carried out semi-
structured interviews with 28 members of the faculty to discuss 
key policy areas. These interviews took place by phone or in 
person lasting 25 min to 1.5 h and addressed a number of key 
issues including a strengths, weaknesses, opportunities and 
threats (SWOT) analysis, new drug development models, 
regulatory environment and funding. 
5.2.2. Faculty: inclusion criteria and demographics 
The primary cancer drug development faculty was selected from 
senior clinical and non-clinical active researchers from across 
Europe and the USA. The inclusion criteria required they be 
active publishers in the last five years and regularly invited to 
speak at major conferences on cancer drug development 
(among others AACR, EORTC, NCI, AACR). The final list was 
reviewed for geographic, speciality and gender balance before 
finalisation. Questionnaires were sent to all faculty members 
(n=102) for whom verified contact details were present. In 
addition, the questionnaire was forwarded to an additional 16 
faculty from the initial listing. 
In order to ensure an accurate analysis of critical data, 
demographic information was elicited from the questionnaire 
including: 
•  age and gender; 
•  clinical/non-clinical and research domain (NCE / 
Biological) 
•  geographic location. 
As the questionnaire was distributed as 'open', additional faculty 
were added if they fulfilled the criteria of geography and 
seniority. All responses were anonymous and faculty were 
provided with full details of the purpose of the questionnaire and 
its future use/distribution. 
5.2.3. Questionnaire development 
Between 4 December 2008 and 15 March 2009, 12 members of 
the selected faculty were interviewed on a one-to-one basis as 
part of the semi-structured interviews to build the questionnaire. 
This was then externally validated when in beta-version. In 
addition, a review of the background literature was undertaken 
including review of prior policy studies and public research 
funding organisations, this information was incorporated into the 
results where relevant. 
Four key policy areas were identified: 
1.  Funding (particularly public sector)  Investment by 
national bodies (philanthropic and federal) as well as 
supra-national initiatives. 
2.  Environment for R&D  This included basic 
infrastructure (dedicated beds, laboratory space, bio-
banking etc.) and intellectual environment (i.e. training 
and career development in early phase clinical trials 
and pre-clinical drug development). 
3.  Pubic-private interactions  What PPP models had the 
faculty experienced? Where the current deficiencies 
and how could this be rectified? 
4.  A variety of distinct areas that were considered 
essential for the 'success' of future cancer drug 
development (e.g. regulatory and drug 
reimbursement). 
The results of the qualitative survey were discussed with 
members of the external advisory board and other key faculty 
members. Specific questions were chosen in each area and 
responses were built around a semi-quantitative Likert scale. A 
free-text response area was also provided, due to the need to 
broadly capture public policy views from this faculty. 
The beta-version of the questionnaire was subsequently 
circulated to 10 randomly chosen faculty members and further 
evolved following feedback, including adding a demographic 
profile section onto the beginning of the questionnaire. The final 
version was checked for legibility and time-to-complete (15-20 
min), and pre-letters were sent to all faculty members prior to its 
electronic distribution in July 2009, with a two-week deadline on 
completion. Follow-up notices were sent one week before 
deadline and additional reminder letters were sent two weeks 
after the deadline 
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5.2.4. Questionnaire analysis 
Responses were entered into a standard excel spreadsheet and 
converted into a 10-point Likert scale. A Likert item is a 
statement in which the respondent is asked to evaluate 
according to any kind of subjective or objective criteria, 
generally, the respondent's level of agreement or disagreement 
is measured. Usually five-ordered response levels are used, but 
in this case we used a 10-point scale to improve statistical 
analysis. Sub-group analysis according to demographic profiles 
was undertaken. In terms of the other data characteristics, there 
was very little difference among the scale formats with regards 
to variation around the mean, skewness or kurtosis. 
Likert scales may be subject to distortion from several causes. 
Respondents may avoid using extreme response categories 
(central tendency bias); agree with statements as presented 
(acquiescence bias) or try to portray themselves or their 
organisation in a more favourable light (social desirability bias). 
We have attempted to avoid the acquiescence bias by providing 
a scale with equal numbers of positives and negatives. The 
anonymous nature of our approach also reduces the social 
desirability bias. 
After the questionnaire was completed, each item was analysed 
separately, or in some cases item responses were summed to 
create a score for a group of items (summative scale). We 
considered individual Likert items as interval-level data due to 
the 10-point scale, equidistant adjacent pairing about a mid-
category and visual analogue scale with equal spacing of 
response levels. Secondary analysis of data treated as ordinal 
was undertaken to check internal consistency. 
When treated as ordinal data, Likert responses were collated 
into bar charts, central tendency summarised by median, mode 
and mean, dispersion summarised by the range across 
quartiles, as well as analysis using non-parametric tests (e.g. 
Chi-square test, Mann-Whitney test, Wilcoxon signed-rank test, 
Kruskal-Wallis test). Responses to several Likert questions in 
the questionnaire were summed when questions using the 
same Likert scale, defendable as an approximation to an 
interval scale and thus treated as interval data measuring a 
latent variable and subject to parametric analysis. 
5.3. Results of the Clinician and Scientist Survey 
5.3.1. Interviews with drug development faculty 
Policy literature to date has focused almost exclusively on 
commercial drug development, whilst ignoring the roles of public
funders and the academic community. In Europe, public funders 
of cancer drug development have undergone major 
environmental changes since the 2004 introduction of the 
European Clinical Trials Directive. Whilst funders and academic 
institutions have long conformed with the standards of ICH 
GCP, the new requirements for laboratory studies to be carried 
out to GCP (GCLP) in addition to continued issues surrounding 
acceptability of rodent-only toxicology, increased administration 
associated with Clinical Trials Authorisation process, plus 
requirements for all clinical trial supplies to be made to GMP 
standards in a licensed facility
z have led to perceived and real 
down-turns in investigator-driven cancer drug development. 
In addition to the changes in regulatory and legal requirements, 
public funders and host institutions have also experienced major 
changes over the last five years in the following areas: PPP, 
contracts, timeliness and paediatric oncology. 
[I] Public-private partnerships 
There is not one model governing the interaction between public 
funders/host institutions and the myriad of pharmaceutical and 
biotechnology firms. In the latter, most of the faculty interviewed 
were clear that public funders/institutions retained substantial 
control over the relationship, including ownership of trial data, 
protocol design, trial completion and publication of results. With 
major pharmaceutical companies, however, the balance often 
tipped the other way to almost exclusively developed and run 
early phase clinical trials, which do not undergo the peer review 
mechanisms found in public funders/institutions. In some cases, 
the academic faculty had found the protocol development was 
conducted with their input, and then the trial was run in a third 
party country. 
[II] Contracts 
The unanimous view from interviews was a geometric 
progression in complexity and time-lines for arranging contracts 
between parties prior to beginning pre-clinical and clinical 
projects. This increased bureaucracy was not only confined to 
PPP, but also to public-public. On average, there are 6 to 11 
agreements per project, all taking significant time and 
negotiation. Complexity increases substantially with advanced 
biologicals, in particular for gene therapies suffering from the 
ubiquitous 'patent stacking' problem. 
[III] Timeliness 
Across the board, it was expressed that time needed for public 
funders/host institutions to pursue cancer drug development in 
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either pre-clinical or clinical phases, particularly the latter, had 
dramatically increased. A variety of reasons were given 
including contract negotiation (see above), lack of major centres 
with sufficient critical mass and infrastructure resources 
(specifically directed at larger Phase II studies), under-
funding/low sourcing from public funders, and time needed to 
validate PK and primary/secondary PD processes. 
Faculty were clear that public funders/host institutions had 
played a major role in cancer drug development over the last 20 
years. In addition to the role of national bodies supporting pre-
clinical and clinical development (e.g. UK, National Cancer 
Institute (NCI), Cancer Research UK (CRUK)), other 
organisations such as the Southern Europe New Drug 
Organisation (SENDO) have also been instrumental in 
supporting academic investigators. However, faculty also 
stressed this complex funding arrangements between public 
and commercial sources have always been around in one form 
or another. Whilst there might indeed be a higher attrition rate in 
publicly supported post-Phase I development, many of the 
NME's were highly novel, providing supplemental proof-of-
principle data benefiting other programmes; thus the knowledge 
derived from these studies was critical to future generations of 
drug development. Indeed, public funding was expressed as 
particularly important to many high-risk research areas, such as 
complex cell therapies, novel derived antibodies and gene 
therapeutics. 
Faculty primarily involved with biologics research were different 
in this respect to their colleagues involved with NME as they 
considered public funding to have driven (and continuing to 
drive) the development of very novel biologicals. These faculty 
were clear this was a key area for public support, targeting truly 
risky innovative approaches rather than developing 'me too' or 
second-in-class medicines. Furthermore, their emphasis on 
proof-of-concept studies as a way to improve overall attrition 
rates and truly novel approaches has been supported by other 
studies [1]. Again, the importance of both funder and host 
institution support was made with notable examples of 
translation into major advances in cancer drug discovery (e.g. 
New Agents Committee of the Cancer Research Campaign, 
CRUK). 
[IV] Paediatric oncology 
The paediatric oncology drug development community had 
specific key issues. Whilst paediatric oncology outcomes have 
improved dramatically over the last 30 years, there remains 
large gaps for new medicines. The research community, 
through International Society of Paediatric Oncology (SIOPE)
and Innovative Therapies for Children with Cancer (ITCC), has 
been active in promoting this area at both national and 
European levels for the last decade. Their work has clearly 
identified the major policy areas for drug development in 
paediatric oncology. 
Each year in Europe, approximately 12,000 new childhood 
cases of cancer are diagnosed and approximately 3000 children 
succumb to cancer. Childhood cancers differ significantly from 
adult cancers in terms of histology and sensitivity to 
conventional treatments, explaining why the prognosis of 
children with cancer has dramatically improved over the last 40 
years. Standard treatments have been developed by academic 
clinical research networks at the national, European and 
international levels (SIOP); however, involvement by the 
pharmaceutical industry has been limited. Despite improved 
paediatric disease-free survival rates (ca. 65% across all 
paediatric cancers), cancer is still a life-threatening disease in 
children and remains the major cause of death from disease 
beyond the age of 1 year. Cure is often only achieved at a 
substantial cost (major organ toxicity, developmental 
abnormalities, secondary tumours). These long-term soliloquy 
constitute significant health care burden, reducing both life 
expectancy and quality of life for childhood cancer survivors. 
Access for children to innovative-targeted therapies is extremely 
limited in Europe, partially due to paediatric oncology not 
representing a large, and hence financially attractive, area for 
drug marketing. This limited commercial potential results in 
pharmaceutical companies often not undertaking drug 
development specific for targets only present in paediatric 
malignancies. 
Failure to develop effective new treatments for childhood 
cancers is of major concern, given the consequences of 
delaying the clinical evaluation of a potentially active drug. As a 
consequence, years of socially and economically useful life are 
lost, both for the child and the parents, in addition to the tragic 
human costs to the individual child, family and friends. 
In addition to the general lack of paediatric drug development in 
Europe, major disparities currently exist between European 
member states. In some countries, such as the UK and France, 
only a small number of experimental studies can be conducted 
because of major difficulties in obtaining new drugs for 
evaluation. In other countries, such as Germany, every child 
has the right to receive any drug that is marketed in adults, even 
if no safety or efficacy data are available to support its use in 
children. Furthermore, in many countries new drugs are not 
available at all for children, leading to desperate parents 
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inappropriately transferring terminally ill children to foreign 
countries for treatment (particularly the USA). 
The regulation on Orphan Medicinal Products, adopted in 1999, 
has significantly improved the level of drug development in rare 
diseases in Europe. On 14 December 2000, the Health Council 
adopted a resolution on paediatric medicinal products [5]. In 
addition, the EU Regulation on paediatric medicines entered 
into force in late January 2007 [6]. This Regulation aims to 
establish a legislative framework to fulfil the following main 
objectives: 
•  to increase availability of medicines specifically 
adapted and licensed for use in the paediatric 
population; 
•  to increase information available to the patient/carer 
and prescriber about the use of medicines in children, 
including clinical trial data and 
•  to increase high-quality research into medicines for 
children. 
These will be achieved through a system of requirements and 
incentives. The main elements of the finalised Regulation 
include: 
•  the establishment of a new body, the Paediatric 
Committee, sited at the European Medicines Agency 
(EMEA); 
•  a requirement for new products and products currently 
covered by patent protection to include paediatric data 
based on a paediatric investigation plan (PIP), and a 
six-month extension of the supplementary protection 
certificate (SPC) if PIP information is incorporated into 
the Summary of Product Characteristics (SmPC); 
•  for orphan medicinal products, a two-year extension of 
market exclusivity if information arising from a 
completed PIP is incorporated into the SmPC; 
•  For off-patent products, a new category of marketing 
authorisation called the paediatric use marketing 
authorisation associated with 10-year data and market 
protection; 
•  an European database of paediatric clinical trials, 
partially to be publicly accessible; 
•  a requirement to submit paediatric clinical trial data to 
the regulatory authorities; 
•  coordination of an European Paediatric Clinical Trials 
Network; 
•  funding for the study of off-patent medicines provided 
through the European Community Framework 
Programmes (FP6, FP7) and 
•  an identifying symbol on the package of all products 
authorised for use in children. 
The US Food and Drug Administration has implemented similar 
regulatory initiatives (Paediatric Exclusivity and Paediatric 
Rule, 1997), which have significantly increased the number of 
paediatric studies [7]. These European and international 
developments are expected to create a significant demand for 
pharmaceutical companies to increase the number of paediatric 
clinical trials with new anti-cancer drugs. 
During the past 10 years, initiatives have been undertaken by 
paediatric oncologists in Europe to promote the clinical 
evaluation of new anti-cancer compounds in children within 
national academic paediatric oncology groups. In 1995, 
collaboration was established between the Pharmacology 
Group of the French Society of Paediatric Oncology (SFOP) 
and the New Agent Group of the UK Children's Cancer and 
Leukaemia Group (CCLG), now representing 20 clinical 
paediatric oncology centres. Other European cooperative 
groups, such as those in the Netherlands, Italy and Germany, 
have recently joined this collaboration and initiated new drug 
trials [8]. 
In addition to clinical research, high-quality and internationally 
competitive basic research on the genetics and biology of 
paediatric malignancies is being performed in Europe. There is 
a strong willingness to translate this research into patient 
benefit, however at present, there is no mechanism for linking 
basic genomic research to drug development and clinical trials. 
Therefore, there is an urgent need to integrate and strengthen 
the existing basic and clinical academic research activities with 
commercial sectors at an European level. The recent call by the 
EU Network of Excellence to structure clinical research in 
paediatric oncology in Europe is a positive step, but more action 
is needed at both EU and Member State levels [9]. 
The specific policy objectives for paediatric oncology drug 
development identified by the ITCC consortium
aa include the 
following. 
•  Prioritisation and selection of anti-cancer compounds 
developed by pharmaceutical companies for adult use 
through a comprehensive pre-clinical R&D drug 
evaluation programme to identify compounds that may 
be also active in paediatric cancers. 
•  Identification and validation of drug targets unique to 
paediatric cancers for therapeutic exploitation. 
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Table 5.1: Strengths, weaknesses, opportunities and threats for public cancer drug development 
Strengths Weaknesses 
•  Innovative studies of leading edge NME with low 
commercial potential at time of invention. 
•  Broad focus on all possible indications (incl. 
paediatric settings) not just 'blockbuster' cancers. 
•  High quality peer review and follow on support. 
•  Commitment to support 'tributary' research during 
projects, not just main hypothesis. Flexibility in 
being able to pursue additional avenues. 
•  Large intellectual network for developing NME and 
associated biomarkers. 
•  Complex multi-funder, multi-institutional 
partnerships, contracts and funding. 
•  Limitations on advanced technologies (although 
many stressed this was now improving due to 
national investment and new public-private 
partnerships) 
•  Insufficient expertise in key areas (QA/QC, project 
managers, GMP) 
•  Problems with knowledge base in particular areas 
of drug development leading to low quality go / no-
go decisions 
•  Complex arrangements coupled to under-
resourced, increasing timelines 
Opportunities Threats 
•  Many research funders / host institutions have 
now made this area a strategic priority (incl. the 
EU IMI although many felt its relative lack of 
funding and direction was a weakness not an 
opportunity) 
•  Huge expansion in new targets and an increasing 
number of NME from the private sector, providing 
major opportunities for advancing outcomes 
•  More understanding of the need for biomarker co-
development to help make the case for parallel 
translational funding with cancer drug 
development projects. 
•  Major regulatory issues (variable response) with 
emphasis by some faculty on (continued) 
acceptability issues of rodent-only toxicology. 
•  Funding is non-sustainable or a change in 
strategic priorities by federal and / or philanthropic 
funders 
•  Process too complex, slow and expensive for 
public sector (or partnership) to absorb. 
•  Failure to develop new public-private models or to 
bridge the gap between private versus public 
investigators 
•  Competitive disadvantages (protocols developed 
with public intellectual input but then run in a third 
country) 
Source: The authors.
•  Demonstration of proof of concept through mechanistic 
hypothesis-testing Phase I/II trials of novel agents by 
establishing a clinical trials network with critical mass 
(numbers of investigator centres and patients) and 
access to contemporary technologies. 
•  Improve information access and ethical aspects of 
paediatric clinical research for life-threatening 
diseases. Specifically, such policies should strive to:  
o  provide fair and equal information access for 
parents and patients across Europe on clinical 
research and updated new therapies via internet-
based dissemination such as professional sites, 
Orphanet or other means of communication; 
o  improve information quality within each trial 
through guidelines and parents participation in trial 
design; 
o  respond to cultural and ethical differences in 
member states and associate candidate countries 
by proposing guidelines and solutions to 
policymakers and institutional entities. 
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Table 5.2: Demographic characteristics of responses to drug development questionnaire 
 
Source: The authors.
•  Training for new clinical investigator centres, which aim 
to join paediatric drug development for young scientists 
and physicians, for all member states and associate 
candidate countries. 
[V] SWOT analysis 
The faculty identified a number of general issues pertinent to 
public cancer drug development (Table 5.1). 
5.3.2. Results of the survey of European and USA key 
opinion leaders 
Response rate of the questionnaire was 70.5% with 79 
responses, acceptable for survey research. Characteristics of 
faculty responders to the questionnaire sent out to the senior 
cancer drug development faculty were analysed (Table 5.2). 
Apart from the sex ratio and age range, the sample was 
reasonably balanced in terms of professional status, geographic 
locality (by region, i.e. Europe or the USA) and area of interest. 
Many of the key issues surveyed could not be sub-analyse the 
response distribution; however, where clear statistical 
differences in responses were found are shown graphically with 
the vertical axis representing number of respondents (Figures 
5.1-5.16). 
[I] Investment in cancer drug development 
Policies surrounding funding of cancer research are absolutely 
critical to the public effort and to PPP. To quantify the views of 
the faculty, we asked three key questions pertaining to the 
public-private role(s) in funding drug development research. 
•  Is private sector support for drug development 
essential? 
•  Is the current level of national public sector investment 
adequate? 
•  Does the public sector have a limited role in cancer 
drug development? 
Results were quite clear that private sector support for drug 
development was essential (Figure 5.1), as shown by the 
number of respondents agreeing or agreeing strongly with the 
question. 
Whilst there was strong view that private sector support was 
essential, there was a clear division between USA and 
Canadian versus European views regarding adequacy of public 
funding at national levels, with the former expressing insufficient 
funding (Figure 5.2). This is at odds with the findings that public 
funding systems, particularly in the USA, have well funded 
programmes of support for both pre-clinical and clinical cancer
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Figure 5.1: Is private sector support for drug development essential?  
 
Figure 5.2: Is the current level of national public sector investment adequate?
drug development. Clearly, the perception is there is 'not 
enough for the job at hand'. Some commentators questioned 
the role of public funding to support cancer drug development, 
however, from a key opinion leader perspective (and in line with 
the pre-survey interviews), they strongly disagree that the public 
role is only 'limited' (Figure 5.3). 
[II] Environment for cancer drug discovery and 
development 
The environment for drug discovery research was identified as 
critical to success during the interview phase. Whilst discussion 
within the pharmaceutical industry has tended to oscillate 
between the 'science problem' and stronger management and 
productivity (cost, speed and decision making), for the public 
sector the concerns have been much broader, even generic 
[10]. In part, this lies with the fact that public sector drug 
development activity is a far more networked, organic structure 
with multiple sovereign parties and complicated funding models 
('source to sink'). A further factor underlying this cultural 
difference, a view that came across strongly in the interviews, is 
that the public sector had much longer strategic planning time 
lines. Typically, 'programmatic' cycles of five-plus years were 
presented, rather than shorter time frames reflected by the 
'project' approach taken by industry. 
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Figure 5.3: Does the public sector have a limited role in cancer drug development? 
 
Figure 5.4: How important is the intellectual (academic faculty) environment? 
Faculty considered intellectual environment and sufficient 
infrastructure support to be the two most critical aspects for 
success in their drug development enterprises (Figure 5.4). 
Technology transfer support and formal industry links, whilst 
generally agreed as useful, were not seen major issues. Our 
data, as well as other findings from this work, strongly suggest 
in cancer drug development a 'two cultures'
bb situation exists 
where only few individuals from either culture makes the 
transition between the public and private sectors. This is a 
critical issue when considering PPP, one often given very little 
attention. 
[III] Models of public-private partnership 
To delve into these cultural issues further, we investigated key 
factors around developing successful PPP working models. In 
this particular area, the views of the cancer drug development 
faculty were much more heterogeneous. The importance of 
R&D alliances for industry has certainly dramatically grown over 
the last decade; however, most of the policy studies and 
commentaries have been focused on PPP. Increasingly, PPP 
have gained traction both at institutional level (greater 
commercial outreach by both principle investigators in the public 
sector and by host institutions themselves) and supra-national 
level (e.g. Innovative Medicines Initiative and the European and 
Developing Countries Clinical Trials Partnership) [11]. 
We asked our faculty the following questions. 
•  Are financial incentives important for PPP? 
•  Should private sector support be short-term project 
based? 
•  Should nationalisation of parts of the drug 
development process be considered? 
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 Figure 5.5: Are financial incentives important for public-private partnerships? 
 
Figure 5.6: Should private sector support be short-term project based?
•  Is the balance between private and public cancer drug 
development correct? 
Funding is considered 'mission critical', however, in response to 
whether financial incentives were important for PPP, faculty was 
split  both disagreeing and agreeing that this was important  
but with the greatest number actually disagreeing (Figure 5.5). 
During interviews, many of the faculty argued both for the role of 
the private sector in PPP to be principally project focused, but 
some also suggested the model needed to evolve with greater 
long term 'infrastructure' commitments by industry (Figure 5.6). 
A controversial area arising during interviews was regarding 
balance between the private and public sectors (Figure 5.7). 
Some of those interviewed suggested that commercial inclusion 
was detrimental to rational cancer drug development and 
potentially stifled innovation. In these interviews, the solution 
tended to focus on greater public sector (particularly 
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Figure 5.7: Should nationalisation of parts of the drug development process be considered?  
 
Figure 5.8: Is the balance between private and public cancer drug development correct? 
governmental) involvement in supporting cancer drug 
development. Discussions were complicated by numerous 
drivers for these views, including the need to develop drugs for 
super-orphan indications and previous histories of difficult 
working relations with industry. Our enquiry whether cancer 
drug development should receive greater public support found 
clear geographic differences in responses. 
Whereas European-based faculty were far more 
neutral/modestly disagreeing with this proposal, responders 
from the USA and Canada clearly felt greater public control was
needed (Figure 5.8). Although we expected this pattern to be 
replicated in the following enquiry of current public-private 
balance correctness, we found a wide spread of responses 
across the spectrum with a non-significant tendency for the USA 
and Canada to disagree. 
Our findings suggest there is still considerable disagreement 
within the public sector cancer drug development community as 
to ideal 'balance' between private and public sector 
partnerships. The opportunity to investigate new models and re-
frame PPP is clearly needed. Policy has tended to focus on 
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Figure 5.9: Is the regulatory environment a key area for success?  
  
Figure 5.10: How important are policies around the reimbursement of new cancer drugs to future success? 
pharmaceutical-biotech alliances, particularly surrounding 'fallen 
angels', as well as partnered and perceived niche products [12]; 
however, the importance of developing true PPP to improve 
innovation (knowledge enrichment, spin off markers) and 
productivity is a largely unexplored area. 
[IV] Key policy areas for 'success' in cancer drug 
development 
What are the key areas for new policy development over the 
next decade to improve innovation in cancer drug discovery and  
development? One of the most important areas, particularly in 
Europe since the introduction of the 'Clinical Trials' Directive, is 
the regulatory environment. The following questions were 
explored. 
•  Is the regulatory environment a key area for success? 
•  How important are reimbursement policies of new 
cancer drugs to future success? 
•  How important are supra-national funding initiatives? 
•  How important are national funding policies from 
research funding organisations? 
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Figure 5.11: How important are supra-national funding initiatives? 
 
Figure 5.12: How important are national funding policies from research funding organisations?  
•  Is institutional support important for success in cancer 
drug discovery? 
•  Are technology transfer and/or incentive schemes 
important policy areas? 
With regards to regulatory environment as a key to success, we 
found substantial splits between the USA, Canada, the 
Netherlands and the United Kingdom versus continental Europe 
(Figure 5.9). This may be partially explained by some European 
countries greater sympathy in including the 'Clinical Trials' 
Directive into national legislation. However, it is clear that for 
both public and private sector cancer drug development 
investigators this remains a hugely serious issue. 
Reimbursement of new drugs was raised by many of the faculty 
as a key policy issue (Figure 5.10) and expressed during 
interviews that if countries or regions failed in their 
reimbursement policies, then public sector alliances would be 
damaged. Perhaps unsurprisingly, American faculty were 
relatively neutral compared with European. The largest positive 
responses came from the United Kingdom, suggesting it has 
become an over-dominant public policy issue skewing the focus 
away from other equally important factors. 
Returning to the importance (or not) of public investment 
policies in cancer drug development, faulty were clear that both 
supra-national and national policies were essential, with a 
clearer consensus in the latter case (Figures 5.11 and 5.12). 
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Figure 5.13: Is institutional support important for success in cancer drug discovery?  
Figure 5.14: Are technology transfer and/or incentive schemes important policy areas?  
Since the EDCTP, publication of PPP in neglected diseases 
report [13], and global initiatives of GAVI and GFATM, it has 
become widely accepted that public funding is essential to drive 
innovation mainly due to the lack of commercial viability found 
by orphan diseases. However, the 'orphanisation' of many 
common cancers through molecular sub-stratification creates 
the same problem of commercial viability for developing 
innovative cancer medicines against rarer indications. Indeed, 
when one considers the rare adult cancers and paediatric 
oncology, such an environment already exists. 
The key environment for public sector drug development 
research lies within investigators' host institutions. Whilst the 
USA has a long history of major federal support for
comprehensive cancer centres [14], Europe has lagged behind, 
although recent initiatives seek to reverse this trend (i.e. cancer 
centre accreditation by OECI [15], Network of Core Institutions 
Initiative by EORTC). Increasingly, both host institutions and 
research funding organisations are offering technology transfer 
support. 
Whilst institutional level support and organisation were seen as 
critical policy areas, faculty were split on the relative importance 
of technology transfer support (Figures 5.13 and 5.14). This 
may reflect a lack of knowledge or reflect stifling versus 
promotion of true innovation, as exclaimed by many American 
faculty with the example of the Bayh-Dole Act [16]. A similar 
view was expressed by a UK Royal Society report viewing IPR
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Figure 5.15: Are new models in PPP are needed? 
 
Figure 5.16: New models for R&D in cancer drug discovery and development are needed. 
as a double-edged sword, both promoting invention and 
exploitation as well as limiting the free flow of ideas and 
information [17]. 
[V] Cancer research and development models 
Turning full circle, we return to the question on whether current 
PPP models or indeed cancer drug R&D models are currently 
appropriate or whether new policies are needed. 
•  Are new models in PPP needed? 
•  Are new models for R&D in cancer drug discovery and 
development needed? 
sResponses to both these statements found major consensus 
that both the current R&D models and PPP arrangements 
require change if cancer drug development is to be successful 
in the future (Figures 5.15 and 5.16). During interviews, various 
solutions and options were offered including major supra-
national re-organisations, harmonisations and key paradigm 
changes in the science approach. The core solutions are 
discussed below. 
5.4. Discussion and Policy Implications 
This section empirically examines the interaction, relationships 
and perceptions around cancer drug discovery and
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development between the public and private sector by focusing 
on the former community. The weaving of both quantitative data 
from the questionnaire and qualitative data from interviews has 
provided one of the first major evidence-based studies of public 
sector cancer drug development. Ideally, we would have had 
more responders from non-English speaking countries, 
particularly those countries increasingly engaged in cancer drug 
development, such as India, Japan and China. In light of our 
high response rates and commonality of views on many policy 
issues, our results are likely to be widely applicable and may 
serve as a benchmark for future high-resolution studies. 
5.4.1. Public-private partnership models 
Models of PPP are currently a key policy area. In the last two 
decades, there has been a proliferation PPP internationally in 
health research, primarily developing and transitional countries 
within Group I diseases (infections, perinatal mortality, etc). 
Whilst the notion of PPP is not new with such models existing 
as early as 1969,
cc there have been rapid changes in 
conceptual and operational approaches. These changes have 
often been driven by perceived or real deficiencies in public 
health, often including UN sponsorship. Definitions of PPP have 
varied but with common flavour – ‘a collaborative relationship 
between entities to work toward shared objectives through a 
mutually agreed division of labour’ [18] or ‘...a group of allies 
sharing the gaols, efforts and rewards of a joint undertaking’ 
[19]. 
Despite the globalisation of the cancer burden, surprisingly little 
thought has been given to the nature of international PPP in any 
domain of cancer research with most of the focus being placed 
upon carcinogen control and national cancer control 
programmes. Indeed, such a deficiency is apparent across all 
aspects of non-communicable diseases. In the domain of 
cancer drug development, our data from key opinion leaders 
clearly show both public and private sectors are necessary. 
Whilst there might be disagreement over the current and ideal 
balance of public and private sector, what is absolutely clear is 
new models are urgently needed. An integral part of this finding 
was the expression by that the overall R&D model for cancer 
drug development needs changing to reduce attrition rates, 
increase the rate and sophistication of parallel biomarker 
development, and to process the vast numbers of combination 
regimens and indications for the next generation of cancer 
drugs. Some of our data suggest that in certain geographic 
regions the appetite for greater public sector involvement in key 
cancer drug discovery areas is substantial. In particular, the key 
PPP areas for policy development were: 
•  strong institutional support and dedicated funding from 
public research organisations; 
•  new models increasing freedom to operate for 
important translational leads within specific projects, 
via improving support, light touch governance and a 
substantial decreasing administrative bureaucracy 
(nationally legislative, private-contractual, public-
contractual). 
•  Partnerships supporting trans-national cooperation and 
collaboration focused on key cancers, including 
'orphans' and not commercially attractive cancer. 
The need for these new policy approaches was tempered by 
expressions that these partnerships should be in the 'public 
good', subject to high-quality peer review and fully and publicly 
disclosable upon completion. Clear organisational policies, 
guidelines, selection of partners and governance was seen as 
essential to ensure an appropriate balance of public funding to 
compete priorities and transparent probity in the conduct of drug 
development research. Work in other areas of PPP could easily 
be applied to protect the legitimacy and integrity of such models 
[20]. 
5.4.2. Investing in cancer drug development 
Public funding remains a key area for cancer drug development. 
Whilst there was acknowledgement that budgetary concerns 
were putting increasing pressure on both national and 
philanthropic funding, the faculty expressed a need for debate 
around the issue of the public funding of cancer drug 
development research (and in cancer research per se). Both in 
the USA and Europe, federal funders were considered relatively 
slow to support public sector involvement in cancer drug 
discovery, and although there was clear recognition that supra-
national initiatives were needed, there was disagreement about 
how this funding should flow. For example, the European faculty 
agreed with the identified bottlenecks that had been identified 
[21], however, remained broadly neutral on whether the IMI was 
sufficiently resourced to achieve such ambitious aims. Indeed 
part of the problem identified was the substitutional nature of 
this funding in many member states. Crucially, and a major 
difference commercially, faculty viewed the role of public 
funding as to provide long-term stable infrastructural funding 
with arms-length governance to allow creative partnerships. Key
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multi-national, multi-group initiatives aimed at specific barriers in 
cancer drug development were further considered important 
areas for new PPP funding initiatives. However, most faculties 
did not see financial incentives as key drivers in such public-
private partnerships, instead commenting that patient outcomes 
and benefits were the most critical test of drug development 
irrespective of commercial viability. 
Previous research has supported the importance of public 
sector investment in basic sciences [22], as well as correlated 
between federal funding and privately funded research [23]; 
however, the importance of public sector investment for drug 
development research for  specific therapeutic area has not 
been extensively examined. Our findings strongly support the 
need for the public sector investment across all areas of cancer 
research, including drug discovery and development. It is clear 
there is not a simple linear relationship between the public and 
private sector investment in drug development research, where 
the public sector performs the more 'basic' aspects and the 
private sector exploits this. Rather, there is a more complex 
interplay along the entire development pathway continuing into 
post-marketing. One critical point made by faculty was a need 
for both the private sector and public policymakers to appreciate 
cancer drug development extends past Phase IV and not 
considered fait accompli once marketing authorisation is given. 
Key policy issues are the following. 
•  Requirement for specific federal programmes aimed at 
critical scientific hurdles and orphan areas. 
•  National, and less so supra-national policies, directed 
at public sectors are considered essential. Currently 
many countries do not have sufficient public sector 
support. 
•  Investment in dedicated training cancer drug 
development programmes for both clinical and non-
clinical faculty. 
5.4.3. Environment for cancer drug development 
Our findings indicate intellectual environment (‘trained drug 
development faculty embedded in centres with sufficient critical 
mass’), and infrastructure provisions were considered the most 
important areas for institutional and national policies. Many 
faculty commented the time had come to be more rational about 
which major technologies centres should invest is and which 
centres they should 'have' via external strategic alliances. Many 
comments focused on the role of federal funding to provide 
dedicated facilities for clinical development as well as key 
clinical technologies. Whilst public funding is recognised as
essential for proof-of-concept work feeding into downstream 
product development, national RFO's and institutions have a 
broader role in providing dedicated clinical facilities plus specific 
facilities to support development work in such areas as novel 
biologicals
dd. Both Europe and the USA have major supra-
national initiatives aimed at drug development (IMI and Critical 
Path Initiative); however, faculty saw these as lesser priorities 
than ensuring sound institutional level and national level 
policies. 
A number of countries clearly identified over-regulation and 
reimbursement of new cancer drugs as critical policy issues. In 
the case of regulatory impact, there is a clear difference in 
opinion between the countries that have been subjected to the 
full force of multiple regulations and those, it appears that have 
not been. Issues of over-regulation continue to overshadow all 
aspects of public sector clinical cancer research, remaining one 
of the greatest future threats for both public and private sectors. 
Regarding government intervention, some faculty pointed to the 
additional impact (both negative and positive) of government 
legislation (in the case of Europe this mostly focused on the 
impact of Directives and Regulations). Whilst agreeing that a 
balanced approach [25] was essential, the key policy issue 
focused on the interface between policymakers and the public 
sector drug development community, with a clear view that in 
the battle for the legislative 'hearts and minds', the private 
sector had disproportionate access to and influence on 
policymakers. 
In summary, this paper is a first examination of public sector 
opinions of cancer drug development. Results show strong 
opinions for the need of PPP, although conflict on the degree of 
regulation and public-private balance. What is undisputed is the 
need for re-examination of cancer R&D models in order to 
increase efficiency in cancer drug development and ultimately 
affecting cancer outcomes. New policy approaches are needed, 
including greater transnational cooperation, support of 
translational research and degree of institutional involvement. 
Funding for this new approach and cancer R&D remains 
problematic, with no clear resolution on best balance of short- 
versus long-term planning and degree of bureaucracy. 
Investment in intellectual environment remains important, in 
addition to examination of regulation bottlenecks. Ultimately, the 
goal is best cancer outcomes with cooperation the key to 
improving cancer survival. 
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6. SUPPORTING AND ENABLING 
INNOVATION IN ONCOLOGY: ISSUES IN 
PUBLIC POLICY 
6.1. Background and Objectives 
This chapter addresses the question of value of pharmaceutical 
innovation, particularly in oncology, from a societal perspective 
and endeavours to address the following questions: first, how 
do we derive value from innovation; second, is medical 
innovation in health care worthwhile; third, what approaches are 
in place to assess the value of (pharmaceutical) innovation, 
particularly in European countries and, fourth, from a public 
policy perspective, how do we provide incentives for 
pharmaceutical innovation particularly in oncology. 
Section 2 outlines the methodology employed in this chapter. 
Section 3 critically appraises the contribution of pharmaceutical 
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innovation to health, health care and well being by drawing on 
international literature. Section 4 debates whether health and 
pharmaceutical innovation have been worthwhile from a societal 
perspective, then discussing evidence on clinical and 
socioeconomic benefit. Section 5 outlines the different 
approaches to valuing pharmaceutical innovation in oncology 
and in Europe in particular and focuses on clinical effectiveness, 
rate of return regulation and value based pricing. Section 6 
discusses available incentives to drive the process of 
therapeutic innovation forward. Finally, Section 7 draws the 
main conclusions. 
6.2. Data and Methods 
Both primary and secondary data sources were used to provide 
the evidence base for this chapter
ee. The geographical focus of 
analysis is the European Union, although evidence is drawn 
from elsewhere, particularly the USA. 
Secondary data were acquired by meta-analysis of existing 
literature on innovation benefits using sources collated from 
academic databases (primarily Medline and IBSS) as well as 
governmental bodies, non-governmental organisations and 
industry publications. Two phrases entered into search engines: 
'value of innovation' and 'pharmaceutical innovation', 
originally producing 1083 and 1008 results, respectively, and 
subsequently filtered for inclusion and resulted in 60 relevant 
studies. 
Primary data were acquired by means of a questionnaire survey 
in 15 EU countries (UK, Germany, France, Italy, Spain, the 
Netherlands, Sweden, Czech Republic, Switzerland, Denmark, 
Poland, Slovakia, Greece, Finland and Portugal). The survey 
asked experts in each country to reflect on national policies to 
assess the value of pharmaceutical innovation, circumstances 
under which price premia are awarded to new medical 
technologies, and existence of bias or preference towards 
certain types of new treatments (e.g. oncology agents) versus 
others (e.g. new anti-retroviral treatments). The survey tool also 
distinguished between breakthrough and incremental 
innovation. Experts included academics and a range of decision 
makers. 
6.3. Contribution of Pharmaceutical Innovation to 
Health and Well Being 
6.3.1. What is innovation? 
The term innovation implies a new way of doing something. It 
may refer to incremental, radical, and revolutionary changes in 
thinking, products, processes or organisations [1]. The objective 
of innovation is positive change, to make someone or 
something better. In economics the change must increase 
value, customer value or producer value. Innovation leading to 
increased productivity is the fundamental source of increasing 
wealth in an economy. 
Similar to the above generic definition of innovation is applied to 
medical and pharmaceutical innovation, and comprises both 
radical (breakthrough) and incremental innovation. Health care 
markets often treat breakthrough innovation differently from 
incremental innovation, with often processes in place to enable 
stakeholders to differentiate between these two innovation 
types. Some systems attempt to adopt a specific framework in 
order to recognise different types of medicines based on their 
innovative potential. For example, the US Food and Drug 
Administration (FDA) distinguishes between priority review and 
standard review drugs. Standard review ‘is applied to a drug 
that offers at most, only minor improvement over existing 
marketed therapies’, whereas priority review is applied to ‘drugs 
that offer major advances in treatment, or provide a treatment 
where no adequate therapy exists’. Although some studies have 
attempted to quantify the differential effects of standard versus 
priority review drugs on health outcomes, only tentatively 
suggesting a significant effect, this area requires more research 
to substantiate these claims. 
One issue particularly pertinent is incorporation of post-
marketing information of drug safety or efficacy and the method 
for price premium adjustment, if at all, to reflect this new 
information. This is important given the current debate about ex-
ante versus ex-post value assessment (and therefore pricing) in 
some policy settings, notably the United Kingdom, and perhaps 
Sweden. 
6.3.2. Impact of pharmaceutical innovation on health 
Over the past 25 years, medical and pharmaceutical 
innovations, both breakthrough and incremental, have 
transformed treatment of severe illnesses such as cancer and 
rheumatoid arthritis, and dramatically improving patients' lives. 
Achieving even incremental innovation requires significant 
investment and commitment in resources and therefore 
perceived as a challenge for health care systems. Critics 
typically site (rising) pharmaceutical spending as a major 
contributor to spiralling health care costs, suggesting pricing 
practices and pharmaceutical/biotechnology industry profits are 
largely to blame for health care budget crises in many countries. 
Others believe the opposite to be true  rather than being the 
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problem, pharmaceutical innovation on the part of the overall 
pharmaceutical/biotechnology industry has added significant 
value to patients, to the economy and to the larger society. In a 
recent study on the relative importance of medical innovations, 
clinicians were asked to identify and rank the health care 
technologies they consider most valuable to themselves and 
their patients. Pharmaceutical interventions, such as ACE 
inhibitors, statins, PPIs, H2 blockers and inhaled steroids, were 
all ranked very highly on that list reflecting the therapeutic 
benefit they deliver [2]. 
Indeed, the evidence on the value of medical and 
pharmaceutical innovation and its contribution to health, 
productivity and return on investment (ROI) is substantial and 
growing. For example, treatments for heart attacks deliver a $7 
return on each $1 of invested in new therapies, such as 
thrombolytic medicines, stents and long-term drug therapies 
(1984-1998) [3]. Improved treatments for low birth-weight 
infants show a $6 return for each $1 incremental investment in 
new therapies, including special ventilators and artificial 
surfactants (1950-1990) [3]. 
Specific classes of drugs, such as statins, have proven to 
deliver extraordinary value [4] in a number of ways, both for 
primary and secondary heart disease prevention. Early, statin 
initiation following an acute heart attack reduces the risk of fatal 
heart disease or a recurrent heart attack by 24%; every dollar 
spent on statin therapy in heart attack survivors (versus usual 
care) has produced health gains valued as high as $9.44. In 
Type II diabetes patients, statin therapy to lower cholesterol 
also decreases the risk of coronary events by 25%; every 
additional dollar spent on statin therapy in Type II diabetics with 
high cholesterol produces health gains valued at $3. Beta-
blockers are another example of high-positive return on 
investment, as treatment of heart attack patients with beta-
blockers show a 35 to 1 return [4]. In cardiovascular disease, 
GDP gains resulting from increased public/charitable medical 
research in the UK deliver an additional rate of return ranging 
from 20%-67%, whilst the internal rate of return from the value 
of UK net health gains was over 9% [5]. 
Drug innovation has also transformed the treatment of grievous 
illnesses, including cancer where significant value has been 
delivered both at societal and patient levels with the promise of 
future progress. Research estimates that innovative cancer 
drugs have increased the 1-year crude cancer survival rate from 
69.4% to 76.1%, the 5-year rate from 45.5% to 51.3% and the 
10-year rate from 34.2% to 38.1% (1975-1995) [6]. These 
increases accounted for 50%-60% of the gains in age-adjusted 
survival rates during the first 6 years after diagnosis, added 
more than 1 year of life to patients diagnosed with cancer in 
1995 and increased the life expectancy of the entire US 
population by 0.4 years (since lifetime risk of being diagnosed 
with cancer is roughly 40%) [6]. Further research suggests the 
value to the patient of a cancer-free life year is actually closer to 
about $300,000, well above the typical $30,000-75,000 per 
QALY values used as thresholds in health economic 
evaluations [7,8]. 
If society continues to fund further research in cancer therapy, it 
is likely greater rewards could be expected. Recent studies 
suggest a cure for cancer might be worth $47 trillion [9], whilst a 
1% reduction in cancer mortality worth $500 billion [9,11]. 
Despite increasing evidence on the impact of pharmaceutical 
innovation in society, there is concern the value of 
pharmaceutical innovation may not be fully recognised; there 
are gaps in measurement, value affected by pricing, or/and 
reimbursement policies. Metrics, standards and tools to assess 
drug value are often incomplete and inadequate, as they 
typically measure and assign a value to life years saved with 
some estimate of quality adjustment and direct cost offsets, but 
fail to additionally measure a number of important parameters of 
interest, such as: 
•  value to society, not only from the view point of the 
health care system, but on overall economic 
productivity; 
•  value to the patient, the caregiver and also the 
physician and 
•  value over time, of the value achieved during the initial 
treatment period and also of the benefits realised over 
the duration of the patient's life (e.g. avoiding costs of 
future treatments). 
Even when a more comprehensive set of metrics is considered, 
payers and insurers have frequently made explicit decisions to 
exclude some sources of value (e.g. impact on productivity) 
from their assessments of the relevant technologies or 
interventions. 
Assessments of value do not take into account the fact that 
patent protection only allows pharmaceutical and/or 
biotechnology companies to realise the benefits of their 
innovation for a fixed period, whilst society enjoys the same 
benefits in perpetuity. For example, the manufacturer of Prozac 
enjoyed the financial benefits of this innovation during its 
effective patent term post-launch, but millions of patients 
continue to enjoy these benefits today at much reduced 
(generic) prices. In sum, if all the benefits of drug innovation 
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were appropriately quantified and considered, the value of such 
innovation over the past three decades would potentially be 
even larger than initially estimated. 
6.4. Is Health Care and Pharmaceutical Innovation 
Worthwhile? 
This section discusses the societal benefits of innovation, 
illustrating how clinical benefits, such as faster recovery (partial 
or total), higher tolerability, higher survival rate or life 
expectancy, are more relevant to some therapeutic areas than 
others, but the socioeconomic benefits gained (e.g. higher 
productivity) have much in common. 
6.4.1. Therapeutic/clinical benefits 
[I] Life expectancy and survival 
One of the benefits of pharmaceutical innovation across an 
ever-increasing range of therapeutic areas is the increased 
likelihood of an efficacious therapy for any given disease 
existing which ultimately reduces morbidity and the probability 
of mortality. Numerous studies have attempted to model the 
decline in mortality rates for a variety of clinical conditions (e.g. 
coronary heart disease, diabetes, colorectal cancer) attributable 
to the introduction of new pharmaceutical therapies over the last 
50 years. 
Although this link between pharmaceutical innovation and 
increased life expectancy might seem obvious, econometric 
analyses have nonetheless been carried out to estimate the 
quantitative impact of the approval of new drugs on mortality 
rates from HIV and rare diseases [12]. Though the results of 
regression analyses support the hypothesis that increased 
availability of new drugs is associated with a decline in mortality 
rates, the mechanism by which this might occur is unclear. 
Some of these clinical benefits potentially contributing to 
increased life expectancy/decreased mortality are 
disaggregated in the following sections. 
[II] Higher probability of faster or full recovery and 
preventing re-emergence 
The link between improved therapeutic/clinical benefits and the 
development of innovative pharmaceuticals is often preceded 
by a progression in knowledge of disease aetiology. Chronic 
myeloid leukaemia (CML) is one example where understanding 
of the molecular basis at a genetic level led to rational design of 
a successful targeted therapy. Aided by well-established 
diagnostic procedures and prognostic factors, the development 
of Imatinib, a tyrosine kinase inhibitor which helps slow cancer 
cell proliferation, significantly improved the chances of 
remission for sufferers of CML, such that 87% of patients now 
achieve remission [13]. 
If new treatments show higher probability of faster/full recovery 
or a higher probability of preventing re-emergence, then payers 
are typically inclined to award price premia over existing 
therapies across surveyed countries. 
[III] Slowing disease progression 
In an age where chronic diseases are becoming increasingly 
prevalent, slowing disease progression is of significant 
importance. Diabetes, affecting 1.4 million people in the United 
Kingdom [14] and several million across Europe, is associated 
with debilitating long-term clinical complications, including 
retinopathy, peripheral neuropathy, cardiovascular disease, 
hypertension and nephropathy. 
Innovation has affected diabetes therapy through the discovery 
of glitazones, a group of molecules that increase sensitivity to 
insulin therapy, revolutionary in non-insulin-dependant diabetes. 
In an economic evaluation in the UK NHS setting, Beale et al. 
found rosiglitazone combination therapy combined with 
metformin resulted in better glycaemic control than traditional 
treatment consisting of metformin and sulphonylurea [15]. 
Patients on rosiglitazone combination therapy enjoyed a greater 
life expectancy with an average 123 life years gained per 1000 
obese patients. As this treatment delays the onset of insulin 
therapy, it also results in significant improvement in patients' 
quality of life. The reaction of payers to a value proposition 
promising to slow disease progression and delay or exclude 
more invasive therapy is also very positive in principle. 
[IV] Less severe side effects 
Adverse side effects can decrease treatment compliance and in 
the long-term result in higher costs  unused and wasted 
medication in the UK NHS is currently valued at £100 million 
annually [16]. This is an important issue in psychiatry where 
patients' suitability for community versus institutional care is 
conditional on medication adherence. Selective serotonin re-
uptake inhibitors (SSRIs) used in depression treatments have 
fewer side effects than traditional tricyclic antidepressants 
(TCAs). Several studies have shown, despite the price premium 
awarded to SSRIs, treatment substitutions could be made with 
virtually no change in overall costs due to reduced readmissions 
[17].  However, a review assessing the economic benefits of 
TCAs and SSRIs found although direct medical costs were 
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lower with SSRIs administration, it was difficult to make a 
definitive evaluation of the overall socioeconomic impact of 
prescribing SSRIs versus TCAs due to the omission of possible 
confounding variables [18]. 
The importance of increasing tolerability is particularly relevant 
to CNS therapeutics as side effects often have behavioural 
consequences. For example, third-generation antihistamines 
developed from active ingredients of second-generation agents, 
retain the activity of the parent compound but with improved 
tolerability and pharmacokinetics yet fewer side effects of 
reduced drowsiness and improved safety. 
[V] Broader, easier dosing and administration to 
improve compliance and efficacy 
One area in which such incremental innovation occurs is in the 
development of new drug delivery methods. Clinical benefits of 
innovative drug delivery forms include a simpler dosing 
regimen, improved compliance, improved pharmacokinetic 
profile, increased safety and fewer adverse side effects [19]. 
To improve compliance, the dosing regimen can be simplified to 
involve fewer, higher dosage administrations. Methylphenidate, 
prescribed for attention deficit disorder, can now be 
administered twice daily, resulting in increased efficacy of the 
drug whilst reducing the amount of disruption in a child's school 
routine.  
[VI] Quality of life: Greater physical, psychological 
and social self-sustainability 
In some cases, the treatment itself may cause a decrease in 
quality of life. For example, intravenous chemotherapy 
treatment is toxic and unpleasant to administer. In the majority 
of cases improvements in quality of life are recorded. Treatment 
for multiple myeloma has benefited from recent developments in 
the production of an oral form of immunomodulatory drugs such 
as thalidomide benefiting from lower toxicity and increased 
patient quality of life [20].  Another example of improvement in 
quality of life is for mental illnesses where discoveries in 
neuropharmacology have enabled patients to participate in their 
family and community whilst receiving treatment. 
It is often difficult, however, to assess of individual quality of life. 
This is particularly true with regards to mental health patients as 
their subjective opinion of their quality of life often diverges from 
objective bystanders such as caregivers. Consequently, effort in 
developing new surveys have been made to capture a more 
accurate quality-of-life assessment to be used for treatment 
decision making. 
6.4.2. Socioeconomic benefits 
[I] Reduced total costs of treatment and non-drug 
spending 
One of the primary socioeconomic benefits potentially accruing 
to the payer (and society) as a result of innovative therapies is a 
net reduction in total treatment costs, for example as a result of 
increased compliance leading to increased efficacy. Kleinke 
suggested six 'value propositions' to categorise innovative 
pharmaceuticals, depending how costs and benefits of the drug 
are realised with respect to time and the size of the population 
(Table 6.1) [21]. 
In particular, it has been suggested newer drugs prescriptions 
appear to reduce overall total non-drug medical spending. 
Evidence gathered from the 1996 US Medical Expenditure 
Panel Survey (MEPS) found a positive correlation between the 
age of a drug and the health care spending patients consuming 
the drug [22].  The study found newer pharmaceutical therapies 
reduced all types of non-drug health care spending, with the 
reduction of inpatient spending being most significant; their 
model suggested that increases of $18 in prescription charges 
were offset by a reduction of $71.09 in non-drug charges. In line 
with the notion that newer therapies provide direct economic 
benefits compared to older therapies, these publications were 
thought to have important implications for pharmaceutical 
policy. 
However, this set of analyses has been criticised for not 
accounting whether the medication prescription was 
concomitant with or post-dated the non-drug health care costs, 
as this has implications for the direction of causality in the 
relationship between health care costs, severity of illness and 
drug age. The studies were also carried out over very limited 
time periods with little longitudinal data. Controlling for these 
factors reduces the significance of the results of the Lichtenberg 
model and brought into question its reliability [23].  Therefore, 
further work needs to be undertaken in this area, particularly 
using longitudinal data and analysing policy implementation 
effects. 
[II] Costs and outcomes 
Any reduced costs have to be considered alongside the change 
in the delivered clinical benefits, as the relationship between 
cost-savings and socioeconomic benefits is far from 
straightforward. In this context, cohort studies from the 
American Medicare system investigated patient outcomes 
admitted for hip fracture, colorectal cancer treatment or 
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Table 6.1: The six economic categories for innovative medicines 
 
Source: Adapted from [21].
myocardial infarction across states with different levels of 
Medicare spending [24].  They found patients in higher 
spending states received more care, although this did not lead 
to significantly lower mortality rates, better functional status or 
better health services satisfaction. What cannot be concluded 
from this study, however, is whether reducing spending in some 
areas could have a negative effect on health outcomes. Further 
research is needed to understand the dynamics of reducing 
spending without adverse effecting patients, whether this is 
feasible and in what therapeutic areas. 
One problem with properly assessing the cost savings from new 
therapies is ideal settings found in clinical trials are often not 
replicated in real life. To this end, Cutler et al. carried out an 
empirical study modelling the effects of hypertensive therapy 
over the last 40 years using data from the Framingham Heart 
Study and the US national survey to estimate health outcomes 
in the absence of innovation in CHD treatments [25].  Although 
their model had limitations including the inability to control for 
lifestyle factors associated with CHD such as exercise and 
sodium intake, their static analysis suggested that US$17.5 
billion in costs have been avoided as a result of decreased MI 
and stroke compared to annual costs of anti-hypertensive 
medication at $8.8 billion, suggesting a cost-to-benefit ratio in 
favour of this treatment. 
Treatment costs may not always be offset by accrued savings, 
resulting in government or payer making judgments about the 
'willingness to pay' threshold. Statin use in the UK NHS is one 
example, where value avoided costs statin use was calculated 
at £218 million but not offset by the total statin costs estimated 
at £3.2 billion. Nonetheless, statins are estimated to have saved 
approximately 17,400 lives [26]. 
[III] Innovation as a driver of increased costs 
Many health policymakers regard innovation, both technological 
and pharmaceutical, as primary reasons for increased health 
care costs [3]. Treatment for indications such as myocardial 
infarction are now more labour, capital and knowledge intensive 
than 30 years ago. Some argue although many new medical 
treatments represent genuine medical advances providing novel 
therapeutic opportunities for patients, there is also a tendency 
for inappropriate application and over-use. For example, the 
USA has twice as many MRI machines per capita than Western 
European countries, yet arguably provides no difference in 
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health outcomes [27]. In this context, Health Technology 
Assessments (HTA) play an important role in informing 
decisions about appropriate rate of technology diffusion 
according to evaluated benefits, drawbacks and cost-
effectiveness of an innovative treatment, intervention or 
technology. 
[IV] Increased costs and R&D 
It is argued that bringing an innovative pharmaceutical product 
to market, with all associated clinical and socioeconomic 
benefits, is costly and manufacturer profits are needed to 
ensure cash flows for future R&D. However, closer examination 
of American pharmaceutical manufacturers' gross margins 
versus their R&D expenditure in a time series analysis reveal 
the pharmaceutical industry behaves consistently with a rent-
seeking model, with industry R&D investments only slightly 
surpassed by risk-adjusted capital costs. Evidence suggests as 
firms evaluate potential profit opportunities, they increase R&D 
investments and may over-invest to almost eradicate any supra-
normal profit [28]. 
Although intense debate exists as to what amounts excessive 
profits, an issue particularly relevant to the United Kingdom with 
a profit regulation scheme negotiated between the NHS and the 
pharmaceutical industry, profits nevertheless act as powerful 
incentives for innovation. Ideally, innovation could be directed at 
those areas where significant social returns can be made. One 
suggested method to achieve this is via the distribution of 
financial rewards from the health care payer to the innovator 
themselves, at a value in line with the social value of the 
(incremental) innovation, thereby aligning social objectives with 
industry objectives [29].  Although such models face many 
obstacles in terms of practical implementation, they raise 
important questions about the way in which the equity and 
efficiency objectives of both society and the pharmaceutical 
industry can be achieved simultaneously. 
[V] Loss of work costs and higher productivity 
One important aspect health care payers may consider is the 
benefit accrued in terms of lower loss of work costs and higher 
productivity in the work force. Importance of such costs are 
demonstrated in the example of varicella (chicken pox): from a 
health care payer's perspective, routine childhood vaccination 
would cost $2 per case prevented, $2500 per QALY, whereas 
alternative calculations accounting for additional loss of work 
and medical costs find $5 savings per $1 spent vaccinating [30].
Impaired performance is also an issue where an illness does 
not prevent work attendance but nonetheless affects the 
individual in their workplace. For example, the indirect costs of 
migraine to the employer were recently estimated to be US$12 
million [31].  Older therapies such as sumatriptan have been 
demonstrated to be cost-effective, analysis of migraine-related 
productivity losses in US firms suggested the replacement of 
standard therapy with newer rizatriptan would result in 
additional annual savings of US$84-US$118 per employee by 
avoiding productivity losses [32]. 
[VI] Preventing spread of infectious disease 
Prevention of pandemics of infectious diseases, which have 
debilitating economic effects from workforce productivity plus 
diminished quality of life, is also an issue to considered. For 
example, an innovative therapy recently involved in 
reimbursement decisions in several countries is the human 
papillomavirus (HPV) vaccine, with demonstrated 98% efficacy 
against HPV16/18 infection during clinical trials. Infection with 
strain HPV16/18 is associated with 97% of cervical cancer and 
without screening programmes found in some countries, there 
would be several thousand deaths per year from cervical 
cancer. In the United Kingdom alone, it is estimated an absence 
of screening would lead to 5000 deaths annually from cervical 
cancer [33].  Benefits of this new vaccine need to be offset 
against its modest administration costs to the eligible population 
 if administered to all females in the United Kingdom under the 
NHS, it would represent an additional annual outlay of 
approximately £10 million for the Department of Health [34]. 
[VII] Decreasing resistance 
Therapy resistance results in many inefficiencies, due to wasted 
medications, greater clinician attention required and effecting 
patient's quality of life through protracted suffering. Resistance 
is particularly an issue in antibiotic treatments. Bacterial 
resistance to antibiotics can be exacerbated by using 
inappropriate spectrum antibiotics, inadvertently selecting those 
bacteria harbouring resistance. Developing new generations of 
antibiotics has been key to increasing the choice of different 
treatments available, enabling physicians to select the 
appropriate treatment for a given strain of bacteria. For 
example, fourth-generation cephalosporins can target a much 
wider range of gram-positive and gram-negative bacteria than 
their first-generation counterparts, resulting in a wider range of 
therapeutic uses. 
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Table 6.2: Criteria for assessing new technologies in 15 EU countries (2009) 
 
Source: The authors, based on responses received.
6.5. Different Approaches to Valuing Pharmaceutical 
Innovation in Europe 
6.5.1. Valuing innovation in the context of drug 
reimbursement 
Few would disagree that pharmaceutical innovation is 
worthwhile, although many would argue not all of the features 
discussed in the previous sections are weighed equally due to 
differences in opinion across different settings, often dominated 
by individual value judgments. Indeed, the debate surrounding 
the value of innovation centres not only around clinical criteria, 
but also socioeconomic and budgetary. This is done with a view 
to decide how new products should be reimbursed and whether 
the decision to reimburse them meet a number of criteria. The 
type of criteria applied in this context and across study countries 
vary (Table 6.2), and range from therapeutic assessment of 
cost-effectiveness and budgetary impacts to cross-country price 
comparisons. 
All countries apply multiple criteria to inform decisions about 
inclusion of new products in the reimbursement list and the rate 
at which a new product might be reimbursed. More often than 
not, valuing an innovative new medicine becomes a function of
the price the same medicine commands in neighbouring 
countries. 
Despite the wide range of criteria used explicitly or implicitly to 
inform pricing and/or reimbursement decisions, explicit 
strategies used in practice to value pharmaceutical innovation 
are limited. Evidence suggests that European countries apply 
three different approaches to valuing pharmaceutical innovation: 
first, rate of return regulation which, based on its application in 
the United Kingdom, includes incentives to conduct R&D. 
Second, assessment of clinical/therapeutic benefit of individual 
technologies by ranking new treatments based on their 
therapeutic potential, as is currently undertaken in France and 
less so in Italy. Third, HTA to inform the relative effectiveness of 
new treatments. Several countries apply HTA explicitly (the 
United Kingdom, the Netherlands, Sweden, Switzerland, 
Finland, Poland), whilst in others HTA plays an increasing role 
but not used explicitly in decision making. All three approaches 
are pursued nationally due to national management of health 
and pharmaceutical care budgets. Supra-national bodies such 
as the EC have no competence in deciding on allocation or 
spending of health care budgets and by default have no 
competence in passing judgment on methodological valuation of 
new technologies or treatments. The following sections outline
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each of the three approaches identified and also discuss the 
role of European institutions in value assessment. 
6.5.2. Rate-of-return regulation 
Rate-of return regulation applies in the case of the United 
Kingdom, through the Pharmaceutical Price Regulation Scheme 
(PPRS), which regulates the profits of pharmaceutical 
companies and, indirectly through profits, the prices of 
medicines. The scheme has been in operation in the United 
Kingdom for more than 50 years and administered by the UK 
Department of Health. 
The PPRS objectives are: first, to deliver value for money for 
the UK NHS by securing the provision of safe and effective 
medicines at reasonable prices, and to encourage efficient 
development and competitive supply of medicines; second, to 
encourage innovation by promoting a strong and profitable 
pharmaceutical industry capable and willing to invest in 
sustained R&D for future availability of new and improved 
medicines benefiting patients and industry; third, to promote 
access and uptake for new medicines and fourth, to provide 
stability, sustainability and predictability to help the NHS and 
industry develop sustainable financial and investment 
strategies. The scheme applies to branded generics, vaccines, 
in vivo diagnostics, blood products, dialysis fluids, branded 
products supplied through tendering processes on central or 
local contracts and biotechnology products. 
The relatively free pricing in the United Kingdom  which is, 
nevertheless, subject to negotiation and moderate reduction in 
prices each time the scheme is re-negotiated  makes it an 
attractive market for the launch of new pharmaceutical products. 
It also provides clear incentives for innovation through the return 
on capital employed (ROCE) and R&D allowances. A thorough 
assessment of the true socioeconomic value of innovative 
pharmaceutical products in the United Kingdom is particularly 
important, as the United Kingdom is a priceleader in 
international reference pricing. The countries, which reference 
prices to the United Kingdom, represent approximately 25% of 
global pharmaceutical markets (though not all products in each 
country are referenced to the United Kingdom,) [35]. 
The scheme has been criticised on several occasions for non-
transparency, capital over-investment and for inefficiencies. The 
divergence between price and value was the main focus of an 
Office of Fair Trading (OFT) investigation report [35], calling for 
radical overhaul of the scheme in favour of value-based pricing. 
The key argument in favour of a new approach from the OFT 
perspective is that ‘...neither the profit nor the price controls take 
account of the therapeutic value of drugs. This undermines the 
extent to which they can help secure value-reflective prices for 
the NHS. For a scheme that sets out to deliver value for money 
for the NHS and give companies the right incentives to invest, 
we consider this to be a significant flaw... the UK is almost 
unique in the world in not taking explicit account of the 
therapeutic benefits of drugs in its pricing system’. 
The 2009 PPRS will become effective on 1 January 2009 [36], 
following re-negotiation, and will include several options for 
patient access schemes, whether financially or outcome-based, 
the latter implying flexible pricing based on the clinical evidence 
produced and risk sharing between the Department of Health 
and individual companies. 
6.5.3. Assessment of clinical/therapeutic benefit 
Our survey has shown all surveyed countries examine available 
clinical evidence very closely (Table 6.2); however, in two 
countries it appears the strength of the clinical evidence forms 
the basis for a classification of drugs as highly innovative, 
innovative or as me-too. 
France applies the principle of therapeutic benefit rendered 
(Amelioration du Service Medical Rendu, ASMR), where 
pharmaceutical pricing and reimbursement is decided by 
negotiations between the pharmaceutical industry and a variety 
of organisations. The Transparency Committee (CT) initially 
decides whether or not reimbursement is granted, the scope of 
indications for which the drug is to be prescribed, and ultimately 
determines rate of reimbursement (ranging from 30% to 65%). 
However, prices are determined by the Comité Economique des 
Produits de Santé (CEPS) based on 'improvement in medical 
benefit rating' (ASMR) or 'incremental medical benefit', as 
judged by the CT (Table 6.3). 
The ASMR rating is not the sole deciding factor for determining 
the final price. Although ASMR 1 to 4 products will be priced 
higher than their existing alternatives, with ASMR 5 
pharmaceuticals not given a price premium compared to 
existing products, expected sales levels and external reference 
pricing are also considered. If the new drug is expected to 
increase the overall sales level in that therapeutic group, a 
lower price than existing drug may be justified. Overall, CEPS 
would like to keep prices at or below the EU average. 
An Italian algorithm was developed to quantify the value of 
innovation, in the hope of capturing patients, policymakers and 
pharmaceutical companies' perspectives in the innovation 
process [38]. The Innovation Assessment Algorithm (IAA) had 
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Table 6.3: ASMR categories in France 
 
Source: [37]. 
Table 6.4: The IAA algorithm 
 
Source: [38].
three key aims: first, to take into account and incorporate 
different properties of drug innovation; second, to provide a 
numeric weight as a measure of the innovative value of a drug 
and third, to reassess innovation over time, by incorporating 
clinical evidence emerging post-marketing authorisation. The 
final score gives greater weight to earlier 'efficacy' branches 
than effectiveness branches. Whilst several models have been 
suggested to explicitly quantify innovation in such a manner, 
this model is significant by identifying innovation aspects in the 
early-intermediate R&D stage, as well as differentiating between 
therapeutic innovation, common innovation and industrial 
innovation (Table 6.4). 
Recent evidence suggests analysis of innovation per se is 
directly influencing policy in Italy. Indeed, a similar hierarchical 
scheme devised by the AIFA along similar lines, divides 
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Figure 6.1: Assessing therapeutic innovation in Italy. 
 
Source: [39].
pharmaceuticals into three broad categories: those for fatal or 
serious conditions resulting in permanent disability/ 
hospitalisation, those eliminating or reduce the risk of serious 
diseases (e.g. hypertensive treatments), and lastly those for 
'non-serious' diseases such as hay fever. Interestingly, a clear 
distinction is made between pharmacological innovation (i.e. a 
new method with necessarily increased efficacy) and 
technological innovation perhaps not providing therapeutic 
innovation (Figure 6.1). Ceteris paribus, the former would be 
rated higher than the latter under their new scheme. AIFA have 
also stressed the importance of incorporating post-marketing 
data into their algorithm. 
Although the IAA algorithm may appear to have high 
informational requirements, a similar framework might be useful 
in structuring the economic information required from 
pharmaceutical companies to enable greater transparency of 
health system priorities. Such scientific approaches provide a 
robust and reliable method of quantifying innovation, and 
attractive as they simultaneously pacify several stakeholders. 
The particular model mentioned above also takes into account 
economic information emerging post-authorisation (ex-post). 
6.5.4. Health technology assessment in assessing 
value of innovation 
The varying nature and complexity of health technologies, in 
combination with limited national budgets, has resulted in 
tensions between delivering cost-effective health care and 
improving or sustaining a country's manufacturing and research 
base. As a result, it has become increasingly important to 
achieve a balance between affordable health care and the use 
of innovative health technologies, including pharmaceuticals. 
Thus, it is necessary to both consider the value (in both medical 
and economic terms) of a product, plus who benefits from 
innovation, the optimal usage
ff, and the appropriate placement 
in the spectrum of care [40]. 
The HTA can assist in meeting these challenges by determining 
which technologies are ineffective versus effective, and define 
the most appropriate indications for use of the technology [41].  
Moreover, HTA can serve to validate a new technology and 
define its role in health care system. These are important 
benefits to enable governments to make value-driven decisions 
concurrently supports innovation, and garners patients and 
physicians with the information needed to make the best 
treatment choices [42]. 
However, the effectiveness of HTA in achieving the above 
benefits, particularly in terms of encouraging innovation, hinges 
on properly performed assessments as well as appropriate 
implementation and use of subsequent recommendations. HTA 
can encourage innovation if the assessments are properly done 
and consider a wide range of costs and benefits associated with 
a new technology, rather than focus solely on acquisition costs. 
In particular, adoption costs need to be viewed in terms of 
broader benefits ensued if a technology were integrated into the 
health system, as budget-driven constraints on the general 
diffusion of technologies do not necessarily result in the 
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selection of the most effective or cost-effective products. This 
may require governments to allow additional funding and 
flexibility between budgets allowing expenditure levels are 
driven by value, as opposed to arbitrary spending caps [40]. 
The utility of HTA in encouraging innovation and value-added 
health care depends on the assessment process, including 
when and how the review was performed, and resultant 
decision-making procedures. In particular, the following issues 
can potentially affect the effective use of HTA in meeting these 
objectives [39, 43-45]. 
•  Delays in the HTA process can result in deferred 
reimbursement decisions, restricting patient access to 
needed treatments. 
•  Evidence requirements can pose significant hurdles for 
manufacturers, particularly small, innovative 
companies, potentially discouraging sponsors from 
pursuing breakthrough technologies. 
•  As HTA becomes widespread, assessments occur 
earlier in the technology diffusion process, which may 
introduce greater uncertainty in the process and the 
potential for innovations to appear more or less 
beneficial than when assessed at latter stages. 
•  Current assessment methodologies may limit the 
comparability and transferability across countries and 
studies. 
•  Lack of transparency, accountability and stakeholder 
involvement in the HTA process can decrease the 
acceptance and implementation of assessment results. 
•  Limited skilled HTA personnel and international 
collaboration between review agencies can stymie the 
efficiency and effectiveness of assessments. 
•  Separate processes for organisations dedicated to 
economic assessments, reimbursement/pricing 
decisions and practice guideline development may 
hinder the effectiveness and efficacy of the overall 
decision-making process, leading to unnecessary 
duplication of efforts and resource use. 
In addition, HTAs are more likely to be used by decision makers 
if policy instruments (e.g. reports, practice guidelines) are 
available to act on the assessment, and if prior commitments to 
effectively use the assessments are established. Moreover, as 
technology cost-effectiveness and patient demand may change 
with time, periodic review of HTA recommendations are 
important. To achieve these objectives, greater participation and  
collaboration among stakeholders, particularly HTA personnel, 
government officials, industry, health providers and patients, is 
required. Without adequate input and understanding of the HTA 
process, stakeholders may mistrust the evidence and 
subsequent recommendations of the assessment. 
Overall, in order for HTA to be of optimal benefit, the 
assessment process needs to be linked with innovation and 
other aspects of policymaking. To the latter, it is important that 
HTA recognise the complexities of decision making, whereby 
subjective and normative concerns are duly considered. 
Otherwise, HTA may be limited in its powers to impact upon the 
policy process and subsequent access to new and effective 
products. The role of HTA in encouraging innovation and value 
in health care could be improved by better understanding and 
addressing the inherent challenges in the HTA process, as 
outlined below. 
The introduction and growth in HTA in Europe parallels an era 
in health policy that places greater emphases on measurement, 
accountability, value for money and evidence-based policies 
and practices. Moreover, the advent of randomised control trials 
and subsequent availability of data, growth in medical research 
and information technology and increased decentralisation of 
health system decision making have all contributed to an 
increased need for HTA activities [46]. 
In Europe, the first institutions or organisational bodies 
dedicated to the evaluation of health care technologies were 
established in the 1980s, initially at the regional and local level 
in France and Spain and, later, at the regional level in Sweden 
in 1987 [43,47]. During the following decade, HTA programmes 
have been established in almost all countries, either through the 
provision of new agencies or institutes, or in established 
academic units or governmental and non-governmental entities 
(Table 6.5). Broadly speaking, such bodies fall into two general 
strands: 1) independent (‘arms-length’) review bodies that 
produce and disseminate assessment reports on a breadth of 
topics, including health technologies and interventions, and 2) 
entities under governmental mandate (e.g., from health 
ministries) with responsibilities for decision making and priority 
setting, typically pertaining to the reimbursement and pricing of 
heath technologies. The latter type of HTA body serves either 
an advisory or regulatory function. 
In parallel with establishing HTA entities, many EU countries are 
investing resources in HTA and associated evaluation activities. 
For example, Sweden dedicates €5 million/year on the Swedish 
Council on Technology Assessment in Health Care (SBU) and 
the Dutch Fund for Investigative Medicine spends €8.6 
million/year on health evaluations [41]. 
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Table 6.5: Institutions and advisory bodies responsible for HTA activities in selected EU countries (2008) 
 
Note: 
1 These are not an exhaustive list of the agencies available in the country. 
Source: The authors; adapted and enhanced from [43].
6.5.5. Role of European institutions 
Over the past 3 years, the High Level Pharmaceutical Forum 
has provided impetus for debate and potential coordination 
among national pharma policymakers. Prior to its conclusion in 
2008, the High Level Pharmaceutical Forum Working Group on 
Pricing recently submitted a questionnaire to all Member States 
with the aim of identifying demand-side benefits viewed as 
important when assessing the value of an innovative medicine 
[48].  The benefits identified by the Member States fell into three 
broad categories: therapeutic/clinical benefits, quality-of-life 
improvements and socioeconomic benefits (Table 6.6). 
Despite EU institutions having no competence in health care 
policy harmonisation, it has been an important achievement to 
gather the Member States and other stakeholders around the 
table to understand some of the driving developments at 
Member State level. More than anything, ‘the Pricing Working
Group of the High Level Pharmaceutical Forum has worked out 
a set of guiding principles which demonstrate that dialogue 
between Commission, Member States and multiple 
stakeholders is possible in an attempt to meet the needs of 
patients, payers and industry alike’ [49]. 
6.6. Fostering Innovation in Oncology: A List of 
Priorities 
In order to foster innovation in oncology, a list of priorities 
emerge in a number of areas: first, the role of science, research 
and innovation policy; second, the role of pricing and 
reimbursement systems in encouraging and rewarding 
innovation; third, the continuous evaluation of oncology drugs; 
fourth, the encouragement of long-term innovation and fifth, the 
optimisation of resource allocation in health care. 
P
o
l
i
c
y
 ecancer 2010, 4:164 
 
 122  www.ecancermedicalscience.com 
 
Table 6.6: The benefits of pharmaceutical innovation
1 
 
Note: 
1 Adapted from EC Progress Report.
6.6.1. The role of national and supra-national science, 
research and innovation policy 
[I] Guiding government policymaking 
The analysis and discussion in Chapters 3, 4 and 5 suggest that 
a new challenging role is emerging for government, which is 
both complex and sophisticated, requires scarce resources be 
more optimally used, and encourages collaboration and shared 
decision making with other stakeholders (charitable and private 
sectors), beyond partisanship. This holds in (bio-)medical as 
well as other areas of research [50]. 
In an era of globalisation, the role of government in incentivising 
pharmaceutical R&D in general, and encouraging oncology 
R&D in particular, is by no means limited, but rather, multi-
dimensional and pro-active. Government should encourage 
private innovation, leveraging investment in innovation to spur 
economic growth; this can be achieved both directly, through 
the funding of basic research in key or/and under-researched 
areas such as rare cancers, or indirectly through the use of 
market mechanisms such as tax incentives. 
The role of government is also significant in basic technology 
research, where the expectations of long-term public benefit 
exceed the expectations for private returns to those undertaking 
the research [51]. The use of collaborative consortia with private 
co-funding or cost-sharing should not be excluded but 
altogether encouraged. 
More generally, however, a shift in the way that government 
encourages innovation in the private sector is needed. Direct 
funding of R&D is a useful tool and can leverage additional 
resources from the private sector. Yet, encouraging the 
development of new cancer drugs and the technologies on 
which they can be delivered probably requires a proactive 
stance in indirect measures. For instance, prescriptive and 
coercive regulations have been found to be cumbersome, 
expensive and inefficient tools for incentivising private 
investment in technology. It could be the case that output- or 
performance-based regulations be adopted in this respect. 
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Tax incentives (e.g. research and development credits) could be 
further fine-tuned and targeted so as to serve specific 
objectives, for instance targeting areas of work such as rare 
diseases and rare cancers. In the same spirit, aspects of 
intellectual property can be used to encourage innovation, e.g. 
through enhanced market exclusivity periods. 
As creation of knowledge becomes global and their individual 
funders, whether public, private or charitable, can only fund or 
have partial access to (new) knowledge development, a new 
model may be needed in the future where funders of innovation 
in key areas such as oncology must learn to cooperate as well 
as compete. Importantly, open access to innovation and 
knowledge may be needed with society reflecting on its 
implications (e.g. harnessing the potential of some technology 
platforms faster) as well as the requirements to achieve it (e.g. 
re-thinking the global regulatory environment, or intellectual 
property). 
[II] Lessons learned from recent initiatives are 
national and supra-national level 
In Europe, the EU Slovakian Presidency in 2008 made 
headlines with selecting cancer as its main health priority. As a 
result, an European Partnership for Action Against Cancer was 
formed (2009-2013), which aims to support Member States and 
stakeholders (academic, institutions, industry) by creating a 
framework for identifying and sharing cancer prevention and 
treatment information, capacity and expertise [52].  This action 
will be launched end September 2009, and funded until 2013 by 
the EC in addition to the Research and Development 
Framework Programme. This action is supported by two other 
EU level initiatives: the Innovative Medicines Initiative (IMI) and 
the European Roadmap (ESFRI). The IMI is a public-private 
partnership for medicines development [53-55] with an 
additional focus on cancer research, whilst the ESFRI supports 
clinical trial and bio-banking initiatives. 
One of their main goals is cancer research, focusing on 
translational, transnational and partnered collaborations. 
Specifically, their aim is to achieve coordination of one third of 
cancer research from all funding sources by 2013. These goals 
will be driven by multi-stakeholder working groups undertaking 
the work directly or, most likely in the case of cancer research, 
will monitor work done by outside organisations. 
The outlined European programmes have undertaken to combat 
the fragmented state of Europe's cancer research programmes 
and convert this variability into a cooperative strength. Although 
many of these programmes are relatively recent in the history of 
cancer drug development (European Partnership Action Against 
Cancer 2009; FP6 2002; FP7 2007; IMI 2007), they are a step 
towards cohesive cancer research and outcomes. The addition 
of public-private partnership is encouraging, and will hopefully 
make Europe more competitive globally. 
Furthermore, although EC level cancer research governance 
and funding appears to be more cohesive than previously, 
cancer research funding on a charitable level does not. At 
country level, there is at least one cancer charity per country, 
many with overall umbrella cancer charities supplemented 
further by specific cancer charities. Although cohesive data are 
difficult to come by, significant sums are invested by these 
organisations in cancer research
gg. As administrative costs are 
obviously duplicated by these organisations, this is a further 
area for investigation to increase cooperation. 
Nationally, many countries explicitly support cancer research  
the newer members to the EU still are exploring, developing or 
implementing their cancer plans. To date, all cancer plans 
support cancer research in Europe, either through their umbrella 
medical research organisations (i.e. UK Medical Research 
Council) or via specific cancer organisations (i.e. German 
Cancer Research Center). Some countries may have more than 
one organisation supporting cancer research, such as via a 
medical research programme plus a national cancer programme 
(i.e. UK, NL), or may have more than one cancer organisation 
(i.e. France). Thus, it appears, that not only may Europe itself 
be fragmented, albeit less than before, there may be national 
fragmentation as well. 
On the other hand, some research institutions could be 
financially neglected if the work they perform is not transnational 
 very likely in the case of very new, very specialised 
technology only found in a few locations. The EC initiatives 
must take care not to neglect these special cases, as they could 
be sources of breakthrough technology platforms and/or 
treatments. National and charitable funding may be the only 
source for these special interest groups; supplementation by 
public-private partnerships may be an interesting addition with 
some protectionist provisions for the public institutions involved. 
Meanwhile, American cancer research is less fragmented, 
solely due to its central organisation under the National Cancer 
Institute (NCI) and its funding is directly approved by the US 
Congress. Not only does the NCI support molecular research, it 
also supports translational research. There is a specific Drug 
Development Platform whose purpose somewhat mirrors the 
European IMI goal of speedier cancer drug entry into the 
market. 
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Furthermore, the NCI has an additional purpose of supporting 
cancer research occurring in other countries via its International 
Portfolio. Clinical trials are a large portion of this, but also 
collection of international experimental medicines protocols and 
trials, provision of education and expertise, and participation at 
board level on other cancer research organisations. 
The NCI is currently examining its public-private partnership 
directive, with a proposal that the NCI would be a 'safe haven' 
for encouraging public-private partnerships, outlining issues of 
intellectual property and any other barriers. Nationally, there is 
room for expansion in public-private partnership, which the NCI 
is currently aware of [56]. At the FDA level, there are some 
projects occurring nationally, only one of which is supporting 
cancer research [57]. At the state level, there are some public-
private partnerships with industry and academia, usually with 
private hospitals. 
Globally, it appears that cancer research with focus on 
medicines is still relatively in its infancy, with only recently 
organisations and programmes given focus and direction. 
Public-private partnerships appear still in their infancy, both in 
Europe and the US and could perhaps benefit from examining 
other areas with expertise, such as information technology, 
which has resulted in major progress. Fragmentation still 
occurs, particularly on the charitable level, and although this 
may have negative consequences in terms of administration 
costs and research duplication by other countries, there may be 
benefits to highly specialised research areas still at 
experimental stage. 
[III] Focus on rare cancers and re-thinking regulation 
Rare cancers belong to the group of rare diseases that are 
normally defined as diseases with a prevalence of less than 50 
in 100,000. Even when defined more conservatively by taking 
into account some peculiarities of natural history and prognosis, 
rare cancers represent about 20% of all cases of malignant 
neoplasms, including all cancers affecting children and 
teenagers and many affecting young adults [59]. There are 
significant variations in incidence and mortality rates for different 
types of rare cancers. There are also significant survival 
differences for the same type of rare cancers between EU 
member states [60]. In addition to these, there are several 
problems related to the treatment of rare cancers in Europe, 
including variability in access to treatment, variability in the 
availability of information about treatment, lack of medical 
expertise in the management of rare cancers leading to less 
than optimal treatment outcomes, potentially higher costs for 
patients with rare cancers and their families, lack of registries 
and tissue banks for rare cancers and difficulty in conducting 
clinical trials. 
The recognition of rare cancers as a special case (which, 
nevertheless, affects a significant proportion of the cancer 
patient population) and requires multi-dimensional action. In this 
respect, the ESMO recommendations on stakeholder actions 
and public policies in rare cancers [60] highlight the multiplicity 
of actions needed to encourage research and development, 
access and uptake of new treatments. Such actions relate to 
reorganising regulation, encouraging research and clinical trials 
through collaborative actions and networks, calling for 
consensus guidelines on multi-disciplinary treatment, 
addressing patient access to care, as well as improving access 
to information on rare cancers and education of health care 
professionals. 
6.6.2. Need for pricing and reimbursement systems to 
reward and encourage innovation 
Health systems worldwide are struggling with containing costs 
whilst improving patient access and health outcomes. Drug 
spending has come under particular pressure and scrutiny, 
despite accounting for only 10%-20% of total system cost and 
generating significant value. Managing drug spending should be 
a priority, however, current approaches to containment may 
have a detrimental impact on patient access and health 
outcomes: top down price cuts in countries (e.g. Italy) and 
'jumbo grouping' (e.g. Germany), significant discrepancies in 
access (e.g. 'post code prescribing' in the UK) and, potentially, 
outcomes (e.g. Cancer survival rates in the UK vs France) and 
delays in getting innovative drugs to patients as they go through 
time-consuming HTAs. 
A key aspect is timely patient access to innovative, life-saving 
therapies. Upfront access restrictions stand in the way of this. A 
more progressive debate could facilitate the global goals of 
improving patient access and health outcomes whilst managing 
costs and appropriately rewarding innovation. Pricing and 
reimbursement systems can fulfil the goal of encouraging 
innovation, provided they take into account a number of criteria. 
The first is timely access, ensuring that patients get timely 
access to innovative therapies, unfettered by overly restrictive 
reimbursement, coverage and/or pricing considerations. The 
second criterion is value-based reimbursement and could be 
linked to an explicit and objective assessment of incremental 
value relative to existing standards of care. The third criterion is 
comprehensive pricing and reimbursement in the sense that the 
metrics considered when assessing the value of new treatments
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and setting reimbursement levels should include all elements of 
value. The fourth criterion relates to flexibility. The total drug 
benefits and costs to the health system must be assessed over 
time, by population segment and in a real-life context  with 
prices/reimbursement levels adjusted as new data on relative 
value becomes available. Finally, a fifth criterion is 
collaboration. Payers, providers and manufacturers need to 
work together, rather than antagonistically, to explore new 
pragmatic ways of delivering value to the patient constituency. 
Each of the above criteria is discussed in turn. 
[I] Timeliness in accessing new and effective 
treatments 
It must be ensured that patients get timely access to innovative 
new drugs, unfettered by overly restrictive reimbursement/ 
coverage and/or pricing considerations. This is not an easy 
task, partly because payers' use of restrictive coverage/ 
reimbursement or pricing policies often interfere with physicians' 
ability to make important decisions about individual patient care. 
Timely access to care can suffer further as many countries have 
long registration, approval and reimbursement times, serving as 
a blunt instrument to deny treatment to requiring patients. 
Finally, the absence of data early on in a new technology's 
assessment process is currently taken as evidence of 
equivalency, heavily weighing assessments against rewarding 
pharmaceutical innovation. 
What policymakers must focus on is enabling 'fast track' 
approval and reimbursement procedures to ensure timely 
access to innovative drugs (e.g., FDA fast-track process for 
priority drugs) [61]. Also, establishing processes for conditional 
reimbursement/pricing decisions, enabling prompt access for 
drugs whilst real-world market data are collected and analysed 
is of great importance. In certain cases, launch prices can be 
negotiated using data from Phase III trials, with agreement to 
reassess pricing decisions 1 year later when Phase IV trial 
results become available. Finally, it must be ensured that 
guidelines and recommendations provide sufficient flexibility for 
physician discretion in individual cases (e.g. reimbursement with 
prior authorisation for drugs that might be recommended for a 
small share of the patient population) to meet potentially 
atypical patient preferences or clinical circumstances. 
[II] The role value-based pricing in improving 
rationality in decision-making 
When payers use coverage, reimbursement and/or pricing 
mechanisms to manage drug spending, they should do so in a 
value-based way-linked to an explicit and objective assessment 
of its incremental value relative to existing standards of care. 
Current challenges include the following two aspects: first, drug 
pricing/reimbursement systems do not always base their 
decisions on an explicit assessment of a drug's value, often 
relying heavily on cross-country price comparisons and/or intra-
country reference price groups to set prices. Second, 
pricing/reimbursement systems often struggle with how to 
measure and explicitly reward drug innovation, with significant 
variations in the approaches used. 
There can be positive responses to these challenges. Where 
controls are exerted over drug pricing/reimbursement, 
policymakers could ensure that these are based on 
mechanisms that explicitly link pricing/reimbursement decisions 
to an assessment of a drug's value. Finally, developing explicit 
mechanisms to appropriately reward valuable innovation via 
drug pricing/reimbursement (when the drug offers an 
incremental benefit over the existing standard of care as 
measured in a comprehensive way) would be an important step. 
[III] Societal approach and other metrics 
When assessing drug value and setting pricing/reimbursement 
levels, all elements of value, including societal, should be 
included. However, when value is assessed, pricing/ 
reimbursement systems frequently choose to focus on value 
exclusively from the health care system (payer) point of view 
rather than the broader societal or patient/physician (e.g. 
consider cost offsets to the health care system such as hospital 
stays and/or other drug costs avoided, but not from increased 
worker productivity or provider efficiency). Another problem is 
that most evaluations of drug costs are based on list prices, 
rather than actual observed net costs in a treatment setting. 
It is imperative that standard guidelines for assessing benefits of 
drugs based on a broader range of applicable metrics are 
established. These should include humanistic, patient-focused 
benefits such as quality of life (QoL), longer term direct cost 
offsets, indirect system costs that might or might not be covered 
by payers such as worker productivity, and benefits to 
caregivers as well as patients (e.g. enhanced patient and 
physician convenience that translates into improved compliance 
and better outcomes). Furthermore, new standards and tools to 
more accurately and consistently assess the more challenging 
metrics may need to be developed (e.g. patient reported 
outcomes such as QoL). 
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[IV] Risk sharing 
Risk sharing refers to a contractual arrangement between a 
health care payer/provider and a supplier. Traditionally, payers 
absorb all risks associated with purchasing new medical 
technologies. In this regard, payers make a decision on whether 
the technology offers an effective use of their funds, based on 
the information available at the time of launch. Risk sharing is 
an attempt to redistribute the balance of risk between the payer 
and the supplier of the medical technology, and typically 
involves the supplier of the medical technology providing a 
'guarantee' relating to the performance of the technology. The 
guarantee may relate to one or more outcomes of treatment 
[62]. These could include for instance (a) clinical outcomes, (b) 
humanistic or quality-of-life outcomes, (c) resource use (e.g. a 
reduction in hospitalisations), (d) financial outcomes (e.g. a 
reduction in the amount spent treating a condition) and (e) 
economic outcomes (e.g. the achievement of a particular cost-
effective threshold). 
As the pressure on health care budgets intensifies and the cost 
of some of the more novel treatment remains high, it is likely 
that the use of risk sharing agreements will intensify in the 
future. This may be on two fronts: first, in terms of admitting new 
treatments onto national formularies, and second, in terms of 
enabling faster uptake. Enabling innovative pricing solutions, for 
example through pilot schemes making selected innovative 
medicines available for time-limited periods [63], or through 
patient-specific franchise schemes, could contribute to faster 
access and uptake of new therapies. This would have particular 
application in the case of oncology due to the limited number of 
patients. 
[V] Flexible decisions 
Total drug benefits and costs to health systems need to be 
assessed over time and in a real-life context, with 
prices/reimbursement levels adjusted as new data on relative 
value becomes available. 
In many countries though, value assessments are conducted at 
drug launch, using only data collected during the treatments' 
clinical development process; as new data becomes available, 
prices need to be allowed to be in line with demonstrated value. 
Furthermore, the value of a drug and its price is typically set 
based on the initial indication, with little or no flexibility to evolve 
it or change it for different indications in which the dosing and/or 
value over existing therapies could be significantly different. 
Optimal mechanisms must be determined, in order to allow for 
drug price/reimbursement variations across different indications/ 
sub-populations based on value propositions. 
Pragmatic and viable processes must be created, so that 
pricing/reimbursement levels are allowed to fluctuate both up 
and down over time as meaningful new data becomes available, 
including potential for 'temporary' pricing/reimbursement for 
novel drugs with limited evidence at launch. Finally, it is 
important to establish appropriate requirements for ongoing 
data collection on the part of drug manufacturers to provide 
support for ongoing price/reimbursement adjustments. 
[VI] Collaboration between stakeholders 
Payers, providers and manufacturers must work together, not 
antagonistically, to establish pilots to investigate new pragmatic 
ways of managing drug spend, avoiding wholesale 'top down' 
change. 
Unfortunately, most pricing/reimbursement systems are not 
collaborative in their design and operation, with payers often 
issuing top-down directives, little sharing of data, and 
assessments made by relatively closed, non-transparent and 
often political HTA bodies. In addition, drug regulators give little 
or inconsistent guidance on trial design. Finally, reform often 
include multiple changes to the current system wholesale, 
without a clear and open debate of the alternatives and/or 
productive piloting before roll out. 
In order to face these challenges, an inclusive process for 
defining pragmatic, effective changes to drug approval and 
pricing/reimbursement approaches must be developed, 
ensuring these are transparent to all (e.g. manufacturers 
understand what trials/data will be required for drug approval, 
reimbursement and pricing decisions well in advance). Pilots to 
test new approaches to drug pricing/reimbursement must also 
be established (i.e. in the areas outlined in above points I 
through IV) before large-scale implementation. Finally, 
effectively sequencing and staging the rollout of any changes 
(e.g. begin with a few newly launched drugs and expand as 
required) rather than attempting to enact wholesale change is 
an important part of the process. 
[VII] Minimising externalities 
The above will be able to deliver significant benefits if the key 
negative externalities often associated with the process of 
enabling access are minimised or altogether eliminated. Such 
negative externalities often emerge from international price 
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referencing and comparisons, as well as exchange rate 
differentials and depreciations/appreciations. 
6.6.3. Continuous evaluation of oncology drugs 
Although ex-ante evaluation provides manufacturers with the 
incentive to invest in gathering the evidence that the health 
service requires to make approvals and also encourage 
innovation in areas/therapies where a substantial clinical benefit 
can be demonstrated, one drawback of the use of ex-ante as 
opposed to ex-post evidence is that there will be uncertainty 
surrounding the cost-effectiveness of the treatment outside the 
RCT setting at the time of launch. Although further ex-post 
reviews can also be suggested, these may be difficult to ensure 
as once a pharmaceutical product is approved, the incentive to 
carry out further trials is diminished and may even be deemed 
unethical. There is also concern that if ex-post evaluation slips, 
the evidence-based approach to health systems could be 
compromised [64]. Nonetheless, a balance between the value 
of the economic information surrounding the drug and the value 
of availability of the drug to patients needs to be achieved (as is 
often emphasised in HTA). 
On the other hand, it should be made clear to pharmaceuticals 
that ex-post evidence is as crucial as ex-ante evidence in 
proving the value of a new treatment. In order to do this, there 
needs to be acceptance of data obtained in naturalistic settings, 
and methodologies on how best to extract value from such data 
need to be strengthened. Ownership of such data is also 
important, as the cost associated with gathering evidence is 
substantial  creating this evidence should provide the scope 
for collaboration between the payer community and 
manufacturers. 
6.6.4. Encouraging long-term innovation 
Innovation  whether breakthrough or incremental  can lead to 
greater subsequent understanding of the aetiology of a disease 
(i.e. there could be said to be a positive externality from 
discovery and use of a new drug). The underlying premise in 
this regard is that knowledge and innovation have a cumulative 
impact on the understanding of a disease and that impact is 
often not quantifiable. This may have important dynamic 
implications for future R&D. 
A meaningful pricing system able to deal with both the short- 
and the long-term implications of and benefits from innovation 
would probably be complicated to create. Whilst it is often very 
difficult to anticipate the future gains from innovation and 
directly incorporate these into a pricing system, governments
must encourage such developments to take place. Stratified 
pricing arrangements such as these seen in France would send 
a clear message to the research-based industry that innovative 
products have recognisable value within the pricing system, 
although, clearly, the starting point vis-à–vis, which ASMR a 
new medicine represents may be different for different 
stakeholders. Importantly, there need to be separate (although 
interconnected) rules targeting value for money and providing 
incentives to foster long-term innovation. 
6.6.5. Optimising resource allocation in health care 
The way resources are allocated does not necessarily 
guarantee their optimal use. There may be cases of resource 
misallocation, which could potentially lead to waste and might 
also affect access to care. Even if we accept that health care 
resource allocation operates in silos, evidence shows that even 
the pharmaceutical budget can be further optimised. Further 
focus is needed on the demand-side and the behaviour of 
clinicians, and very importantly, on the use of information 
systems in real time, both by payers as well as providers. For 
instance, a recent study found general practitioners performed 
no better than chance at ranking drugs in 6 therapeutic groups 
in order of list price [16]. 
A case where a potentially significant resource re-allocation 
could take place is the off-patent segment. Despite strong 
emphasis of European governments in generic medicines over 
the past two decades, recent evidence suggests that the 
savings accruing to health insurers from the more intensive use 
of cheaper generics may have not been realised [65]. There are 
three dimensions of savings that contribute to the total savings 
foregone to health insurance from greater use of generics. The 
first and most obvious dimension reflects the level of generic 
penetration in a molecule market, post-patent expiry. Generic 
penetration is a measure of the share of a molecule market that 
is purchased as generic. Yet, examining the level of generic 
penetration in some key market, one realises the unfulfilled 
potential in some of them. Whilst the United Kingdom and 
Germany lead with 76% and 66% generic penetration, 
respectively, generic penetration in Spain is 50% in France 33% 
and in Italy 19%. Italy, France and Spain could realise the 
largest savings by increasing their generic penetration, although 
there is significant room for improvement in all study countries 
for these molecules. 
The second dimension of savings that contributes to total 
foregone savings is the price difference between the originator 
drug and the generic equivalent. The larger the difference 
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Table 6.7: Generic policies, savings foregone and impact on stakeholders, 2003-2004, seven countries
1 (based on five off-patent molecules
2) 
 
Notes:   
1 United Kingdom, Germany, France, Italy, Spain, Canada, USA. 
                
2 Omeprazole, simvastatin, lisinopril, paroxetine and metformin. Simvastatin was under patent in the USA in 2003 and 2004; therefore, no 
additional savings can be calculated in this particular case. 
Source: [65].
between the two and the smaller the generic penetration, the 
greater are the foregone savings to health insurance. 
Finally, the third dimension that contributes to total foregone 
savings is the difference between the actual purchased generic 
price and the lowest generic price. This dimension reflects the 
degree of efficient purchasing in the generics market itself, 
independent of generic penetration and originator brand prices. 
Often this dimension of savings is the most neglected by 
policymakers, despite the fact that in some cases, the generic 
price spread may exceed 10 to 1 from highest to lowest. By 
estimating the effect of additional generic penetration that could 
occur
hh and assuming that health insurers are in a position to 
procure more cost effectively to the lowest available price on the 
market, the additional savings to health insurance (or the 
savings that currently health insurance foregoes) can be 
calculated. Table 6.7 shows the total savings forgone for five 
genericised molecules across seven countries: improved 
genericisation and more efficient purchasing could have saved 
health insurers over $3 billion in 2004, amounting to a savings 
on current sales in the order of 43.8%. 
This has significant implications for health insurance as it 
overpays for commodity products that can be acquired more
cost effectively, as recent evidence from the Netherlands 
suggests [66,67].  It also has significant implications for the type 
of medicines that health insurance is able to finance, given a 
relatively inelastic budget. Should a resource reallocation occur 
from the commodity part of the market to the top-end of the 
market, patient access to needed modern medications could 
improve in many instances. At the other end of the spectrum, 
evidence also suggests that the uptake of new cancer drugs is 
slow and inadequate in many countries and leads to significant 
inequities in access [68]. 
The important message from this discussion is that the uptake 
and diffusion of innovation may require resource reallocation 
without compromising patient quality of care, but in itself could 
have positive implications for access, equity and quality. In 
pursuing this re-allocation where possible, health insurers may 
be providing a signal and an indirect incentive to innovators to 
continue their effort. 
6.7. Concluding Remarks 
This chapter has illustrated that innovation in the 
pharmaceutical sector brings significant tangible benefits to the 
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patient, the health care payer and the economy in terms of 
clinical and economic effects. It concludes that, from a historical 
perspective, the socioeconomic and monetary benefits from 
pharmaceutical innovation are significant as evidence 
demonstrates, but that the incentives provided by society to 
continue the process of innovation are often blurred by the 
frequent policy objective to satisfy reimbursement cost control 
and inertia. The chapter also concludes that cost-effective 
considerations, in the context of health technology assessment, 
are an important factor in determining the value of new 
medicines, but may need to be supplemented with a broader 
incentive structure that takes into account not only static (single 
technology, in the short term), but also dynamic considerations 
(innovation as a whole over the longer term). Finally, the 
chapter proposes that in valuing pharmaceutical innovation it is 
important to consider the context in which such innovation is 
taking place, together with strategic issues in resource 
allocation in the entire pharmaceutical value chain and 
elsewhere in health care. 
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7. CONCLUSIONS AND POLICY 
IMPLICATIONS 
7.1. Introduction 
Cancer is becoming of increasing importance in society both on 
an individual and broader level, with governance playing a 
growing role. Cancer incidence has been globally increasing 
steadily over the past half century due to greater longevity, 
lifestyle (particularly smoking) and environmental influences, as 
well as improved diagnostics. Cancer mortality is now in most 
high-income countries the first or second cause of overall death, 
whilst in middle and low-income countries it is slowly increasing 
its ranking. Not only is cancer having an economic impact due 
to its increasing contribution to health care costs, it also is 
associated with high indirect costs due to the loss of ability to 
work. 
Cancer treatments have improved tremendously over the past 
three decades and as a result outcomes have improved. The 5-
year relative survival rates (1990-1994 diagnosis) for three 
major cancers average globally for breast cancer 75% (range 
40%-82%), prostate 63% (20%-89%) and colorectal 52% (22%-
63%). Treatments consist now of surgery, radiotherapy and 
chemotherapy, either independently or more often in 
combination, in addition to the newest addition to the arsenal, 
targeted biological treatments. This latter addition has been 
proven to be most successful with late stage cancers, which 
until now have had dismal outcomes, often with less than 10% 
5-year survival rates. 
Targeted biological treatments are now the newest direction in 
cancer research and development (R&D) with greatest promise 
for future oncology drugs. New oncology discoveries have 
uncovered genomic complexities, finding each tumour has a 
unique generic code. This complexity is compounded by 
oncology research methodology where ill, in place of healthy, 
individuals are test subjects, new molecules are tested in 
combination with best practice consisting of other treatments, as 
well as large numbers of cancer sites each with its own genetic 
fingerprint. As a result, oncology pharmacology R&D has the 
highest failure rate, particularly during Phase III, and 20% 
higher costs than other new molecular entities (NME). Despite 
this failure rate, this is one of the most active portions of total 
R&D, with new compounds in development phase increase 
twofold from 2005-2009. 
Due to this complex interplay of oncology and pharmacology 
R&D, this report maps current oncology funding and 
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management of R&D structures in Europe and the USA, 
examining public-private relationships and current oncology 
R&D strategies, as a result producing oncology innovation 
recommendations. Specifically, the objectives of the report are 
(a) to map current funding and management of oncology R&D 
via questionnaire and interviews of oncology experts; (b) to 
produce a high-resolution bibliometric analysis of oncology drug 
R&D in order to better understand the public-private mix in 
research activity; (c) to investigate the cumulative life-time 
funding of specific oncology drugs; (d) to review current public 
policy affecting oncology drug R&D, specifically, public R&D 
investment policies, transnational investment policies, 
regulatory policies, and drug reimbursement policies and (e) to 
propose future oncology policies supporting the R&D process. 
 
7.2. Funding 
The report captured both public and private funding of oncology 
R&D, important in estimating long-term outlook for cancer 
outcomes and oncology care. 
Generally, there are two types of motivation for publicly funded 
research: economical and political/social reasons. The former 
helps create new knowledge and new products thus contributing 
to the wealth of a country, whilst the latter represent a social 
driver as cancer is a significant and public disease. Both are 
important together to create new knowledge, new treatments 
and ultimately improve oncology patient outcomes. 
7.2.1. Results of public and private research funding 
organisations survey 
Public oncology R&D funding can be sourced from a variety of 
sources: national governments, regional authorities, charities, 
non-governmental organisations (NGOs) and supra-national 
organisations. This funding can be directly tagged for oncology 
research from these organisations or indirectly flow into 
oncology research via overall budgets (i.e. hospital budgets). 
One hundred and fifty three public research funding 
organisations (RFO) in the EU (UK 19, France 12, Belgium 12, 
Italy 11) and 21 in the USA were identified satisfying the 
criterion of greater than €1 million annual oncology R&D 
spending. The EU RFOs spent collectively €2.79 billion whilst 
the American RFOs spent €5.8 billion in 2007. However, the EU 
figure does not include the European Commission investment 
(through programmes such as FP6, FP7 or IMI) and is likely to
be an underestimate. If the estimated annual average spend on 
cancer research is included, the EU figure is closer to €3 billion. 
After the USA, the United Kingdom was the largest investor in 
oncology R&D (€1.1 billion) followed by Germany (€426 million), 
France (€389 million) and Italy (€233 million). Accounting for 
population differences still found the USA and United Kingdom 
at the top (€19, €18 per capita, respectively) followed by 
Sweden (€12.1), the Netherlands (€8.8) and Norway (€7.2). 
Specific oncology drug development had similar absolute 
leaders (USA €1.67 billion, UK €305 million, France €67 million) 
and per capita leaders (USA €5.60, UK €5.1, Sweden €2.22). 
Although comparing the US and the UK appear to have large 
funding differences, these are reduced when only the EU 15 are 
compared, and further still when examining trends, as the EU 
has increased funding 34.7% from 2004 to 2007 whilst the USA 
only increased 9.7%. This trend furthers When direct and 
indirect funding are added together, finding the EU investing 
0.011% of GDP, or €3.64 per capita, and the USA 0.018% 
GDP, or €5.74 per capita. 
With the exception of the USA and the United Kingdom who 
have strong national cancer strategies and national funding, the 
remaining countries do not appear to have coherent national 
strategies, rather favouring an ad hoc approach to oncology 
R&D funding. Examination of the direction of RFOs spending 
found treatment, including oncology drug development, 
predominant, ranging from under 10% to over 70% of the RFOs 
investments. 
Although government funding remains the major source of 
public funding, charitable investment in oncology R&D cannot 
be ignored. In Europe, this amounted to over €300 million in 
2007, and in the USA over €230 million. 
Examination of private spending found the 17 top 
pharmaceutical companies globally spending collectively €3.1 
billion in 2004, with 59% sourced from European companies. 
With regards to public-private enterprises, these are becoming 
of increasing importance, particularly in Europe. Currently, 68% 
of oncology drug R&D projects in the USA have joint funding, 
compared to 57% in the EU and 31% in the rest of the world. 
This is rapidly changing with redirection of focus. 
The European Commission (EC) has since the millennium 
redirected its focus on oncology R&D, specifically for 
translational and transnational projects. Its previous Framework 
Programme (FP) 6 (2002-2006) invested €480 on 108 projects 
and the current FP7 (2007-2013) has so far invested €265 on
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65 projects with more to date. Wider European cooperation, 
long-term impact and translational research are key to 
successful funding. The Innovative Medicines Initiative (IMI) is a 
public-private partnership focusing on speeding up the process 
of drug discovery to treatment. 
The USA's National Cancer Institute (NCI) has a similar 
programme, the Drug Development Platform, to speed up drug 
discovery to marketplace. Overall, the NCI's oncology 
investment was $4.83 billion, providing funding to public, private 
and academic research activities both nationally and 
internationally. Other countries also invest in oncology R&D, 
some as molecular and some as translational. 
7.2.2. Policy implications 
Six issues came to light with our oncology public funding 
survey. 
First, there are funding gaps between the USA and Europe and 
within Europe between countries. European dominating 
countries are France, Germany, Italy and the United Kingdom in 
absolute terms, whilst in per capita terms the Netherlands and 
Sweden are the strongest funders, and the newest European 
Member states are the weakest. Europe has considerably 
increased its funding since 2004, reflecting increased political 
interest, both economically and socially, in oncology research 
outcomes. 
Second, it appears publicly funded research is more likely to 
support basic rather than applied research, industry supporting 
the latter. 
Third, research funding appears fragmented in Europe, with 
duplication in some areas and insufficiencies in others. The EC 
creation of the Framework Programme, with focus on 
transnational and translational research hopes to rectify this 
rather than create another layer of bureaucracy. 
Fourth, indirect funding and charitable funding are two 
additional areas of oncology R&D investment. In Europe in 
particular, these sources can be considerable. Annually in 
Europe, the main oncology charities invest over €500 million in 
cancer research, whilst almost half of annual oncology R&D 
comes from indirect sources such as academia and health care 
systems. This is significantly greater than invested in the USA, 
and an often overlooked area of oncology R&D funding. 
Fifth, the main investors in private oncology R&D are 
pharmaceutical companies, whose investment into research has 
increased steadily over the years with significant portions (7%-
12%) earmarked for oncology. Despite this investment, the New 
Drug Applications have remained flat and less New Chemical 
Entities have been approved in recent years. This has driven 
large pharma companies to invest more in in-license start-up 
biotech companies, as well as pursue defined public-private 
partnerships (PPP). 
Sixth, in oncology in particular, PPP have become more 
interesting due to the uniqueness of oncology research itself in 
addition to its complexity. Collaboration of industry with 
academia can reduce economic risk and smooth the operational 
process. Many pharma companies have now placed their 
research centres close to relevant major academic areas. More 
than half of all oncology research in Europe and the USA is now 
through PPP, and likely to increase in the future. 
7.3. Capturing Investment in Oncology Through 
Research Outputs 
The bibliometric analysis was a useful addition to our report, 
giving us information on research outputs with regards to total 
output, per country, per cancer site, partnerships and industry 
investment. This information is useful to pinpoint leaders and 
opportunities for oncology investment and shows where future 
breakthroughs may come from in what discipline. 
7.3.1. Results of the bibliometric survey on oncology 
research output 
Bibliometric analysis of 19 cancer drugs, selected for their 
treatment success, published in the Web of Science between 
1963 to mid-2009 produced 28,752 papers for analysis. Paper 
outputs rose from 200 annually in 1980 to 2000 annually by 
2007-2008. Examination of 15 main oncology research 
countries found the USA the leader (33%) followed by Japan 
(10.6%), Italy (7.5%) and the United Kingdom (7.1%). 
Although international collaboration is increasing, neighbouring 
countries still favour each other (USA:Canada, UK:NL). An 
examination of the 15 countries versus the 19 selected 
oncology drugs found that countries appear to concentrate on 
certain drugs and produce less research on others. 
Furthermore, the oncology research portfolio per country had 
poor correlation to its internal oncology burden, with the 
exception of melanoma in Australia. Initially, the USA and 
Europe dominated oncology research outputs; however, this is 
changing dramatically with the Rest of World (RoW) beginning 
to dominate. 
The type of oncology research performed changed with time 
from basic to clinical, although per drug this was not necessarily 
the case. Different countries produced different types of 
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research (i.e. basic: India, China; clinical: Spain, Greece), with 
15% of papers describing phased clinical trials, primarily Phase 
II. 
The presence of 26 leading pharma companies, including the 
12 associated with development of the 19 selected drugs, 
among the addresses of the papers occurred on 1589 papers, 
or 5.5% of the total. Dominating companies responsible for 
oncology paper outputs were Aventis (274 papers), 
AstraZeneca (173) and BristolMyerSquibb (155). 
7.3.2. Policy implications 
The results show that oncology research has increased 
dramatically over the years, and continues to grow even for 
older compounds. Main oncology R&D countries are the US, 
Japan and Europe, although China recently has significantly 
increased its output, whilst collaborations between countries 
have remained stable since the 1990s. This latter finding is 
surprising, as proximity still appears to play a major role in 
international collaborations, despite the advances in global 
markets and communication. 
Furthermore, it appears the burden of a specific disease is not 
reflected in its oncology R&D output, either nationally or 
internationally. In addition, there appears to be a gradual mixing 
of basic to applied research, which means that policy 
approaches for translational research must understand and 
support this. It appears also, that this research has a variety of 
funding mechanisms supporting it, from industry, government 
and philanthropic sources. Without the basic underlying 
research, translational research cannot be completed, thus 
completely ignoring basic research through funding and policy 
will have long-term negative impacts. 
7.4. Public Policy in Oncology Development 
A unique aspect to this report is a comprehensive survey of 
oncology clinicians with regards to their opinions on public 
policy issues affecting cancer, never before completed. This 
survey was unique in its elicitation of oncology issues influenced 
by public policy, with both quantitatively and qualitatively 
responses, in addition to its international responders. 
7.4.1. Results of our public policy survey of oncology 
clinicians 
Our survey of leading oncology clinicians globally on public 
policy issues surrounding oncology R&D yielded a number of 
interesting results. Respondents felt strongly that PPP were the 
way of the future; however, how this partnership should best be 
defined was not clearly resolved. Some felt financial incentives 
were important, whilst others did not and the length of private 
support was disputed (from neutral to agree). 
Differences in country of origin occurred, with Europeans less 
agreeable to nationalisation of drug development than 
Americans and Canadians. Americans felt reimbursement 
policies were less important to success than the RoW, whilst all 
agreed that the degree of national public sector investment was 
inadequate to meet future oncology demands. 
Furthermore, it was agreed that the current R&D models were 
unsufficient for specific oncology needs with re-examination in 
order. Potential new policies should include greater 
transnational cooperation, support of translational research and 
a degree of institutional involvement. Regulatory bottlenecks 
must be closely examined and quickly resolved to meet future 
oncology needs. Unresolved was ideal degree of funding by 
public versus private, in particular to meet long versus short-
term goals. Overall, it was clear that continued investment in 
intellectual public research remains important to meet best 
cancer outcomes. 
7.4.2. Policy implications 
Despite the globalisation of the cancer burden, surprisingly little 
thought has been given to the nature of international PPP in any 
domain of cancer research with most of the focus being placed 
upon carcinogen control and national cancer control 
programmes. 
In the domain of cancer drug development our data from key 
opinion leaders clearly shows that both public and private 
sectors are needed. Whilst there might be disagreement over 
whether the current balance of public and private sector is 
correct, what is absolutely clear is that new models for this 
relationship are urgently needed. An integral part of this finding 
was that the key opinion leaders were clear that the overall 
model of R&D in cancer drug development needs to be 
changed to reduce attrition rates, increase the rate and 
sophistication of parallel biomarker development, and work on 
the vast number of combination regimens and indications 
necessary for the next generation of cancer drugs. 
In particular, the key areas for policy development to arise for 
PPP are: 
•  Strong institutional support and dedicated streams of 
funding from public research funding organisations. 
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•  New models that increased the freedom-to-operate in 
terms of following important translational leads within 
the context of specific projects. This would be achieved 
by improved support, light touch governance and a 
substantial decrease in administrative bureaucracy at 
every level (national legislative, private-contractual, 
public-contractual). 
•  Partnerships that supported trans-national cooperation 
and collaboration focused on key cancers, including 
those traditionally viewed as 'orphan' and thus not 
particularly commercially attractive. 
The need for these new policy approaches was, however, 
tempered by a view that these partnerships should be in the 
'public good', subject to high-quality peer review and upon 
completion fully and publicly disclosable. 
The findings also indicate that the intellectual environment 
(‘trained drug development faculty embedded in centres with 
sufficient critical mass’) and infrastructure provision were 
considered the most important areas for institutional and 
national policies. Many of the faculty commented that the time 
had come to be more rational about which major technologies a 
centre needed to build in and which they should 'have' by dint of 
strategic alliances with other groups. 
Whilst public funding has been recognised as essential for 
proof-of-concept work feeding into downstream product 
development, there is a clear view that national RFO's and 
institutions have a broader role in providing dedicated clinical 
facilities, as well as specific facilities to support development 
work in such areas as novel biologicals. 
Finally, a number of countries clearly identified over-regulation 
and reimbursement of new cancer drugs as critical policy 
issues. The issue of over-regulation continues to overshadow all 
aspects of public sector clinical cancer research and this 
remains one of the greatest threats to the future for both public 
and private sectors. 
7.5. Fostering Innovation in Oncology: A List of 
Priorities 
In order to foster innovation in oncology, a list of priorities 
emerge in a number of areas: first, the role of science, research 
and innovation policy; second, the role of pricing and 
reimbursement systems in encouraging and rewarding 
innovation; third, the continuous evaluation of oncology drugs; 
fourth, the encouragement of long-term innovation and fifth, the 
optimisation of resource allocation in health care. 
7.5.1. The role of national and supra-national science, 
research and innovation policy 
(I) Guiding government policymaking 
In an era of globalisation, the role of government in incentivising 
pharmaceutical R&D in general and encouraging oncology 
R&D, in particular, is by no means limited, but, rather, multi-
dimensional and pro-active. The active involvement of 
government can be achieved both directly, through the funding 
of basic research in key or/and under-researched areas such as 
rare cancers, or indirectly, through the use of market 
mechanisms such as tax incentives. 
The role of government is also significant in basic technology 
research, where the expectations of long-term public benefit 
exceed the expectations for private returns to those undertaking 
the research. The use of collaborative consortia with private co-
funding or cost-sharing should not be excluded but altogether 
encouraged. 
A shift in the way that government encourages innovation in the 
private sector is needed. Direct funding of R&D is a useful tool 
and can leverage additional resources from the private sector. 
Yet, encouraging the development of new cancer drugs and the 
technologies on which they can be delivered probably requires 
a proactive stance in indirect measures. For instance, 
prescriptive and coercive regulations have been found to be 
cumbersome, expensive and inefficient tools for incentivising 
private investment in technology. Rather, output- or 
performance-based regulations could be adopted in this 
respect. 
Tax incentives (e.g. research and development credits) could be 
further fine-tuned and targeted so as to serve specific 
objectives, for instance, targeting areas of work such as rare 
cancers. In the same spirit, aspects of intellectual property can 
be used to encourage innovation, e.g. through enhanced market 
exclusivity periods. 
As the creation of knowledge becomes global and individual 
funders of new knowledge creation, whether public, private or 
charitable, can only but fund or have access to a finite fraction 
of (new) knowledge development, a new model may be needed 
in the future, where funders of innovation in key areas such as 
oncology must learn to cooperate as well as compete.
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Importantly, open access to innovation and knowledge may be 
needed and society needs to reflect on the implications of this 
(e.g. harnessing the potential of some technology platforms 
faster) as well as the requirements to achieve it (e.g. re-thinking 
the global regulatory environment, or intellectual property). 
(II) Lessons learned from recent initiatives at national 
and supra-national level 
Research funding programmes operating at European level 
have undertaken to combat the fragmented state of Europe's 
cancer research programmes, convert this variability into a 
cooperative strength as well as pay particular attention to 
translational research. Although many of these programmes are 
relatively recent in the history of cancer drug development, they 
are a step towards cohesive cancer research and outcomes. 
The addition of public-private partnership is encouraging, and 
will hopefully make Europe more competitive globally. 
Although EC level cancer research governance and funding 
appear to be more cohesive than previously, cancer research 
funding on a charitable level does not. There is at least one 
major cancer charity per country, many with overall umbrella 
cancer charities supplemented further by specific cancer 
charities. Although cohesive data are difficult to come by, 
significant sums are invested by these organisations in cancer 
research. As administrative costs are obviously duplicated by 
these organisations, this is a further area for potential increase 
in cooperation. 
Nationally, many countries explicitly support cancer research  
the newer members to the EU still are exploring, developing or 
implementing their cancer plans. To date, all cancer plans 
support cancer research in Europe, either through their umbrella 
medical research organisations (i.e. UK Medical Research 
Council) or via specific cancer organisations (i.e. German 
Cancer Research Center). Some countries may have more than 
one organisation supporting cancer research, such as via a 
medical research programme plus a national cancer programme 
(i.e. UK, NL), or may have more than one cancer organisation 
(i.e. France). Thus, it appears, that not only may Europe itself 
be fragmented, albeit less than before, there may be national 
fragmentation as well. 
On the other hand, some research institutions could be 
financially neglected if the work they perform is not transnational 
 very likely in the case of very new, very specialised 
technology only found in a few locations. EU-wide initiatives 
must take care not to neglect these special cases, as they could 
be sources of breakthrough technology platforms and/or 
treatments. National and charitable funding may be the only 
source for these special interest groups; supplementation by 
public-private partnerships may be an interesting addition with 
some protectionist provisions for the public institutions involved. 
Meanwhile, American cancer research is less fragmented, 
solely due to its central organisation under the National Cancer 
Institute (NCI) and its funding is directly approved by the US 
Congress, supporting both molecular research and translational 
research. There is a specific Drug Development Platform whose 
purpose somewhat mirrors the European IMI goal of speedier 
cancer drug entry into the market. 
Furthermore, the NCI has an additional purpose of supporting 
cancer research occurring in other countries via its International 
Portfolio. Clinical trials are a large portion of this, but also 
collection of international experimental medicines protocols and 
trials, provision of education and expertise, and participation at 
board level on other cancer research organisations. 
The NCI is currently examining its public-private partnership 
directive, with a proposal that the NCI would be a 'safe haven' 
for encouraging public-private partnerships, outlining issues of 
intellectual property and any other barriers. 
Globally, it appears that cancer research with focus on 
medicines is still relatively in its infancy, with only recently 
organisations and programmes given focus and direction. 
Public-private partnerships appear still in their infancy, both in 
Europe and the United States and could perhaps benefit from 
examining other areas with expertise, such as information 
technology, which has resulted in major progress. 
Fragmentation still occurs, particularly at charitable level, and 
although this may have negative consequences in terms of 
administration costs and research duplication by other 
countries, there may be benefits to highly specialised research 
areas still at experimental stage. 
(III) Rare cancers, regulation and incentives 
Rare cancers, even when defined more conservatively by taking 
into account some peculiarities of natural history and prognosis, 
they represent about 20% of all cases of malignant neoplasms, 
including all cancers affecting children and teenagers and many 
affecting young adults. There are significant variations in 
incidence and mortality rates for different types of rare cancers. 
There are also significant survival differences for the same type 
of rare cancers between EU member states, as there is 
variability in access to treatment, the availability of information 
about treatment, and a lack of medical expertise in the 
management of rare cancers. 
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The recognition of rare cancers as a special case requires multi-
dimensional action to encourage research and development, 
access and uptake of new treatments. Such actions relate to re-
organising regulation, encouraging research and clinical trials 
through collaborative actions and networks, calling for 
consensus guidelines on multi-disciplinary treatment, 
addressing patient access to care, as well as improving access 
to information on rare cancers and education of health care 
professionals. 
7.5.2. Encouraging and rewarding innovation through 
the reimbursement system 
Health systems worldwide are struggling with containing costs 
whilst improving patient access and health outcomes. Drug 
spend has come under particular pressure and scrutiny, despite 
accounting for only 10%-20% of total system costs. Managing 
drug spending should be a priority; however, current 
approaches to containment can be blunt and regressive, with 
detrimental impact on patient access and, potentially, health 
outcomes. Pricing and reimbursement systems can fulfil the 
goal of encouraging innovation, provided they take into account 
a number of criteria. 
The first among them is timely access, ensuring that patients 
get timely access to innovative therapies, unfettered by overly 
restrictive reimbursement, coverage and/or pricing 
considerations. In order to do that, a number of actions can be 
operationalised: there can be 'fast track' approval and 
reimbursement procedures to ensure timely access to 
innovative drugs (e.g. FDA fast-track process for priority drugs). 
In addition, establishing processes for conditional 
reimbursement/pricing decisions, enabling prompt access for 
drugs whilst real-world market data are collected and analysed 
is of great importance. In certain cases, launch prices can be 
negotiated using data from Phase III trials, with agreement to 
reassess pricing decisions 1 year later when Phase IV trial 
results become available. Finally, it must be ensured that 
guidelines and recommendations provide sufficient flexibility for 
physician discretion in individual cases (e.g., reimbursement 
with prior authorisation for drugs that might be recommended 
for a small share of the patient population) to meet potentially 
atypical patient preferences or clinical circumstances. 
The second criterion is value-based reimbursement. This could 
be linked to an explicit and objective assessment of incremental 
value relative to existing standards of care. 
The third criterion is comprehensive pricing and reimbursement 
in the sense that the metrics considered when assessing the 
value of new treatments and setting reimbursement levels 
should include all elements of value, including societal aspects. 
The fourth criterion relates to flexibility. The total drug benefits 
and costs to the health system must be assessed over time, by 
population segment and in a real-life context  with 
prices/reimbursement levels adjusted as new data on relative 
value becomes available. A fifth criterion is collaboration. 
Payers, providers and manufacturers need to work closer 
together, to explore new pragmatic ways of delivering value to 
the patient constituency. Finally, it is important that standard 
guidelines for assessing benefits of drugs based on a broader 
range of applicable metrics are established. These should 
include humanistic, patient-focused benefits such as quality of 
life (QoL); longer term direct cost offsets; indirect system costs 
that might or might not be covered by payers such as worker 
productivity; benefits to caregivers as well as patients (e.g. 
enhanced patient and physician convenience that translates into 
improved compliance and better outcomes). New standards and 
tools for more accurately and consistently assessing the more 
challenging metrics may need to be developed (e.g., patient 
reported outcomes such as QoL). 
7.5.3. Risk sharing 
Traditionally, payers absorb all risks associated with purchasing 
new medical technologies. Risk sharing is an attempt to 
redistribute the balance of risk between the payer and the 
supplier of the medical technology and typically involves the 
supplier of the medical technology providing a 'guarantee' 
relating to the performance of the technology. The guarantee 
may relate to one or more outcomes of treatment. These could 
include for instance (a) clinical outcomes, (b) humanistic or 
quality-of-life outcomes, (c) resource use (e.g. a reduction in 
hospitalisations), (d) financial outcomes (e.g. a reduction in the 
amount spent treating a condition) and (e) economic outcomes 
(e.g. the achievement of a particular cost-effectiveness 
threshold). 
As the pressure on health care budgets intensifies and the cost 
of some of the more novel treatment remains high, it is likely 
that the use of risk sharing agreements will intensify in the 
future. This may be on two fronts: first, in terms of admitting new 
treatments onto national formularies and, second, in terms of 
enabling faster uptake. Enabling innovative pricing solutions, for 
example  through pilot schemes making selected innovative 
medicines available for time-limited periods, or through patient-
specific franchise schemes, could contribute to faster access 
and uptake of new therapies. This would have particular 
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application in the case of oncology due to the limited number of 
patients. 
7.5.4. Minimising (negative) externalities 
Significant benefits can be gained if key negative externalities 
were minimised or altogether eliminated. Such negative 
externalities often emerge from international price referencing 
and comparisons as well as exchange rate differentials and 
currency depreciations or appreciations. 
7.5.5. Continuous evaluation of oncology drugs 
Although ex-ante evaluation provides manufacturers with the 
incentive to invest in gathering the evidence that the health 
service requires to make approvals and also encourage 
innovation in areas/therapies where a substantial clinical benefit 
can be demonstrated, one drawback of the use of ex-ante as 
opposed to ex-post evidence is that there will be uncertainty 
surrounding the cost-effectiveness of the treatment outside the 
RCT setting at the time of launch. 
Ex-post evidence is, nevertheless, as crucial as ex-ante 
evidence in proving the value of a new treatment. In order to 
enable this, there needs to be acceptance of data obtained in 
naturalistic settings and methodologies on how best to extract 
value from such data need to be strengthened. Ownership of 
such data is also important, as the cost associated with 
gathering such evidence is substantial and creating this 
evidence should provide the scope for collaboration between 
the payer community and manufacturers. 
7.5.6. Optimising resource allocation in health care 
The way resources are allocated does not necessarily 
guarantee their optimal use. There may be cases of resource 
misallocation, which could potentially lead to waste and might 
also affect access to care. Even if we accept that health care 
resource allocation operates in silos, then evidence shows that 
even the pharmaceutical budget can be further optimised. In 
order to do this further focus is needed on the demand-side and 
the behaviour of clinicians, and, very importantly, on the use of 
information systems in real time, both by payers as well as 
providers. It is also important to measure the performance of 
systems in general and of different policies in particular. Any 
efficiency savings emerging should be reallocated and re-
invested with a view to improving health care services and 
patient’s quality of care. 
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